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Abstract
Natural products play a pivotal role in the treatment of cancer; identiﬁ-
cation of compounds such as taxanes and the vinca alkaloids were semi-
nal landmarks in natural product drug discovery. Jerantinine A (JA), a
novel Aspidosperma alkaloid isolated from plant species Tabernaemontana
corymbosa, was previously reported to possess cytotoxic activity against
vincristine-resistant nasopharyngeal carcinoma cells and is therefore an
ideal candidate for biological investigation. Furthermore, Tabernaemon-
tana corymbosa has been placed in the endangered list of threatened species
by the International Union for Conservation of Nature (IUCN) thus making
it a priority to elucidate the biological activity of this alkaloid. Herein, we
report detailed biological evaluation of JA on various human-derived carci-
noma cell lines. Our preliminary screens showed that signiﬁcant inhibition
of cell growth and colony formation accompanied time- and dose-dependent
induction of apoptosis in human cancer cell lines after treatment with JA.
Dose-dependent accumulations of cleaved PARP and caspase 3 further con-
ﬁrmed apoptosis. Profound G2/M cell cycle arrest was observed 24 h after
treatment in all cell lines. Characteristics of mitotic arrest including inhi-
bition of tubulin polymerisation, microtubule disruption, and aneuploidy
were clearly observed. DNA fragmentation was also evident in cells treated
i
with JA. Indeed, signiﬁcant increases in phosphorylated-γH2AX were in-
dicative of DNA damage caused by double strand breaks and were relatively
similar to levels caused by vincristine. Investigations into JA’s ability to
overcome vincristine resistance demonstrated that it is not a substrate of
Pgp. The role of reactive oxygen species (ROS) in acquired resistance and
cell death have also been widely studied. JA induced signiﬁcant levels of
ROS in treated cells, possibly contributing to their apoptotic destiny. Pro-
teomic analyses also corroborated the phenotype of JA-treated cells with
increased expression of ROS-neutralising enzymes, aberrant expression of
proteins involved in the spindle assembly checkpoint critical to mitosis,
and decreased expression in all tubulin proteins detected by LC-MS/MS.
A genome-wide RNAi screen revealed several candidate genes involved in
mediating sensitivity to JA. The genes corresponding to c-Jun-N-terminal
kinases, JNK1/2, were selected for subsequent investigation based on their
involvement in multiple pathways that were identiﬁed using bioinformatic
tools. JNK1/2 were knocked down in MCF-7 and MDA-468 cells and then
treated with JA. MTT assays revealed some loss of sensitivity, suggesting
that these proteins were indeed involved in mediating cell sensitivity to JA.
ii
Publications
Raja V, Lim KH, Leong C, Kam TS, Bradshaw TB. Novel antitumour in-
dole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting
microtubules. Investigational New Drugs 2014; 32: 838-50.
Lim KH, Raja V, Bradshaw TB, Lim SH, Low YY, and Kam TS. Ibo-
gan, Tacaman, and Cytotoxic Bisindole Alkaloids from Tabernaemontana.
Cononusine, and Iboga Alkaloid with Unusual Incorporation of a Pyrroli-
done Moiety. Journal of Natural Products 2015; 78: 1129–1138.
iii
Acknowledgements
First and foremost, I would like to thank God for giving me this wonderful
opportunity to pursue my passion and interests over the course of these
three years. It truly was a blessing! My heartfelt thanks to my supervisor,
Dr. Tracey Bradshaw, for guiding me throughout these years of study.
She has instilled a solid foundation in me to build my future career on.
Her kindness, patience, and perseverance as a supervisor and as a person
will never be forgotten. May God bless her and her family abundantly. I
would also like to thank my secondary supervisor Dr. Kuan-Hon Lim
for allowing me to work on these precious compounds and for graciously
taking care of me during my time in Malaysia. His tireless eﬀorts to isolate
and identify new compounds are inspirational. I thank my lab colleagues
Amer Alhaj Zen, Anchala Kuruppu, Badraldin Hamad, Hamad
Alkahtani, Khalid ELfsei, Melchior Cini, Mohannad Qazzaz, Mo-
hammed Al-Hayali, and Tiangong Lu who made each and every day
at the lab a wonderful experience. Special thanks to Anchala Kuruppu,
Khalid ELfsei, and Mohannad Qazzaz for maintaining my cell lines while I
was away. I would like to thank my collaborators, Dr. Thomas Kislinger
and Ankit Sinha back home at the University of Toronto for allowing me
to work and run my samples at their lab. I would also like to extend my
iv
gratitude to our collaborators Dr. Chee-Onn Leong and Dr. Felecia
Chung for welcoming me into their lab and introducing me to invaluable
skills in the ﬁelds of genomics and proteomics. I want to acknowledge Dr.
Charles Matthews for continually challenging me to think outside the
box. Heartfelt thanks go out to friends back home who have encouraged me
throughout this time. Finally and most importantly, to my parents,Ashok
and Mary, I do not have the words to express my thanks and gratitude
to you both. Your love, prayers, and never-ending support have sustained
me through my highs and lows. You will forever be a source of inspiration
in my life. To my brother, Sanjay, your support and advice have always
helped me get through some hard situations. My deepest gratitude and
appreciation for everything that you have done and continue to do for me.
I love you all!
v
Abbreviations
A549 Adenocarcinomic human alveolar basal epithelial cells
ABCB1 ATP-binding cassette 1
AMPS Ammonium per-sulfate
APC/C Anaphase-promoting complex/cyclosome
ATCC American Type Culture Collection
ATP Adenosine triphosphate
AURK(s) Aurora kinase(s)
BCL-2 B-cell lymphoma 2
BRCA1 Breast cancer 1, early onset
BRCA2 Breast cancer 2, early onset
BSA Bovine serum albumin
BUB1B Budding-uninhibited-by-benzimidazoles-1-homolog-beta
CASP Caspase
CDK Cyclin-dependent kinases
CIN Chromosomal instability
CML Chronic Myelogenous leukaemia
COX2 Cycloxygenase 2
CTLs Cytotoxic T lymphocytes
DAOY Desmoplastic cerebellar medulloblastoma
vi
DAVID Database for Annotation, Visualisation,
and Integrated Discovery
DHFR Dihydrofolate reductase
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
DSB(s) Double strand break(s)
DTT DL-dithiothreitol
ECM Extracellular matrix
EGFR Epidermal growth factor receptor
EMT Epithelial-mesenchymal transition
ERK Extracellular signal-regulated kinase
FACS Fluoresence-activated cell sorting
FAP Familial adenomatous polyposis
FBS Foetal bovine serum
FDA US fod and drug administration
FGF Fibroblast growth factor
FSC Forward scatter
G1 phase Gap 1 phase
G2/M phase Gap2/Mitosis phase
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GDP Guanosine diphosphate
GI50 Concentration inhbiting growth of cells by 50%
GIST Gastrointestinal stromal tumours
GLUT1 Glucose transporter 1
vii
GO Gene ontology
GST Glutathione S-transferase
GTP Guanosine triphosphate
h Hour
HCT-116 Colorectal carcinoma wildtype
Her2 Human epidermal growth factor receptor 2
HIF1 Hypoxia inducible factor
HMEC-1 Microvascular endothelial cells
HPLC High performance liquid chromatography
HT-29 Colon adenocarcinoma
HTS High throughput screening
IAA Iodoacetamide
IGF1/2 Insulin-like growth factor 1/2
JA Jerantinine A
JAA Jerantinine A acetate
JA-R HCT-116 Jerantinine A-resistant colorectal carcinoma
JB Jerantinine B
JBA Jerantinine B acetate
JE Jerantinine E
KB Nasopharyngeal carcinoma
MAPK Mitogen-activated protein kinase
MCC Mitotic checkpoint complex
MCF-7 Breast ductal carcinoma
MCL-1 Myeloid cell leukemia 1
viii
MDA(s) Microtubule-disrupting agents
MDA-468 Metastatic breast adenocarcinoma
Mdm2/Hdm2 Mouse double minute 2/ Human double minute 2
MDSCs Myeloid-deprived supressor cells
MED1 Primitive neuroectodermal tumour medulloblastoma
MEK Mitogen-activated protein kinase kinase
MEM Minimum essential medium
mg Milligram
MGMT O(6)-Methylguanine-DNA-methyltransferase
MIA PaCa-2 Pancreas adenocarcinoma
ml Millilitre
MMPs Matrix metalloproteinases
MPS1 Monopolar spindle 1
MRC-5 Normal lung tissue
MRP(s) Multidrug resistance protein(s)
MSI Microsatellite instability
MT(s) Microtubule(s)
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide)
MudPIT Multidimensional Protein Identiﬁcation Technology
Myc Myelocytomatosis oncogene
NCI National Cancer Institute
NK Natural Killer Cells
NNMC Nottingham Nanotechnology and Nanoscience Centre
ix
NOXA Phorbol-12-myristate-13-acetate-induced protein 1
NSAIDs Non-steroidal anti-inﬂammatory drugs
NSCLC Non-small cell lung cancer
p53/TP53 Tumor protein 53
PARP Poly ADP ribose polymerase
PBS Phosphate-buﬀered saline
PDGF Platelet-derived growth factor
PDL1 Programmed-cell death ligand 1
Pgp Permeability-glycoprotein
PI Propidium iodide
PI3K Phosphoinositide 3-kinase
PI6INK4A Cyclin-dependent kinase inhibitor 2A
PK Protein kinase
PLK1 Polo-like kinase
PPAR-γ Peroxisome proliferator-activated receptor gamma
PTEN Phosphatase and tensin homolog
PUMA p53 upregulated modulator of apoptosis
Rb/pRb Retinoblastoma protein
RNA Ribonucleic acid
RNAi RNA interference
ROS Reactive oxygen species
rpm Revolutions per minute
RPMI-1640 Roswell Park Memorial Institute
S phase Synthesis phase
x
SAC Spindle assembly checkpoint
SCF Stem-cell factors
SEM Scanning electron microscope
shRNA Short hairpin RNA
SSC Side scatter
TBA(s) Tubulin-binding agent(s)
TGF-β Transforming growth factor beta
TKIs Tyrosine kinase inhibitors
TM Transmembrane
TSP-1 Thrombospondin-1
TUBB β-tubulin
TXNRD1 Thioredoxin reductase 1
U373 M Glioblastoma astrocytoma (high MGMT)
U373 V Glioblastoma astrocytoma (low MGMT)
UW228-3 Posterior fossa medulloblastomas
VEGF Vascular endothelial growth factor
V-R HCT-116 Vincristine-resistant colorectal carcinoma
γH2AX Phosphorylated histone 2A, member X
µl Microlitre
µM Micromolar
xi
Contents
Abstract i
Publications iii
Acknowledgements iv
Abbreviations vi
List of Figures xix
List of Tables xx
1 Introduction 1
1.1 Cancer and Incidence . . . . . . . . . . . . . . . . . . . . . . 1
1.2 The Nature of Cancer . . . . . . . . . . . . . . . . . . . . . 2
1.3 Hallmarks of Cancer . . . . . . . . . . . . . . . . . . . . . . 3
1.3.1 Self-suﬃciency in growth signals . . . . . . . . . . . . 4
1.3.2 Insensitivity to antigrowth signals . . . . . . . . . . . 6
1.3.3 Evading apoptosis . . . . . . . . . . . . . . . . . . . . 7
1.3.4 Limitless replicative potential . . . . . . . . . . . . . 10
1.3.5 Sustained angiogenesis . . . . . . . . . . . . . . . . . 11
1.3.6 Tissue invasion and metastasis . . . . . . . . . . . . . 13
1.4 Enabling Hallmarks of Cancer . . . . . . . . . . . . . . . . . 15
1.4.1 Tumour-promoting inﬂammation . . . . . . . . . . . 15
1.4.2 Genome instability and mutation . . . . . . . . . . . 17
1.5 Emerging Hallmarks of Cancer . . . . . . . . . . . . . . . . . 20
1.5.1 Reprogramming energy metabolism . . . . . . . . . . 20
1.5.2 Evading immune destruction . . . . . . . . . . . . . . 22
1.6 Treatment of Cancer . . . . . . . . . . . . . . . . . . . . . . 23
1.6.1 Surgery . . . . . . . . . . . . . . . . . . . . . . . . . 24
1.6.2 Radiotherapy . . . . . . . . . . . . . . . . . . . . . . 24
1.6.3 Chemotherapy . . . . . . . . . . . . . . . . . . . . . . 25
1.6.3.1 Alkylating agents . . . . . . . . . . . . . . . 27
1.6.3.2 Anti-metabolite agents . . . . . . . . . . . . 28
1.6.3.3 Hormones . . . . . . . . . . . . . . . . . . . 29
1.6.3.4 Targeted agents . . . . . . . . . . . . . . . . 29
1.6.3.5 Natural Product Drug Discovery . . . . . . 37
1.7 Aims and Objectives . . . . . . . . . . . . . . . . . . . . . . 48
xii
2 Antiproliferative Screening of Jerantinine A 50
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . 54
2.2.1 Jerantinine A, jerantinine B, and acetate derivatives
potently inhibit growth of cancer cells . . . . . . . . . 54
2.2.1.1 Investigating cross-resistance between jer-
antinine A and vincristine . . . . . . . . . . 58
2.2.1.2 Jerantinine A acetate has potent growth in-
hibitory activities against the NCI60 cell
line panel . . . . . . . . . . . . . . . . . . . 61
2.2.1.3 Jerantinine A inhibits the ability of cancer
cells to form colonies . . . . . . . . . . . . . 63
2.2.1.4 Jerantinine A induces apoptosis . . . . . . . 66
2.2.1.5 Biomarkers of apoptosis . . . . . . . . . . . 69
2.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
3 Cellular Mechanism of Jerantinine A 76
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . 78
3.2.1 Jerantinine A causes severe perturbations in cell cy-
cle progression . . . . . . . . . . . . . . . . . . . . . . 78
3.2.2 Jerantinine A inhibits tubulin polymerisation . . . . 83
3.2.3 Jerantinine A causes severe disruption in cyto-
skeletal architecture . . . . . . . . . . . . . . . . . . . 86
3.2.4 Jerantinine A inhibits activity of kinases involved in
mitosis . . . . . . . . . . . . . . . . . . . . . . . . . . 90
3.2.5 Monitoring DNA double strand breaks by observing
phosphorylated γH2AX . . . . . . . . . . . . . . . . 92
3.2.6 Investigating possible mechanisms by which jeranti-
nine A overcomes vincristine resistance . . . . . . . . 96
3.2.6.1 Overcoming resistance via production of Re-
active Oxygen Species . . . . . . . . . . . . 99
3.2.6.2 Diﬀerences in binding sites on microtubules
can account for the lack of cross-resistance . 102
3.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
4 Genomic and Proteomic Studies in Cells Treated with Jer-
antinine A 107
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
4.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . 110
4.2.1 Genome-wide RNAi screen in MCF-7 cells . . . . . . 110
4.2.1.1 shRNA target validation in MCF-7 and MDA-
468 cells treated with JA . . . . . . . . . . 113
4.2.2 Proteome proﬁling in JA-treated MCF-7 cells . . . . 118
4.2.2.1 Validating the spindle assembly checkpoint . 130
4.2.2.2 Increased expression of ROS scavengers is
indicative of ROS production . . . . . . . . 135
xiii
4.2.2.3 JA treatment causes reduced levels of diﬀer-
entially expressed tubulin types in MCF-7
cells . . . . . . . . . . . . . . . . . . . . . . 137
4.2.2.4 Short-term exposure to jerantinine A po-
tently inhibits growth . . . . . . . . . . . . 140
4.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
5 Concluding Remarks and Future Studies 146
5.1 Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . 146
5.2 Future Studies . . . . . . . . . . . . . . . . . . . . . . . . . . 150
6 Materials and Methods 153
6.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
6.1.1 Cell Lines . . . . . . . . . . . . . . . . . . . . . . . . 153
6.1.2 Cell Culture Media . . . . . . . . . . . . . . . . . . . 155
6.1.3 Compounds . . . . . . . . . . . . . . . . . . . . . . . 155
6.1.4 Chemicals and Reagents . . . . . . . . . . . . . . . . 155
6.1.5 Buﬀers . . . . . . . . . . . . . . . . . . . . . . . . . . 158
6.1.6 Antibodies . . . . . . . . . . . . . . . . . . . . . . . . 158
6.1.7 Software . . . . . . . . . . . . . . . . . . . . . . . . . 161
6.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
6.2.1 Cell Culture . . . . . . . . . . . . . . . . . . . . . . . 162
6.2.2 Compound Stock Solutions . . . . . . . . . . . . . . . 163
6.2.3 MTT Assay . . . . . . . . . . . . . . . . . . . . . . . 163
6.2.4 Generating Vincristine and Jerantinine A-resistant
HCT-116 cells . . . . . . . . . . . . . . . . . . . . . . 165
6.2.5 Clonogenic Assay . . . . . . . . . . . . . . . . . . . . 165
6.2.6 Flow Cytometry . . . . . . . . . . . . . . . . . . . . . 166
6.2.6.1 Cell Cycle Analysis . . . . . . . . . . . . . . 167
6.2.6.2 Annexin V-FITC and Propidium Iodide Apop-
tosis Assays . . . . . . . . . . . . . . . . . . 168
6.2.6.3 Assessing DNA Damage using Flow Cytom-
etry . . . . . . . . . . . . . . . . . . . . . . 169
6.2.7 Tubulin Polymerisation Assay . . . . . . . . . . . . . 171
6.2.8 Confocal Microscopy . . . . . . . . . . . . . . . . . . 172
6.2.9 Kinase Assay . . . . . . . . . . . . . . . . . . . . . . 173
6.2.10 Western Blotting Analysis . . . . . . . . . . . . . . . 174
6.2.10.1 Preparation of cell lysates . . . . . . . . . . 174
6.2.10.2 Determining protein concentration . . . . . 174
6.2.10.3 SDS-PAGE . . . . . . . . . . . . . . . . . . 175
6.2.10.4 Immunoblotting . . . . . . . . . . . . . . . 176
6.2.10.5 Enhanced chemiluminescence detection . . . 177
6.2.11 Caspase 3/7 Assay . . . . . . . . . . . . . . . . . . . 177
6.2.12 ROS-GloTM H2O2 Assay . . . . . . . . . . . . . . . . 178
6.2.13 Proteomics . . . . . . . . . . . . . . . . . . . . . . . 179
6.2.14 Statistical Analysis . . . . . . . . . . . . . . . . . . . 181
References 181
xiv
Appendices 206
A 206
B 211
C 214
C.1 Data Analysis of Genome-wide shRNA Screen . . . . . . . . 215
xv
List of Figures
1.1 The 10 most commonly diagnosed cancers in 2012. . . . . . . 2
1.2 Illustration of how an oncogene becomes activated when a
normal cell becomes a cancer cell after introduction of a
possible risk factor. . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 Six hallmarks of cancer originally proposed by Hanahan and
Weinberg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.4 Cell cycle and implications in cancer. . . . . . . . . . . . . . 7
1.5 Extrinsic and intrinsic pathways of apoptosis. . . . . . . . . 9
1.6 The telomere balance in normal and cancer cells. . . . . . . 11
1.7 Intrinsic components of the VEGF Pathway involved in an-
giogenesis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.8 The early steps of metastasis: tumor invasion, dissemination
and survival in the circulation. . . . . . . . . . . . . . . . . . 14
1.9 The connection between inﬂammation and cancer. . . . . . . 17
1.10 The hallmarks of cancer relative to the nature of genomic
instability in hereditary and sporadic cancers. . . . . . . . . 19
1.11 The various hallmarks of cancer and their eﬀects on metabolism
or how they can be modulated by metabolic changes. . . . . 21
1.12 The cancer immunity cycle illustrating the ability of the im-
mune system to target cancer cells selectively. . . . . . . . . 23
1.13 The "druggable" genome in target-directed drug discovery. . 31
1.14 Eﬄux transporter modiﬁcations by small-molecule tyrosine
kinase molecules and their targets . . . . . . . . . . . . . . . 33
2.1 Jerantinine A is isolated from the leaf of Tabernaemontana
corymbosa which belongs to the Apocynaceae family. . . . . 51
2.2 Jerantinine family of compounds isolated from the Malayan
Tabernaemontana corymbosa. . . . . . . . . . . . . . . . . . 52
2.3 Representative MTT graphs from a single trial displaying
the growth inhibitory properties of JA. . . . . . . . . . . . . 57
2.4 Morphological diﬀerences between HCT-116 (a), V-R HCT-
116 (b), and JA-HCT-116 (c) cells at 40X objective magni-
ﬁcation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
2.5 Growth inhibitory eﬀects of vincristine and JA from one
independent trial in V-R HCT-116. . . . . . . . . . . . . . . 60
2.6 Growth inhibitory eﬀects of vincristine and JA from one
independent trial in JA-HCT-116. . . . . . . . . . . . . . . . 60
2.7 Growth inhibitory activity of JAA against the NCI60-cell
line panel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
xvi
2.8 Eﬀect of JA on colony formation in A549, HCT-116, HT-29
and MCF-7 cells. . . . . . . . . . . . . . . . . . . . . . . . . 64
2.9 Eﬀect of JA on colony formation. . . . . . . . . . . . . . . . 65
2.10 Apoptotic eﬀects of JA on A549 (a), HCT-116 (b), MCF-7
(c) cells at GI50 and 2 x GI50. . . . . . . . . . . . . . . . . . 67
2.11 Representative dot plots illustrating apoptotic eﬀects of JA
(2 x GI50) on A549, HCT-116, and MCF-7 after 24 h, 48 h,
and 72 h exposure. . . . . . . . . . . . . . . . . . . . . . . . 68
2.12 Upregulation and downregulation of pro- and anti-apoptotic
proteins conﬁrm JA-induced cell death. . . . . . . . . . . . . 70
2.13 Schematic representation of apoptotic events. . . . . . . . . 71
2.14 Jerantinine A induces signiﬁcant activation of caspase 3/7
in HCT-116, V-R HCT-116 and MIA PaCa-2 cells after a 48
h exposure. . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
2.15 JA did not induce activation of caspases 3/7, 8, and 9 in
MCF-7 and MDA-468 cells at GI50. . . . . . . . . . . . . . . 74
3.1 Structural similarities between vincristine (a) and JA (b). . . 77
3.2 Eﬀect of JA on the cell cycle in A549 (a), HCT-116 (b),
HT-29 (c), MCF-7 (d), MDA-468 (e). . . . . . . . . . . . . . 80
3.3 Representative cell cycle histogram of JA on HCT-116 cells
24 h, 48 h, and 72 h post-treatment from a single trial. . . . 81
3.4 Representative cell cycle histograms from a single trial of
A549, HCT-116, HT-29, MCF-7, and MDA-468 cells treated
with JA at respective GI50 and 2 x GI50 concentrations for
24 h, 48 h, and 72 h. . . . . . . . . . . . . . . . . . . . . . . 82
3.5 Eﬀect of JA on tubulin polymerisation. . . . . . . . . . . . . 84
3.6 Assembly of microtubules. . . . . . . . . . . . . . . . . . . . 85
3.7 Microtubule destabilisers and stabilisers and their binding
sites on tubulin. . . . . . . . . . . . . . . . . . . . . . . . . . 86
3.8 Eﬀects of JA and vincristine on HCT-116 cells after 24 h
exposure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
3.9 Scanning Electron Microscope (SEM) images illustrating the
extent of cell blebbing caused by JA. . . . . . . . . . . . . . 89
3.10 Eﬀect of JA on the activity of aurora A, B, C and PLK1 . . 90
3.11 JA induces DNA DSBs in HCT-116 and MCF-7 cell after a
24 h exposure. . . . . . . . . . . . . . . . . . . . . . . . . . . 94
3.12 Representative cell cycle histograms and γH2AX dot plots
from an independent trial illustrating induction of DNA DSBs
in HCT-116 and MCF-7 cells after 24 h of JA treatment. . . 95
3.13 Predicted 2-D structural model of Pgp with a schematic
representation showing the distribution of single nucleotide
polymorphisms of the MDR1 gene. . . . . . . . . . . . . . . 97
3.14 V-R HCT-116 cells retain sensitivity to JA despite express-
ing high levels of Pgp. . . . . . . . . . . . . . . . . . . . . . 98
3.15 JA generated signiﬁcantly higher ROS levels in V-R HCT-
116 cells compared to vincristine. . . . . . . . . . . . . . . . 101
3.16 Tubulin binding sites of various MDAs. . . . . . . . . . . . . 102
xvii
3.17 2.4Å crystal structures illustrating that JBA binds to the
colchicine site on microtubules. Images were provided by
Dr. Michel O. Steinmetz et al. (PSI, Switzerland). Refer to
B.2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
4.1 General illustration showing the workﬂow for MudPIT. . . . 109
4.2 MCF-7 transduced with a pooled genome-wide shRNA con-
fers resistance to JA. . . . . . . . . . . . . . . . . . . . . . . 111
4.3 Pathway analyses using DAVID revealed possible involve-
ment of the JNK pathway in conferring sensitivity to JA. . 115
4.4 Top 25 enriched gene ontology (GO) terms from the en-
tire dataset representing upregulated biological processes in
MCF-7 cells as a consequence of JA treatment (1 µM). . . . 120
4.5 Top 25 enriched GO terms from the entire dataset represent-
ing downregulated biological processes in MCF-7 cells as a
consequence of JA treatment (1 µM). . . . . . . . . . . . . . 121
4.6 GO terms representative of biological processes comprising
of proteins present exclusively in the control and absent in
treatment samples (control >8 h = 16 h = 24 h = 0). . . . . 122
4.7 GO terms representative of biological processes comprising
proteins absent in the control but increase in a time-dependent
manner (control = 0 <8 h <16 h <24 h). . . . . . . . . . . . 123
4.8 GO terms representative of biological processes comprising
proteins present in the control that increase in a time-dependent
manner (control <8 h <16 h <24 h). . . . . . . . . . . . . . 125
4.9 GO terms representative of biological processes comprising
proteins present in the control that decrease in a time-dependent
manner (control >8 h >16 h >24 h). . . . . . . . . . . . . . 127
4.10 GO terms representative of biological processes consisting
of proteins present in the control that decrease in a time-
dependent manner (control >8 h >16 h >24 h = 0) . . . . . 128
4.11 The spindle assembly checkpoint and cell fate. . . . . . . . . 131
4.12 MudPIT results illustrating temporal protein expression of
key components in the spindle assembly checkpoint in MCF-
7 cells after JA treatment for 8, 16, and 24 hours. . . . . . . 132
4.13 Western blots validating temporal protein expression ob-
served in MudPIT of key components of the spindle assem-
bly checkpoint in MCF-7, HCT-116 and V-R HCT-116 cells
after JA treatment. . . . . . . . . . . . . . . . . . . . . . . . 133
4.14 JA induces expression of key enzymes involved in detoxiﬁ-
cation in MCF-7 cells after treatment. . . . . . . . . . . . . 136
4.15 JA induces signiﬁcant levels of ROS production in MCF-7
cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
4.16 Jerantinine A (1 µM) reduced levels of various tubulin com-
ponents in MCF-7 cells after treatment. . . . . . . . . . . . . 139
4.17 Blots showing reduction in TUBB in MCF-7 cells correspond
to TUBB levels obtained in MudPIT after 8 h, 16 h, and 24
h exposure to JA (1 µM). . . . . . . . . . . . . . . . . . . . 139
xviii
4.18 JA inhibits growth of HCT-116 cells after only 8 h exposure. 141
4.19 JA does not inhibit growth of MCF-7 cells by 50% at 1µM
after 8 h exposure. . . . . . . . . . . . . . . . . . . . . . . . 141
4.20 Clustered heatmap showing distribution of perturbed pro-
teins across samples . . . . . . . . . . . . . . . . . . . . . . . 143
5.1 SPA assay with biotin-tubulin and streptavidin beads . . . . 152
A.1 Representative MTT graphs from a single trial displaying
the eﬀect of DMSO on all cell lines initially tested. . . . . . 207
A.2 Representative MTT graph from a single trial displaying the
growth inhibitory properties of JA and JAA against a pan-
creatic carcinoma cell line MIA PaCa-2. . . . . . . . . . . . 208
A.3 Eﬀect of jerantinine A and jerantinine A acetate on colony
formation in MIA PaCa-2. . . . . . . . . . . . . . . . . . . . 209
A.4 Comparison of relative IC50 values from clonogenic and MTT
assays for vincristine and jerantinine A in DAOY, MED1 and
UW228-3 medulloblastoma cell lines. . . . . . . . . . . . . . 210
B.1 The eﬀects of Verapamil with Vincristine (A-C) and Jeran-
tinine A (D-F) on the potentiation of inhibitory eﬀects on
colony formation using clonogenic assays. . . . . . . . . . . . 212
B.2 Detailed crystal structures of jerantinine B acetate binding
to the colchicine site on microtubules . . . . . . . . . . . . . 213
C.1 Detection of JA sensitization and resistance-causing eﬀects. . 216
C.2 Blots illustrating knockdown of JNK1/2 in MCF-7 and MDA-
468 cells compared to their respective vector controls (pLKO).217
C.3 Mean MTT graphs of JA-treated (1 µM) MCF-7 cells that
are deﬁcient in either JNK1 or JNK2. . . . . . . . . . . . . . 218
C.4 Mean MTT graphs of JA-treated (1 µM) MDA-468 cells that
are deﬁcient in either JNK1 or JNK2. . . . . . . . . . . . . . 218
xix
List of Tables
1.1 Classiﬁcation of anticancer agents currently used in clinics. . 27
1.2 Novel anticancer medicines based on natural products . . . . 39
2.1 Anti-proliferative activity of jerantinine analogues against
human tumour cell lines and a normal ﬁbroblastic cell line . 55
2.2 Antiproliferative activity of JA and JAA against other tu-
mour cell lines and a normal microvascular endothelial cell
line . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.3 Antiproliferative activity of JA and vincristine against JA-
HCT-116 and V-R HCT-116 cells . . . . . . . . . . . . . . . 59
4.1 List of genes mediating the sensitivity of MCF-7 to JA (these
genes when knocked-down confer resistance). . . . . . . . . . 112
4.2 List of resistance-causing genes (these genes when knocked-
down confer sensitivity to JA) . . . . . . . . . . . . . . . . . 113
4.3 Mean IC50 values of MCF-7 cells transduced with JNK1/2
shRNA variants and subsequently treated with JA 1µM for
72 h. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
4.4 Mean IC50 values of MDA-468 cells transduced with JNK1/2
shRNA variants and subsequently treated with JA 1µM for
72 h. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
4.5 List of proteins associated with biological processes repre-
sented in ﬁg.4.10. . . . . . . . . . . . . . . . . . . . . . . . . 129
A.1 IC50 values obtained from clonogenic assays and MTT assays
for vincristine and jerantinine A in DAOY, MED1, UW228-3
and FB83 cell lines. . . . . . . . . . . . . . . . . . . . . . . . 210
xx
Chapter 1
Introduction
1.1 Cancer and Incidence
Cancer may be deﬁned as one of many diseases characterised by the de-
velopment of abnormal cells that divide uncontrollably whilst having the
ability to metastasise and/or inﬁltrate and destroy normal body tissue [1].
According to Cancer Research UK, 14.1 million new cases of cancer oc-
curred in 2012 with a projected increase of 23.6 million new cases each
year by 2030 [2]. Lung, breast, and colorectal carcinomas accounted for
the majority of categorical cancers in 2012 as seen in Fig. 1.1. Approx-
imately 8.2 million deaths in 2012 were attributable to cancer making it
one of the major causes of death worldwide [2].
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Figure 1.1: The 10 most commonly diagnosed cancers in 2012.
Obtained from http://www.cancerresearchuk.org/cancer-
info/cancerstats/world/incidence/
1.2 The Nature of Cancer
The ability of the cell to proliferate is crucial to maintaining tissue through-
out an organism’s lifespan. Normal processes such as repair of wounds and
replacement of cells that have been subjected to the external or internal en-
vironment of the organism are examples of said maintenance [3]. However,
normal genes called proto-oncogenes that control such processes are not
immune to mutations that may arise from physical (e.g. ionising and ul-
traviolet radiation), chemical (e.g. asbestos and alcohol), biological factors
(e.g. viruses and bacteria), certain hormones, age and diet [4, 5].
Products of these activated oncogenes can be broadly classiﬁed into
six groups: chromatin remodellers, transcription factors, growth factors,
growth factor receptors, signal transducers and apoptosis regulators [6].
Activation of oncogenes via mutations or translocations can occur as ini-
tiating events or during tumour progression and maintenance depending
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Figure 1.2: Illustration of how an oncogene becomes activated when a
normal cell becomes a cancer cell after introduction of a possible risk factor.
Obtained from the NCI, AV Number: AV-8808-3615.
on the type of cancer [6, 7, 8, 9]. The NCI classiﬁes cancer into six ma-
jor categories: carcinoma, sarcoma, myeloma, leukaemia, lymphoma, and
mixed types which may involve cancers in one or more diﬀerent categories
[5]. These malignancies share common genetic alterations that lead to un-
controlled growth, consequently exhibiting certain hallmarks of cancer.
1.3 Hallmarks of Cancer
Investigating molecular mechanisms underlying cancer cells and how they
diﬀer from normal cells is key for selective and targeted treatment. Douglas
Hanahan and Robert A. Weinberg initially conceptualised six distinctive
hallmarks characteristic of cancer cells [10]. They include: self-suﬃciency
in growth signals, insensitivity to antigrowth signals, evading apoptosis,
limitless replicative potential, sustained angiogenesis, tissue invasion and
metastasis (ﬁg. 1.3) [11, 10].
Four additional hallmarks were added in 2011 [11]. They include two
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Figure 1.3: Six hallmarks of cancer originally proposed by Hanahan and
Weinberg.
[11, 10]
enabling hallmarks: tumour-promoting inﬂammation and genome instabil-
ity and mutation. These hallmarks mediate other hallmarks. The other
two new hallmarks of cancer include abnormal metabolism and their abil-
ity to avoid immune destruction [11]. Although cancers do not require the
manifestation of all these hallmarks, no cancer can develop without any of
these hallmarks [11, 10].
1.3.1 Self-sufficiency in growth signals
The most fundamental trait of cancer cells is arguably their ability to sus-
tain chronic proliferation [11]. They have the ability to increase or produce
their own growth factor ligands, which may correspond to expression of cer-
tain speciﬁc surface receptors, resulting in autocrine proliferative stimula-
tion [11]. Alternatively, cancer cells can resort to paracrine signalling where
they send signals to normal cells within the tumour-associated stroma to
supply them with additional growth factors [12, 13]. Furthermore, they can
increase the number of growth factor receptors if there are limited amounts
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of growth factors available, resulting in hypersensitivity, or structurally
modify receptors to facilitate ligand-independent ﬁring [11]. These recep-
tors are capable of activating proteins in downstream signalling cascades
or may disrupt negative feedback loops to fuel cellular proliferation and
survival [14]. For instance, recent research has shown that most cancers
have a disruption in the mitogen-activated protein kinase (MAPK) path-
way [11, 14, 15]. Normally, this pathway is activated when growth factors
bind to receptors on the surface of the cell which send signals via the RAS-
BRAF-MEK-ERK (also known as MAPK) pathway until they reach the
nucleus where transcription factors attach to speciﬁc regions of the DNA
that code for cell proliferation and survival and is switched oﬀ via a nega-
tive feedback loop using RAS GTPase [11, 14]. However, the RAS protein
is mutated in tumour cells and is continually activated in some cancers.
RAS mutations manifest in various isoforms such as K-RAS, N-RAS and
H-RAS. Studies show that K-RAS is the most frequently mutated isoform
in many cancers with an extreme example of pancreatic cancer where 90%
of tumours harbour K-RAS mutations [16]. K-RAS has been shown to
play an important role in promoting colorectal adenocarcinoma in addi-
tion to promoting proliferation of endodermal stem cells. This is signiﬁ-
cant because many cancers of the lung, pancreas, colon, and rectum are of
endodermal origin [16]. In approximately 66% of metastatic melanomas,
mutated BRAF protein remains locked into a constantly active state caus-
ing uncontrolled cell division and increased survival/resistance to apoptosis
[11, 14, 16]. Some cancer cells may adapt to high levels of oncogenic sig-
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nalling by disabling senescence or apoptosis-inducing pathways that are
otherwise present in normal cells to prevent excessive proliferation [17].
1.3.2 Insensitivity to antigrowth signals
Cancer cells need to successfully override growth suppressors in order to
achieve their proliferative capacity. Speciﬁcally, they would need to bypass
normal restrictions placed by tumour suppressors in the cell cycle in order to
continue to proliferate. Two well-documented tumour suppressors include
retinoblastoma (Rb/pRB) and p53 proteins [11]. Both these proteins are
integral in determining if the cell can proceed to proliferate or alternatively
activate senescence or apoptotic pathways to deter cell division (see Fig.1.4)
[18, 19].
Hypophosphorylation of pRB via stops cells from progressing through to
the S phase of the cell cycle. pRB in association with the E2F transcription
factor prevents damaged DNA from replicating and progressing through cell
division, speciﬁcally from Gap 1 (G1) into the DNA synthesis (S) phase,
and is mutated in approximately 40% of all cancers [20]. Consequently,
cancer cells with mutated Rb are incapable of binding to E2F allowing for
uncontrolled progression past the restriction point into the S phase.
The p53 protein is often referred to as the “guardian of the genome”
and is important in determining the fate of a DNA-damaged cell i.e. DNA
repair or apoptosis [21]. It is reported to be mutated in roughly 50% of
all cancers [20, 21]. Normally, p53 is negatively regulated by MDM2 and
hence concentrations of the protein remain low, but various stresses includ-
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ing DNA damage and oncogene activation can actuate p53 by disrupting
its association with MDM2. If the p53 protein is mutated or inactivated
however, it cannot perform its usual functions which include initiation of
apoptosis, DNA repair, or cell cycle arrest in the presence of DNA damage,
leading to carcinogenesis [11, 18, 21, 22].
Figure 1.4: Cell cycle and implications in cancer.
[19]
1.3.3 Evading apoptosis
Apoptosis normally serves as a natural barrier to cancer progression, but
research has shown that highly malignant cancers can overcome this bar-
rier [23, 24]. Almost all cancer cells have the ability to dysregulate intrinsic
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and extrinsic pathways of apoptosis (see ﬁg. 1.5 [11, 25, 26]. The intrinsic
pathway is prevalent under severe cellular stress that can inﬂuence cellu-
lar development, whereas the extrinsic pathway is activated in response
to multiple extracellular apoptotic signals such as Apo2L/TRAIL and Fas
ligand/Fas receptor [11, 25]. Each of these pathways culminate in the
activation of proteases (caspase 8 and caspase 9 respectively) leading to
a cascade of events that are responsible for executing the apoptotic phase
where the cell is then disassembled and consumed by phagocytic cells. Cur-
rent research alludes to the intrinsic pathway as being the barrier to cancer
pathogenesis [11]. Tumour cells can evade cell death through the upregula-
tion of anti-apoptotic proteins such as Bcl-2 and Mcl-1 and survival signals
such as Igf1/2 [11, 23]. Loss of p53 tumour suppressor function renders the
protein unable to sense DNA damage and initiate apoptosis by activating
pro-apoptotic proteins like Noxa and Puma [12, 13, 27].
8
Figure 1.5: Extrinsic and intrinsic pathways of apoptosis.
[26]
Despite advances in chemotherapy and molecular-targeted therapies,
insuﬃcient levels of apoptosis as a result of drug resistance remain a barrier
to successful treatment of patients with metastatic cancer as 90% of them
succumb to their disease [28].
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1.3.4 Limitless replicative potential
Well-established research has illustrated that cancer cells require the abil-
ity to proliferate in an unlimited capacity in order to form tumours. Nor-
mal cells on the other hand, face two barriers to continuous proliferation:
senescence, where cells remain viable but are unable to proliferate and cri-
sis, where they undergo cell death [11, 29]. There are instances where cells
circumvent the crisis phase and enter a state of immortalisation which is
termed as a trait that most established cell lines possess by way of their
ability to proliferate indeﬁnitely without evidence of senescence or crisis
[11, 29]. A large body of evidence indicates that maintenance of telomeres
(multiple tandem hexanucleotide repeats) which protect the ends of chro-
mosomes enable limitless proliferation [11, 29, 30, 31]. Normally, with each
cell division there is a loss of telomeric DNA conferring limited lifespan in
cells. However in virtually all cancer cells, there is an upregulation in telom-
erase, a DNA polymerase enzyme that synthesises telomeres and hinders
the loss of DNA from the ends of chromosomes after cell division, thereby
bestowing these cells with unlimited proliferative capacity [32]. This pro-
cess is partly aided by the loss of tumour suppressor genes such as p53 (see
ﬁg. 1.6) [11, 33].
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Figure 1.6: The telomere balance in normal and cancer cells.
[33]
1.3.5 Sustained angiogenesis
Angiogenesis is deﬁned as the process of forming new blood vessels from
pre-existing vessels. Like normal cells, tumours require nutrition in the
form of oxygen and essential nutrients used to fuel and sustain their growth
and export of waste products. Angiogenesis is usually initiated and tem-
porarily remains active in adults during physiological processes such as
wound healing and the female reproductive cycle [34]. However, during
tumourigenesis, an “angiogenic switch” is continually activated resulting in
the sprouting of new vessels from normally quiescent vasculature to support
neoplastic growth [35]. The “angiogenic switch” is governed by factors that
promote and oppose the process of angiogenesis such as vascular endothelial
growth factor A (VEGF-A) and thrombospondin -1 (TSP-1), respectively.
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VEGF is thought to be one of the most important factors in the angio-
genic process and it binds to speciﬁc receptors located on endothelial cells
lining nearby blood vessels. More speciﬁcally, it binds to the extracellular
portion of the VEGF receptor promoting receptor dimerisation resulting in
activation of the intracellular tyrosine kinase domain that triggers a signal-
ing cascade responsible for the formation of new blood vessels towards the
tumour. Blood vessels formed in the tumour environment are usually aber-
rant in structure resulting in leakiness, microhemorrhaging, endothelial cell
proliferation and apoptosis [36, 37]. Oncogenic signals (RAS and Myc pro-
teins) in addition to growth factors like ﬁbroblast growth factor (FGF) have
been shown to up-regulate the expression of VEGF and other angiogenic
signals implicated in tumour angiogenesis (see ﬁg. 1.7) [38, 39, 24].
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Figure 1.7: Intrinsic components of the VEGF Pathway involved in angio-
genesis.
[40]
1.3.6 Tissue invasion and metastasis
Alterations in the shape of cancer cells and their ability to attach to other
cells are reﬂected in the invasive and metastatic characteristics of most
carcinomas [11]. One such alteration is the loss of E-cadherin in cancer
cells, which is an important cell adhesion molecule. Upregulation of E-
cadherin has been shown to be an important antagonist to invasion and
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metastasis, while reduction of this molecule potentiates these characteris-
tics [11, 41, 42]. This widely-studied process is termed as the “epithelial-
mesenchymal transition” (EMT) where transformed epithelial cells take
on invasive and anti-apoptotic characteristics [11, 43]. Essentially, the
invasion-metastasis cascade begins with local invasion followed by intrava-
sation of cancer cells into blood and lymphatic vessels in the nearby vicinity,
after which cells travel through the lymphatic and cardiovascular systems
and escape through vessels via extravasation forming small cancerous nod-
ules that ﬁnally grow to form macroscopic tumours [11]. Recent studies
have identiﬁed matrix metalloproteinases (MMPs) as key players in mech-
anisms of tumour invasion and metastasis [44, 45]. MMPs have the ability
to degrade extracellular matrix (ECM) proteins and are thought to promote
tumour development via proteolytic breakdown of tissue barriers, invasion,
and the associated facilitation of circulating tumour cell extravasation [44]
(see ﬁg. 1.8) [46].
Figure 1.8: The early steps of metastasis: tumor invasion, dissemination
and survival in the circulation.
[46]
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However, there is increasing evidence that MMPs do not play a crucial
role in the extravasation process, but rather appear to promote intrava-
sation (invasion of cancer cells into the circulation of blood vessels) [44].
The current view emphasises two types of communications that take place
following tissue invasion: cell-cell interactions with host tissue cells and
cell-matrix interactions with components of the ECM [44]. The subsequent
release of growth factors and cytokines as a result of these interactions can
directly or indirectly stimulate tumour growth and generate signals that
promote tumour cell survival [44]. The ability of tumour cells to adapt
to diﬀerent tissues stems from the remodelling of host tissue ECM involv-
ing the secretion of a variety of proteases (serine-, threonine-, cysteine-,
aspartic-, and metalloproteinases) [44].
1.4 Enabling Hallmarks of Cancer
1.4.1 Tumour-promoting inflammation
The association between cancer and inﬂammation was ﬁrst conceptualised
by Rudolf Virchow in 1863 [47]. He hypothesised that the origin of cancer
was at sites of chronic inﬂammation caused by some classes of irritants
and tissue injuries leading to inﬂammation and subsequently inducing cell
proliferation. Although cell proliferation is not the sole cause of cancer,
an environment rich in growth factors, inﬂammatory cells, and activated
stroma can certainly potentiate and/or promote neoplastic risk [47]. The
link between cancer and inﬂammation is further demonstrated by the use
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of non-steroidal anti-inﬂammatory drugs (NSAIDs) in preventing tumour
formation in people with familial adenomatous polyposis (FAP) [48, 49].
In normal wound-healing, cell proliferation is enhanced concurrently
with tissue regeneration. After removal of the assaulting agent that caused
the injury, inﬂammation and cell proliferation subside. However, cells that
sustain DNA damage and/or mutagenic assault (e.g. cancer cells) continue
to proliferate in microenvironments rich in growth factors and inﬂammatory
cells that support growth. Essentially, tumours can be thought of as wounds
that fail to heal and are able to recruit inﬂammatory immune cells in an
eﬀort to survive [50, 47]. These cells then provide the tumour with growth
factors and access to blood supply and nutrients thereby sustaining growth
[50].
Another scientist by the name of Peyton Rous was the ﬁrst to discover
that tumours can arise from exposure to viral or chemical carcinogens that
induce somatic changes [47]. These states are now termed "initiation"
which comprises irreversible DNA alterations that can persist in otherwise
normal tissue indeﬁnitely until the occurrence of a second type of stimu-
lation called "promotion" [47]. Promotion can result from chronic inﬂam-
mation or factors released at wound sites. Promoters are also known to
directly or indirectly induce cell proliferation, recruit inﬂammatory cells,
increase production of reactive oxygen species leading to oxidative DNA
damage, and reduce DNA repair [47].
Recent studies have shown that reactive oxygen and nitrogen species
(ROS and RNS respectively), NF-κB, Wnt-β catenin signalling, angio-
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genic components, interleukins, interferons, cytokines, and chemokines are
all integral to the connection between inﬂammation and tumour promo-
tion/progression [47, 51, 52, 53, 54, 55, 56].
Figure 1.9: The connection between inﬂammation and cancer.
[56]
1.4.2 Genome instability and mutation
The presence of genome instability contributes to tumour progression.
There are various forms of genomic instability namely chromosomal insta-
bility (CIN) and microsatellite instability (MSI) [57]. CIN refers to the high
rate by which chromosome number and structure changes in cancer cells
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over time compared with normal cells. MSI refers to changes in the number
of repeats in microsatellite sequences compared to the number of repeats
present in DNA when it was inherited and is a consequence of increased fre-
quencies of base-pair mutations [57]. High-throughput sequencing studies
suggest that only a handful of genes are mutated, deleted, and/or ampli-
ﬁed at high frequencies in sporadic cancers [57]. These include: p53, epi-
dermal growth factor receptor (EGFR), RAS, PTEN, and P16INK4A [57].
Genome instability manifests diﬀerently in hereditary and sporadic cancers
(see ﬁg. 1.10) [57, 10, 11]. From a hereditary point of view, mutations in
DNA repair genes like BRCA1, BRCA2, etc. are quite common thus lead-
ing to genomic instability. However, sequencing studies in sporadic cancers
reveal that caretaker genes might not frequently be inactivated in the early
stages of cancer development, instead activation in growth signalling as a
result of mutations in oncogenes or anti-oncogenes appears to be acquired
ﬁrst [57]. The resulting DNA replication stress associated with this acti-
vation can lead to genomic instability and selection for TP53 mutations
that ultimately allow cells to evade death and senescence, which is another
hallmark of cancer [57, 10, 11]. Hereditary and non-hereditary cancers
aside, genomic instability arising from the process of cell division remains
to be one of the major driving of forces of tumourigenesis [58]. Four main
mechanisms are involved in maintaining the integrity of the genome during
cell division: ﬁdelity of DNA replication (S-phase), accurate segregation of
chromosomes (M-phase), precise repair of DNA damage (throughout the
cell cycle), and cell cycle checkpoints [58]. Sustained errors and/or muta-
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tions in components belonging to any of the aforementioned mechanisms
can result in cancer.
Figure 1.10: The hallmarks of cancer relative to the nature of genomic
instability in hereditary and sporadic cancers.
[57]
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1.5 Emerging Hallmarks of Cancer
1.5.1 Reprogramming energy metabolism
Cancer cells need to reprogramme cellular metabolism in order to meet
the demands of sustained growth and proliferation. The idea of altered
metabolism in cancer cells was ﬁrst conceptualised by Otto Warburg in the
early twentieth century [59]. He observed that cancer cells in contrast to
normal cells were able to limit their glucose metabolism for energy genera-
tion largely to the glycolytic pathway without further mitochondrial oxida-
tive phosphorylation which was termed "aerobic glycolysis" [59, 60]. Essen-
tially, cancer cells are able to convert incoming glucose to lactate instead
of metabolising it in mitochondria via oxidative phosphorylation [61]. The
approach seems paradoxical considering that this process produces far less
(18-fold) ATP production per molecule of glucose [60]. One way that cancer
cells are able to overcome this is by upregulating glucose transporters like
GLUT1 to increase glucose transport into the cytoplasm [59, 60, 61]. In-
deed, several studies have shown that cancer cells have signiﬁcantly higher
expression of GLUT proteins than corresponding normal epithelial cells at
both the mRNA and protein levels [62, 63]. Many pathways and transcrip-
tional eﬀectors have been implicated in upregulating glucose and glutamine
transporters, namely: Hypoxia-inducible factor 1(HIF1), Myc, p53, Phos-
phoinositide 3-kinase (PI3K) pathway etc. [60, 64, 65]. Arguably one of the
most important aspects of cancer metabolism is the role of reactive oxy-
gen species (ROS) in modulating metabolic signalling pathways [66]. ROS
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increase cell proliferation and survival via post-translational modiﬁcation
of kinases and phosphatases at low levels [60]. At moderate levels, ROS
induce expression of stress-responsive genes like HIF1α, which in turn can
trigger expression of proteins such as glucose transporters (GLUT1) and
VEGF that promote survival. However, when ROS levels are at their high-
est, damage to macromolecules such as DNA induces activation of protein
kinase Cδ leading to senescence and/or apoptosis [67].
Figure 1.11: The various hallmarks of cancer and their eﬀects on
metabolism or how they can be modulated by metabolic changes.
[61]
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1.5.2 Evading immune destruction
The role of the immune system in resisting or eradicating formation and
progression of tumours remains an unresolved and intensely researched is-
sue [10, 11]. The immune system holds the greatest potential for cancer
treatment with no toxicity to normal tissue in addition to long-term mem-
ory to prevent recurrent cancers [68]. There is increasing evidence sup-
porting the idea of immunosurveillance whereby tumours are recognised
by the immune system via tumour-speciﬁc antigens [11, 68]. For instance,
promising antitumoural immune responses were observed in patients with
colon and ovarian tumours that were inﬁltrated with cytotoxic T lympho-
cytes (CTLs) and natural killer (NK) cells [69]. Studies have also found
that immunocompromised mice are more susceptible to cancer than those
with competent immune systems [10, 11]. Figure 1.12 illustrates how the
immune system targets cancer cells [70].
Studies have shown that the tumour microenvironment can inhibit im-
mune responses by upregulating inhibitory and immunosuppressive molecules
such as programmed-cell death ligand 1 (PDL1) and TGF-β [11, 71]. Tu-
mours can also recruit inﬂammatory cells such as regulatory T cells (Tregs)
and myeloid-derived suppressor cells (MDSCs) that are actively immuno-
suppressive [72, 73]. The concept of antitumour immunity is yet to be
strongly recognised as a hallmark of cancer, but is potentially a promising
target for new anticancer therapies.
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Figure 1.12: The cancer immunity cycle illustrating the ability of the im-
mune system to target cancer cells selectively.
[70]
1.6 Treatment of Cancer
The main modes of cancer treatment include surgery, radiotherapy, and
chemotherapy. Other types of treatments such as hormone therapy and
bone marrow, stem cell transplants, and immune therapy are also em-
ployed. These treatments may be used in combination depending on stage,
grade, and location of the tumour. Radiation and surgery are mostly lim-
ited to solid tumours (local or local-regional disease). Chemotherapy on
the other hand is intended to treat systemic disease. Early diagnosis and
developments in such therapies have dramatically increased cancer survival
rates with an estimated two-thirds of cases that will eventually be cured;
however, striking diﬀerences among tumours still pose a challenge to treat-
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ment [74].
1.6.1 Surgery
Surgery is the oldest modality of cancer treatment and remains the most
eﬀective treatment of localised primary tumours and associated regional
lymphatic disease. More patients are cured by surgery when it is used as
a single treatment in comparison with any other individual form of can-
cer therapy [75]. This may be attributed to the fact that surgery oper-
ates by zero-order kinetics, in which 100% of excised cells are killed as
opposed to radiotherapy and chemotherapy which operate by ﬁrst-order
kinetics where only a fraction of cells are killed by each treatment [74, 75].
During the past two decades, major strides in both operative techniques
and combined modality therapy have signiﬁcantly decreased morbidity and
mortality rates associated with surgical resection of solid neoplasms [74].
Surgery is now increasingly being used in speciﬁc clinical situations such
as treating colorectal-liver metastases [74]. Complete surgical resection of
metastases when selected with standard clinical criteria have yielded 30-
40% 5-year survival rates, however, this therapeutic option is limited to
conﬁned metastases which only represent 10-15% of cases [76, 77].
1.6.2 Radiotherapy
Radiation therapy employs the use of high-energy radiation such as X-rays,
gamma rays, and charged particles to shrink tumours and kill cancer cells.
Like surgery, it is usually used for localised tumours conﬁned to a speciﬁc
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region [78]. Approximately 45% of new cancer cases will receive radiother-
apy with this proportion increasing over the next few years [79]. Radiation
therapy kills cancer cells by either damaging DNA directly or creating free
radicals within cells that in turn damage DNA [78]. Radiation also aﬀects
normal tissue, but the premise behind it is that it usually kills cells that
are actively dividing and does not work very quickly on cells that divide
more slowly. Furthermore, normal cells have the added advantage of having
uncompromised DNA repair mechanisms (e.g.p53), whereas components of
these mechanisms are dysfunctional in many tumours. p53 for instance, is
mutated in most cancers which inhibits both DNA repair and apoptosis.
Indeed, research has shown that there is very little apoptosis that occurs in
mutant p53 cell lines after exposure to radiation suggesting that p53 may
be closely linked with radiosensitivity [80, 81, 82].
1.6.3 Chemotherapy
Chemotherapy utilises chemical agents to kill or control the growth of can-
cer cells. These chemical agents are natural products, natural product-
derived or inspired (semi-synthetic), or purely synthetic. The ﬁrst major
stride in chemotherapy emerged from an accidental spill of sulfur mustards
on troops from a bombed ship in the second world war and experience
from the ﬁrst world war [83]. This led to the observation that the men ex-
posed to these gases had markedly depleted bone marrow and lymph nodes.
Subsequently, an initial study utilising nitrogen mustard on lymphoma pa-
tients was carried out in 1943 and results showed marked regression [83].
25
Unfortunately, the regression observed in these studies was short-lived and
incomplete. However, the failure stimulated the development of a new
class of compounds known as antifolates which included aminopterin and
amethopterin, now known as methotrexate. These compounds were tested
in children with leukaemia in 1948 and showed unquestionable remissions
[84]. The use of nitrogen mustard and methotrexate in treating cancer
spurred an arduous search and development of novel anticancer agents that
virtually propelled the ﬁeld of cancer drug discovery into the industry it
has become today. The following table is an adaptation from Goodman
and Gilman (2005) and illustrates the current classiﬁcation system of an-
ticancer agents available today [85]. However, it is worthy of note that
this classiﬁcation scheme is not rigid as many of these agents may fall into
more than one category. For instance, some compounds like mitomycins
are natural products and alkylating agents as well.
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Table 1.1: Classiﬁcation of anticancer agents currently used in clinics.
1.6.3.1 Alkylating agents
Alkylating agents are the earliest classes of drugs used to treat cancer. Ni-
trogen mustards are in fact alkylating agents whose mode of action is to
inﬂict cytotoxic DNA damage in addition to collateral mutagenic damage
[86]. These agents are strong electrophilic compounds that attach to the
alkyl group located at the N7 position of the guanine base in DNA [87]. The
end eﬀect of these agents is to inhibit DNA replication. Most alkylating
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agents are bifunctional, containing two groups capable of interacting with
DNA [88]. Hence, they are able to form bridges between a single strand
or two separate strands of DNA, which interfere with enzymes involved
in DNA replication ultimately leading to growth inhibition or apoptosis
[88]. G2/M arrests are quite commonly observed with most of the damage
occurring in the S-phase of the cell cycle as cells are unable to remove dam-
aged fragments. Unfortunately, these agents do not discriminate between
normal and tumour cell DNA, but are still used to exploit the fact that
cancer cells divide rapidly and are more susceptible to DNA damage as
their repair mechanisms are already compromised.
1.6.3.2 Anti-metabolite agents
Anti-metabolites share a long history with alkylating agents as these com-
pounds were also among the ﬁrst to be used in treating cancer. They are
analogues of essential metabolites required for DNA synthesis [89]. They
target DNA by either inhibiting its synthesis or production of its precur-
sors i.e. nucleotides [89]. Their eﬀects are usually marked by a G1 or
S-phase arrest in the cell cycle [88]. As seen in Table.1.1, antimetabo-
lites are classiﬁed under three subcategories: folate (e.g. methotrexate),
pyrimidine (e.g. ﬂuorouracil), and purine (e.g. pentostatin) analogues. Fo-
late analogues speciﬁcally target dihydrofolate reductase (DHFR) and/or
thymidylate synthase (pemetrexed). Both these enzymes are required for
metabolism of folic acid, a vitamin with an important role in nucleic acid
metabolism. Pyrimidine analogues like ﬂuorouracil, on the other hand, po-
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tently inhibit thymidylate synthase and therefore inhibit thymidine synthe-
sis [89, 90]. Pentostatin, a purine analogue, inhibits adenosine deaminase,
an enzyme involved in the metabolism of adenosine [91]. Resistance to an-
timetabolites has also been observed in the clinic [92]. Various mechanisms
of resistance to antimetabolites have been identiﬁed and include mutations
in metabolic enzymes, altered drug transport, nucleobase salvage pathways,
DNA-damage and cell cycle control pathways [92].
1.6.3.3 Hormones
Hormonal therapeutics plays an important role in the treatment of breast,
prostate, ovarian, and kidney cancer [85]. Cancers originating from hormone-
producing glands use hormones to grow, hence utilising hormone therapy
to block the eﬀects of such hormones or even stop them from being pro-
duced is an eﬀective way to treat these cancers. This kind of treatment
is prescribed for patients who have tumours that are hormone sensitive
or dependent. Hormonal cancer chemotherapy primarily employs the use
of anti-oestrogen therapeutics (e.g. tamoxifen), aromatase inhibitors (e.g.
anastrozole), anti-androgenic therapeutics (e.g. ﬂutamide), and corticos-
teroids (e.g. prednisone) [85]. Tamoxifen and ﬂutamide are antagonists
of the oestrogen and androgen receptors respectively. Anastrozole inhibits
aromatase causing oestrogen deprivation [85, 93].
1.6.3.4 Targeted agents
Most cytotoxic chemotherapeutic drugs were developed and administered
to cancer patients at a time when limited knowledge of molecular mecha-
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nisms underlying cancer was available. With advancements in technology,
researchers have now begun to unearth distinct molecular mechanisms un-
derpinning this group of diseases. Douglas Hanahan and Robert Weinberg’s
assessment detailing the hallmarks of cancer is a testament to the progress
made over decades worth of research [10, 11]. These achievements in un-
derstanding the molecular basis of cancer have led to a revolution in cancer
chemotherapeutics where the development of rationally and molecularly
targeted drugs is considered more desirable than generic intravenous cyto-
toxic chemotherapy [94]. Targeted therapy exploits the diﬀerences between
cancer cells and normal cells with high potency and reduced toxicity (side
eﬀects) compared to conventional chemotherapy. However, because tar-
geted therapies are aimed at speciﬁc molecules that interfere with cancer
cell proliferation, resistance can be observed if mutations occur in the tar-
get resulting in weak interactions that can reduce the eﬃcacy of the agent.
This is why targeted therapy is commonly used in conjunction with more
traditional chemotherapy drugs.
The concept of ’the druggable genome’ is the foundational basis for
rational and targeted drug design and is currently an intense area of re-
search. The druggable genome comprises a subset of the 21,000 genes in
the human genome that express proteins able to bind drug-like molecules
(see ﬁg.1.13) [95]. Most drugs that are available today mainly target can-
cer signalling pathways especially those triggered by tyrosine kinases and
G protein-coupled receptors [96].
In 2002, only about 120 proteins were reportedly targeted by drugs
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Figure 1.13: The "druggable" genome in target-directed drug discovery.
[95]
marketed at the time with a large number of druggable gene families still
underexploited [95]. With vast improvements in high-throughput screening
technologies in the future, chemical leads will be available for most poten-
tially druggable targets, the challenge then would be to discover and assess
the therapeutic utility of leads and targets [95]. However, current eﬀorts
in targeted cancer chemotherapy have focused on protein kinase (PK) in-
hibitors and monoclonal antibodies as they have undoubtedly been front
runners in this ﬁeld over the past two decades.
Targeting protein kinases
As seen in ﬁg.1.13, PKs occupy the largest portion of the druggable genome.
To date, they are the most actively pursued drug targets with 30 distinct
kinase targets being developed to the level of a phase 1 clinical trial [97].
PKs are enzymes that catalyse transfer of phosphate to their substrates [98].
Even though PKs account for only 2% of the genome, they are responsible
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for phosphorylating at least 30% of all cellular proteins [98]. Phosphoryla-
tion plays crucial roles in controlling a wide range of cellular processes that
include cell division, metabolism, survival, and apoptosis [99]. Deregulation
of PKs contributes to the development of many diseases such as cancer. For
instance, constitutive activation of PKs has been found in many cancers
such as chronic myelogenous leukaemia (CML), gastrointestinal stromal tu-
mours (GIST), and various other sarcomas and carcinomas [98, 99]. The
increasing body of evidence illustrating the importance of phosphorylation
in cellular function in cancer has made this family of proteins desirable
targets for drug design. Some of the major approaches in modulating ki-
nase activity include: inhibiting phosphorylation activity by blocking ATP
binding, disrupting protein-protein interactions, and downregulating kinase
gene expression via interference RNA (RNAi) [96]. The following brieﬂy
outlines some of the major kinase inhibitors used in the clinic today.
One of the most successful tyrosine kinase inhibitor molecules devel-
oped to date is Imatinib. It is used to treat CML and GIST. It works by
inhibiting elevated kinase activities of oncogenic proteins bcr-abl and c-kit
that are inherently overexpressed in these cancers [100]. The bcr-abl fusion
protein is a result of reciprocal translocation between chromosome 9 and
22, which was seen in 95% of CML patients [101]; i.e. part of the bcr gene
from chromosome 22 is fused with part of the abl gene on chromosome
9. The product of this fusion is a mutant tyrosine kinase protein bcr-abl.
Normal functioning tyrosine kinases require activation by other cellular
messaging proteins before initiating cell division, however, the fused bcr-
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abl protein is constitutively active and consequently stimulates a number
of cell cycle proteins and enzymes resulting in rapid and sustained cell
proliferation [102]. Imatinib speciﬁcally binds to the ATP binding site of
bcr-abl thus competitively inhibiting enzyme activity of the protein and
hindering proliferative signals [102]. Unfortunately, drug resistance was
observed in patients treated with Imatinib over time and this was due
to a number of reasons that include: drug eﬄux, mutations in the ATP
binding pocket, and drug metabolism etc. [103]. In response to observed
resistance, newer agents such as Nilotinib and Desatinib were developed to
treat Imatinib-resistant tumours [104]. A main mechanism of resistance to
the old generation of tyrosine kinase inhibitors (TKIs) that emerged was
the expression of drug eﬄux pumps. Fig. 1.14 illustrates a new generation
of small-molecule TKIs that modify and overcome problems caused by drug
eﬄux transporters resulting in an increased intracellular accumulation of
anticancer drugs.
Figure 1.14: Eﬄux transporter modiﬁcations by small-molecule tyrosine
kinase molecules and their targets
[105]
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Receptor tyrosine kinase inhibitors targeting epidermal growth factor
receptors (EGFR) have also seen major successes in the clinic.
EGFR is a cell-surface receptor that plays a vital role in cell prolifer-
ation, survival, and diﬀerentiation [106]. Mutations in EGFR can result
in overexpression and ligand-independent activation as is the case in some
cancers, speciﬁcally non-small cell lung cancer (NSCLC) which is preva-
lent in 85-90% of all lung cancers. It is estimated that more than 60%
of all NSCLCs show EGFR overexpression [107]. Increased EGFR sig-
nalling promotes tumour growth through activation of pathways crucial to
invasion, angiogenesis, metastasis, and inhibition of cell death. Drugs like
Geﬁtinib and Erlotinib are competitive inhibitors of the intracellular tyro-
sine kinase domain of EGFR preventing ATP from binding and inhibiting
receptor auto-phosphorylation [108]. This leads to blocking of downstream
pathways that promote tumour progression.
Multi-targeted receptor tyrosine kinases as chemotherapeutic agents
have also been explored in the treatment of cancer. One such example is
Sunitinib, which is approved for treating renal cell carcinoma and imatinib-
resistant GIST. In vitro, sunitinib has been shown to inhibit angiogenesis
and growth of cell lines driven by VEGF, stem-cell factors (SCF), and
platelet-derived growth factors (PDGF) [109].
Monoclonal antibodies such as Erbitux and Herceptin target the extra-
cellular domain of the EGFR receptor preventing the normal ligand from
binding. This in turn blocks activation of downstream pathways that pro-
mote tumour growth and survival [108]. Erbitux is used in the treatment
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of squamous cell carcinoma and head/neck cancers [110]. Herceptin was
developed as a HER2 (member of the EGFR family) blocker in the treat-
ment of a subset of aggressive breast cancers that comprise 30% of cases
[111]. Overexpression of this receptor has been linked to cell proliferation,
cell cycle perturbation, and suppression of apoptosis due to increased ac-
tivation of mitogen-activated protein kinase (MAPK) and PI3K pathways
[108].
Targeting cyclin-dependent kinases
Cyclin-dependent kinases are important molecular targets that represent
a major area of research involving development of potentially active CDK
inhibitors. CDKs play vital roles in cell growth and division as well as
protein transcription [112]. However, CDK/Cyclins are dysregulated in
several cancers resulting in uncontrolled cell proliferation. Hyperactivation
of CDKs has also been reported to confer selective growth advantage to
cancer cells [112]. There have been 20 CDKs and 29 cyclins identiﬁed
to date making this family of proteins highly sought after as potential
chemotherapeutic targets [113].
In February, 2015, the US food and drug administration (FDA) ap-
proved the ﬁrst groundbreaking cyclin-dependent kinase (CDK) inhibitor,
palbociclib, for the treatment of ER+/HER2- breast cancer. It selectively
targets CDK 4,6 and causes G1 arrest in ER+ breast cancer cell lines
[114]. Clinical trials demonstrated that the drug improved progression free
survival in patients to 20 months when used in combination with letrozole
(aromatase inhibitor for treatment of hormonally-dependent breast cancer)
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compared to only 10 months with letrozole treatment alone [115].
Despite this breakthrough, CDK inhibitors have faced disappointing
results in clinical trials. This can be attributed to three reasons in particu-
lar: ﬁrstly, there is a lack of understanding as to which CDKs are actually
being inhibited in vivo contributing to multiple therapeutic eﬀects [114].
Secondly, there has been a lack of stratiﬁed patient cohorts concerning
CDK inhibitors with low speciﬁcity. Palbociclib is a perfect example of
how stratifying patient cohorts can improve on currently used chemother-
apeutics. Lastly, there is a lack of a therapeutic window as many of these
CDKs inherently target several other proteins that are critical to survival
and proliferation of normal cells, making it hard to diﬀerentiate between
healthy and cancerous tissue [114]. However, the approval of palbociclib is
encouraging as it provides key insights into designing next-generation CDK
inhibitors and how they can be used in the clinic.
The future of targeted therapeutics lies in the success and eﬃciency
of stratiﬁed medicine. This ﬁeld of treatment primarily identiﬁes patient
cohorts that are likely to respond to a particular treatment due in part to
the genetic makeup of their disease. It is precisely for this reason that there
is a need to incorporate predictive and pharmacodynamic biomarkers in
drug development as they can be used as powerful tools to guide treatment
strategies [116].
Other molecular targets of interest
Research continues to reveal several other molecular targets that are over-
expressed in various cancers and are currently under investigation: heat
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shock protein 90 (HSP90), matrix metalloproteinases, cyclooxygenase 2
(COX2), the proteasome, histone deactylases, aurora kinases, polo-like ki-
nases and telomerase among others. Agents targeting these molecules are
being designed and are at various stages of clinical development with some
approved as drugs for certain forms of cancers [117].
1.6.3.5 Natural Product Drug Discovery
Compounds that possess biological activities and derived from natural re-
sources such as plants, animals, and microorganisms, are deﬁned as natural
products [118]. The use of natural products in cancer has been prevalent
for the past 30 years and continues to serve as the basis for many of the lead
structures that are used as templates for synthesising novel compounds with
enhanced biological properties [119]. However, large pharmaceutical com-
panies have de-emphasised natural products in drug discovery programmes
due to a lack of reproducibility of extracts, inaccessibility of collection sites,
laborious procedures to isolate and purify bioactive chemical compounds
that often lead to very low yields, and rediscovery of compounds [120]. The
emergence of targeted therapies further steered pharmaceutical companies
away from natural product drug discovery. The development of natural
products is often erratic as it heavily relies on the skill of pharmacologists
to elucidate the mechanism of action and clinicians to identify optimal indi-
cation in the clinic [121]. This is in contrast to targeted therapeutics, which
are designed for a speciﬁc target and/or type of cancer. One advantage that
natural products may have over synthetic compounds is the fact that they
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are natural metabolites: successful molecules that are clinically active have
been suggested to possess properties akin to "metabolite likeness", mean-
ing that natural products are not only biologically active, but are likely
to be substrates for transporter systems involved in delivering compounds
to their intracellular site of action [122]. Furthermore, natural products
have had millenia of evolutionary time to optimise structure-activity and
are often potent and able to resist metabolic deactivation.
While certain tumours with speciﬁc oncongenic addictions have bene-
ﬁted from targeted therapeutics, it is clear that a vast majority of tumours
are not dependent on single "targetable" oncogenic activations. For in-
stance, EGFR mutations account for less than 10-15% of lung adenocarci-
nomas and using EGFR-targeted therapy would primarily be beneﬁcial to
this cohort of patients [121, 123]. In these tumours, chemotherapy remains
to be a cornerstone of treatment and this is where natural products come
to the fore. From the 1940s up until 2008, approximately 175 anticancer
drugs were developed and are commercially available in the United States,
Europe, and Japan; 65% of these were inspired from natural products,
i.e. pure natural products (14% of total), semisynthetic natural products,
mimics, or synthetic molecules with pharmacophores from natural prod-
ucts [124]. These numbers are a testimony to the role of natural products
in cancer chemotherapy. With the approval of rapamycin in 2007, 12 new
natural products have been brought to the market and are illustrated in
table 1.2 [121].
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Table 1.2: Novel anticancer medicines based on natural products
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[121]
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Furthermore, from the 250,000-300,000 plants around the world, only
10% have been systematically investigated for the presence of bioactive
phytochemicals [125]. These numbers are a gross underestimation of the
diversity of natural products present therein, as crude extracts from a single
plant may yield more than 700 compounds [126]. Traditionally, bioassays
were used to screen concentrated extract samples containing complicated
mixtures in a process known as bioassay-guided fractionation. This is a
common procedure for studying crude extracts where fractions are screened
for biological activity and if found to be active, are then further isolated
and puriﬁed [127]. Advances in high-throughput screening (HTS) technol-
ogy have greatly improved pre-fractionation strategies that are capable of
simplifying extracts by removing artefacts such as polyphenolic tannins,
thus making them more suitable for use in bioassays [122]. The use of
high-throughput antiproliferative screening has become an invaluable tool
in modern day drug discovery. The US NCI is widely considered to be a
pioneer in initiating drug screening programmes that have helped in iden-
tifying potential candidates for clinical evaluation. The development of the
NCI 60 human tumour cell line anticancer drug screen in the late 1980s was
a ﬁrst step towards narrowing the myriad of compounds being developed
at the time. The programme was initially intended to supplant the use of
transplantable animal tumours in anticancer drug screening [128]. Detailed
mechanistic studies are then carried out in sensitive cancer lines and are
used as potential models for future in vivo eﬃcacy and toxicity studies.
The following sections provide a brief overview of classical examples
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of natural products that play an important role in cancer chemotherapy
today:
Antibiotics
Actinomycin was the ﬁrst natural product approved for cancer treatment in
1964. It was isolated from a culture broth of a species of Streptomyces where
a series of actinomycins were discovered. Actinomycins generally work by
binding to DNA and inhibiting transcription by RNA polymerase. More
speciﬁcally, they intercalate between adjacent pairs of guanine-cytosine
base pairs of DNA, while their polypeptide chains extend along the mi-
nor groove of the DNA helix [85]. Actinomycin D is currently used to treat
solid tumours in children and choriocarcinoma [129].
Perhaps the most important class of antibiotics used in the clinic are
anthracyclines. They are derived from a bacterium called Streptococcus
peucetius var. caesius. This class of antibiotics comprises of daunoru-
bicin, doxorubicin, epirubicin, and idarubicin. Idarubicin and epirubicin
are analogues of the naturally produced anthracyclines [85]. Daunorubicin
and idarubicin have primarily been used to treat acute leukaemias, while
doxorubicin and epirubicin have been approved for treatment of solid tu-
mours. These agents however, do have the potential to generate fee radicals
that cause cardiotoxicity when used in high doses. Much like the actino-
mycins, anthracyclines intercalate with DNA directly aﬀecting transcrip-
tion and replication. Anthracyclines are able to form a tripartite complex
with topoisomerase II and DNA, which hinders relaxing of super-coiled
DNA and re-ligation of broken DNA strands ultimately leading to apopto-
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sis [85]. As mentioned earlier, these agents are able to generate free radicals
in solution and do so in both normal and malignant tissues [130]. These
radicals attack DNA by oxidising DNA bases leading to strand breaks and
apoptosis. Overexpression of DNA strand break repair mechanisms, drug
eﬄux transporters like Pgp), and glutathione peroxidase prevent oxidative
damage to the cell [85].
Camptothecins
Camptothecin was a well-known natural compound that had remarkable
anticancer properties, but had to be dropped in preliminary clinical trials
due to severe bladder toxicity [119]. Chemical manipulation of the com-
pound lead to the synthesis of two new analogues named topotecan and
irinotecan, which are both approved for colorectal, ovarian, and small cell
lung cancer. Their mechanism of action involves the inhibition of topoi-
somerase I, an enzyme intimately involved in DNA unwinding, transcrip-
tion, and replication [119]. Camptothecins bind to and stablise the DNA-
topoisomerase I cleavable complex aﬀecting religation which results in an
accumulation of DNA single strand breaks [85]. These breaks alone are
not lethal to the cell, however, collision of a DNA replication fork with
the cleaved position can lead to DNA double strand breaks and apoptosis
[85]. At a cellular level, camptothecins target the S-phase of the cell cy-
cle as ongoing DNA synthesis is necessary for cytotoxicity. Experimental
models in mammalian cell cultures elude to three mechanisms of camp-
tothecin resistance: (i) reduced cellular accumulation of drugs caused by
drug eﬄux transporters belonging to the ATP-binding cassette (ABCB1)
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family which include Pgp and multidrug resistance proteins (MRPs) [131]
(ii) alteration of the structure and expression of topoisomerase I. Interest-
ingly, this is the ﬁrst example of self-resistance to endogenous toxic com-
pounds exploited by plants [131] (iii) modiﬁcations in cellular response to
camptothecin-DNA-ternary complex that include activation of downstream
DNA damage checkpoint, repair, and apoptotic cell death pathways [131].
Epipodophyllotoxins
The American Indians were among the ﬁrst to treat skin cancers with ex-
tracts originating from the roots of mayapple, Podyphyllum peltatum [119].
Currently, podophyllin derivatives such as etoposide and teniposide are
used to treat various cancers such as paediatric leukaemia, small cell car-
cinomas of the lung, testicular tumours, Hodgkin’s disease, and large cell
lymphomas [132, 85]. Both these compounds have been shown to exert
cytotoxicity by causing DNA strand breaks as a result of being perma-
nently bound to DNA topoisomerase II in the G2 phase of the cell cycle
[133]. Interestingly, podophyllotoxin itself binds to microtubules and in-
hibits tubulin polymerisation unlike its two analogues [134]. However, like
the anthracyclines, etoposide and tenoposide form a ternary complex with
topoisomerase II and DNA preventing religation of a strand break which
normally follows topoisomerase binding to DNA [85]. Drug eﬄux via up-
regualtion of Pgp, mutations in topoisomerase II, and/or p53 mutations
have all been reported in resistant cells [85].
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Antimitotics: Taxanes and the Vinca Alkaloids
Paclitaxel (Taxol) is arguably one of the most successful microtubule dis-
rupting agents to date. It is widely considered to be the highest grossing
anticancer agent ever produced and is currently approved to treat ovarian,
breast, NSCLC, and head and neck cancers [85]. It was ﬁrst isolated in the
mid 1960s as part of an initiative carried out by a U.S. national institute
screening programme. The compound was isolated from the bark of Taxus
brevifolia (northwest Paciﬁc Yew Tree). It was later discovered that taxol
was actually produced by a fungal endophyte that was isolated from the
Paciﬁc Yew Tree [135]. After its puriﬁcation and isolation from biologi-
cally active crude extracts, paclitaxel was conﬁrmed to have potent antitu-
mour activity against a mouse melanoma B16 model [136]. A more potent
semisynthetic form of paclitaxel called docetaxel was approved by the FDA
in the mid 1990s [137]. Paclitaxel and docetaxel bind to β-tubulin subunits
and stabilise microtubules (MTs) thus preventing disassembly [136, 135].
Its mechanism of action contrasts with that of another microtubule target-
ing family of compounds called the vinca alkaloids.
The vinca alkaloids were isolated from the plant Catharanthus roseus
in 1958, but extracts were generally used as a hypoglycaemic agent in
many parts of Asia prior to its isolation. Vincristine and vinblastine have
since been used to treat many cancers successfully, speciﬁcally childhood
leukaemia, testicular teratoma, and Hodgkin’s disease among many other
cancers [119, 138]. Unlike taxol, the vinca alkloids act by binding to tubulin
dimers (α-β tubulin) thus inhibiting the assembly of microtubules (MTs)
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[139]. However, cancers have developed an eﬀective way of dealing with
antimitotics by overexpressing drug eﬄux pumps such as Pgp which is
encoded by the MDR1 gene [140]. Other compounds such as colchicine
and eribulin also inhibit tubulin polymerisation and bind to diﬀerent sites
on MTs [141].
Tubulin-binding agents (TBAs) have certainly withstood the test of
time and continue to be used actively in modern day combinatorial chemother-
apy. Given the rapid progression of cancer cells through mitosis, the degree
to which they are rendered sensitive to TBAs remains an intensive area of
research. One such area that needs to be addressed is the "proliferation rate
paradox" in antimitotic chemotherapy [142]. The fact that these cytotoxic
drugs are able to kill any dividing cell while promoting tumour regression
even in slow growing tumours is indeed "paradoxical" in nature [142, 143].
However, drawing upon the successes of TBAs in comparison to relatively
unsuccessful mitosis-speciﬁc agents, there is evidence that TBAs not only
interfere with mitosis, but disrupt essential interphase cellular mechanisms
cascading to subsequent phases as well [143]. An additional characteristic
of most TBAs is that they are able to inhibit cancer cell proliferation with-
out causing extensive stabilisation or depolymerisation of the MT network
whilst suppressing MT dynamic instability and simultaneously maintaining
tubulin polymer mass [144]. Increasing evidence suggests that these agents
may exert their eﬀect by inhibiting spindle dynamics resulting in slowing
down of metaphase-anaphase transitions, aberrant chromosomal segrega-
tion, followed by subsequent induction of mitochondrial-mediated apopto-
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sis [144]. Like other classes of anticancer agents, TBAs are not immune
to resistance that stem from alterations of the tubulin/MT binding system
which include tubulin isotype expression, posttranslational modiﬁcations of
tubulin, acquisition of tubulin mutations, and changes in expression levels
of MT-related proteins [144]. Alterations in actin and tubulin cytoskele-
tons have also been implicated in resistance to TBAs using proteomics that
show overlap in protein expression between these two entities [144]. Re-
cent studies have identiﬁed γ-actin as playing a major role in resistance
to TBAs. Distinct mutations in γ-actin were found in TBA-resistant cell
lines [145]. Exogenous expression of mutant and/or silencing of γ-actin
expression induced signiﬁcant resistance to TBAs [145].
The quest for better targeted therapeutics are a mainstay for the future
of cancer chemotherapy, however nature has undeniably played and will
continue to play a pivotal role in humanity’s ﬁght against cancer.
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1.7 Aims and Objectives
The principle aim of this investigation is to investigate antitumour activity
and elucidate the mechanism(s) of action of a naturally isolated indole alka-
loid called jerantinine A (JA). JA belongs to a family of compounds isolated
from the leaf ethanolic extract of the Malayan Tabernaemontana Corym-
bosa. Very little was known about the compound upon commencement
of this study. Previous literature demonstrated JA’s potent antitumour
activity against a nasopharyngeal carcinoma cell line (KB) and vincristine-
resistant (V-R) KB cells [146]. However, activity against a broader spec-
trum of human carcinoma cell lines derived from distinct organ sites had
not been investigated. Therefore, assays to determine growth inhibitory
and cytotoxic activity of JA in two colorectal (HCT-116 and HT-29), two
breast (MCF-7 and MDA468), and one lung (A549) cancer cell lines were
conducted. In addition, the mechanism(s) of action underlying JA’s activ-
ity against KB cells remained unknown. In order to identify mechanisms
of action and putative molecular targets of JA within the cell, a number
of functional assays measuring aspects cell viability, sensitivity, and cell
cycle disruption were undertaken. An additional goal of the study was to
successfully generate vincristine- and JA-resistant HCT-116 cell lines to
examine cross-resistance. Determination of mechanisms of resistance can
often help elucidation of mechanisms of action. In addition, drug eﬄux
pumps contribute to the resistance of many chemotherapeutic agents. It
is therefore necessary to assess how JA bypasses vincristine-resistance as
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previously reported by Lim et al. (2008) [146]. Investigating processes
underlying cell death in response to the agent is also a crucial part of the
study, thus eﬀorts to discover the mechanism(s) of action of this excit-
ing new compound included interrogation of signal transduction pathways
and protein perturbation in cells following exposure to JA and adopting
proteomic and genomic techniques such as Multidimensional Protein Iden-
tiﬁcation Technology (MudPIT) and genome-wide RNAi screens followed
by Western blots and shRNA knockdown studies for data validation.
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Chapter 2
Antiproliferative Screening of
Jerantinine A
2.1 Introduction
It is widely reported that plants of the genus Tabernaemontana comprises
at least 110 species that have a widespread distribution in pantropical re-
gions that are rich in alkaloids [146]. The IUCN has placed Tabernaemon-
tana corymbosa in the red list of endangered species and is therefore a
priority for compound characterisation. Lim et al. (2008) isolated seven
new alkaloids from a leaf ethanolic extract of the Malayan Tabernaemon-
tana corymbosa Roxb. ex Wall. (see ﬁg. 2.1) [146]. JA was among the
seven and it constituted the major alkaloid of the leaf extract. Figure 2.2
below illustrates the chemical structures of these alkaloids in addition to
acetate derivatives. The acetate derivatives possess greater stability than
the parent compounds. Furthermore, converting the 10-OH group to 10-
OCOCH3, reduces the overall polarity of the alkaloids enhancing lipophilic-
ity and diﬀusion across the cell membrane which is hydrophobic in nature.
This could mean a higher concentration of the alkaloids can be achieved
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within treated cells to act on the target(s), leading to slightly increased
potency as demonstrated in a preliminary cytotoxicity screen conducted
by Lim et al. (2008) [146]. Esteriﬁcation is indeed very common among
prodrugs used as it is estimated that approximately 49% of all marketed
drugs are activated by enzymatic hydrolysis [147].
Figure 2.1: Jerantinine A is isolated from the leaf of Tabernaemontana
corymbosa which belongs to the Apocynaceae family.
[146]
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Figure 2.2: Jerantinine family of compounds isolated from the Malayan
Tabernaemontana corymbosa.
Jerantinine A (1), Jerantinine B (2), Jerantinine C (3), Jerantinine D (4),
Jerantinine E (5), Jerantinine F (6), Jerantinine G (7), Jerantinine A
acetate (8), Jerantinine B acetate (9), 10-O-methyljerantinine A (10),
10-O-methyljerantinine B (11) [146].
Based on previous literature, JA was shown to have antiproliferative ac-
tivity against only one cell line, hence it was important to screen the com-
pound against several other cell lines at various concentrations [146]. We
used the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay to examine antitumour activity (refer to 6.2.3). MTT is a
yellow water soluble tetrazolium-based dye that can be metabolised by mi-
tochondrial dehydrogenases of viable cells to form insoluble purple crystal
formazan, the concentration of which is directly proportional to the num-
ber of viable cells. The concentration of the test agent that inhibits the
growth of cells by 50% (GI50) is then derived from dose-response curves and
52
subsequently used to guide treatments in further experiments conducted
throughout the study. In addition to measuring growth inhibition, cell sen-
sitivity using the clonogenic assay was adopted to determine whether single
cells are able to survive challenge and form colonies after a brief exposure
to the test agent.
Markers of apoptosis using ﬂow cytometry and Western blots were also
investigated in order to conﬁrm the nature of apoptosis in cells. This phase
of the study serves to provide a thorough understanding of the antiprolif-
erative proﬁle of JA.
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2.2 Results and Discussion
2.2.1 Jerantinine A, jerantinine B, and acetate deriva-
tives potently inhibit growth of cancer cells
The growth inhibitory properties of jerantinine A, B, and their acetate
derivatives against HCT-116, HT-29, MCF-7, MDA-468, and A549 were
initially investigated using the MTT assay as discussed previously. The
MTT assay was preferred over other cytotoxicity assays such as the sul-
forhodamine B assay and trypan blue staining primarily because of its ca-
pabilities to generate consistently reproducible data quickly and eﬃciently,
which allows for testing of compounds on several cell lines simultaneously.
All cell lines displayed sensitivity to JA; GI50 values of ≤ 4 µM were
consistently obtained (table.2.1, see ﬁg. 2.3). JA most potently inhibited
the growth of breast (MCF-7 and MDA-468) and HCT-116 colon cancer
cells with GI50 values of <1 µM. A549 lung and HT-29 colon cancer cells
were less sensitive to JA with GI50 values of 3.74 and 2.52 µM respectively.
JA was also screened against MRC-5 (normal lung ﬁbroblasts) which ex-
hibited sensitivity with a GI50 value of 1.72 µM. GI50 values of <1 µM were
observed for jerantinine B (JB) in all cell lines. JB diﬀers from JA by re-
placement of the double bond in the piperidine ring in JA with an epoxide
function in JB (see ﬁg. 2.2). The acetate derivatives of jerantinines A and
B (JAA and JBA respectively) were slightly more potent in most of the
cell lines tested compared to parent compounds, which is consistent with
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the idea that the acetate derivatives may be more permeable across the
cell membrane. JBA revealed GI50 values <1 µM in all carcinoma cell lines
examined. JAA and JBA showed the greatest potency enhancement (>4-
fold) when tested against A549. DMSO vehicle had no eﬀect on cancer cell
growth (see ﬁg.A.1). Other cell lines were screened throughout the course
of the study and also found to be sensitive against JA and JAA (see table
2.2).
Table 2.1: Anti-proliferative activity of jerantinine analogues against hu-
man tumour cell lines and a normal ﬁbroblastic cell line
Human cell line 72 h MTT GI50 (µM)
Origin Designation JA
Representative GI50
concentrations useda
JAA JB JBA
Breast
carcinoma
MDA-468
0.803
± 0.07
0.9
0.384
± 0.02
0.392
± 0.04
0.259
± 0.02
MCF-7
0.853
± 0.09
0.9
0.857
± 0.01
0.919
± 0.003
0.480
± 0.03
Colon
carcinoma
HCT-116
0.762
± 0.13
0.8
0.691
± 0.36
0.711
± 0.03
0.358
± 0.02
HT-29
2.520
± 0.28
2.5
2.743
± 0.17
0.628
± 0.03
0.649
± 0.02
Lung
carcinoma
A549
3.741
± 0.65
4.0
0.789
± 0.01
0.578
± 0.03
0.887 ±
0.01
Human foetal
lung ﬁbroblast
MRC-5
1.723
± 0.67
GI50 values were determined by MTT assays following 72 h exposure of
cells to test agents (n=4) and expressed as a mean and standard deviation
of 3 independent trials. Refer to 6.2.3 for experimental methodology.
a JA concentrations used as GI50 values in subsequent experiments.
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Table 2.2: Antiproliferative activity of JA and JAA against other tumour
cell lines and a normal microvascular endothelial cell line
Human cell line 72 h MTT GI50 (µM)
Origin Designation JA JAA
Glioblastoma
astrocytoma
U373 V 0.530 ± 0.08 0.693 ± 0.20
U373 M 0.385 ± 0.04 0.611 ± 0.23
Pancreas
adenocarcinoma
MIA PaCa-2* 0.251 ± 0.01 0.242 ± 0.02
Microvascular
endothelial cells
HMEC-1 0.317 ± 0.06 -
*See appendix A (ﬁg.A.2) for more details
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Figure 2.3: Representative MTT graphs from a single trial displaying the
growth inhibitory properties of JA.
Growth inhibitory eﬀects of JA from one independent trial in A549 (a),
HCT-116 (b), HT-29 (c), MCF-7 (d), MDA-468 (e), MRC-5 (f) cells.
Cells were seeded in 96-well plates at a density of 3 x 103 cells/well. After
allowing to adhere (24 h), cells were treated with JA (n=4) and incubated
for 72 h. MTT assays were repeated ≥3 times. Refer to 6.2.3 for
experimental methodology.
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JA and JAA both displayed similar potencies in U373 V compared to
the counterpart cell line U373 M. U373 V is a vector control cell line that has
low expression of O(6)-Methylguanine-DNA-methyltransferase (MGMT)
in contrast to U373 M. MGMT is a unique protein that repairs O(6)-
alkylguanine lesions in DNA [148]. Alkylating agents like temozolomide
have been known to work best in cells expressing low levels of MGMT,
which is correlated with success in the clinic, as opposed to high levels
which are associated with resistance to such agents [148]. As observed in
table 2.2, U373 V and U373 M are similarly sensitive to JA and JAA, which
means that MGMT status is unlikely to aﬀect the activity of either of these
compounds.
2.2.1.1 Investigating cross-resistance between jerantinine A and
vincristine
As mentioned previously, JA has been shown to have growth inhibitory
activity against a vincristine-resistant KB cell line [146]. In order to con-
ﬁrm and study mechanisms that overcome vincristine-resistance, two cell
lines were developed from HCT-116 wild-type CRC cells: HCT-116 cells
cultured and maintained in 2 µM of JA (JA-HCT-116) and vincristine-
resistant HCT-116 (V-R HCT-116) cells (see ﬁg. 2.4; refer to 6.2.4 for
experimental methodology). V-R HCT-116 cells were made resistant to 2
µM of vincristine, nearly 400 times the GI50 (5 nM) of vincristine against
HCT-116 (see ﬁg. 2.5). HCT-116 cells were unable to develop fold resis-
tance to 2 µM of JA (see ﬁg. 2.6).
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Figure 2.4: Morphological diﬀerences between HCT-116 (a), V-R HCT-116
(b), and JA-HCT-116 (c) cells at 40X objective magniﬁcation.
Both V-R and JA-HCT-116 cells were maintained in 2 µM of vincristine
and JA respectively. V-R HCT-116 cells were smaller and more rounded
in appearance compared to JA-HCT-116 cells which contained large
vacuoles and were much bigger in size.
Table 2.3: Antiproliferative activity of JA and vincristine against JA-HCT-
116 and V-R HCT-116 cells
Human Cell Line 72 h MTT cytotoxicity GI50 (µM)
Origin Designation JA Vincristine
Vincristine-resistant
colorectal carcinoma V-R HCT-116 0.438 ± 0.10 1.64 ± 0.45
Jerantinine A-HCT-116
colorectal carcinoma JA-HCT-116 0.580 ± 0.008 0.004 ± 0.001
Colorectal carcinoma HCT-116 0.762 ± 0.13 0.005 ± 0.001
GI50 values were determined by MTT assays following 72 h exposure
of cells (5000/well) to test agents (n=4) and expressed as a mean and
standard deviation of 3 independent trials. Refer to 6.2.3 for experimental
methodology.
As seen in table 2.3, vincristine retains activity in JA-HCT-116 cells,
however, JA achieves more activity against V-R HCT-116 when compared
to naïve HCT-116 cells (approximately 800 nM; see table 2.3). Studies
probing possible mechanisms of overcoming vincristine resistance will be
discussed in chapter 3.
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Figure 2.5: Growth inhibitory eﬀects of vincristine and JA from one inde-
pendent trial in V-R HCT-116.
Cells were seeded in 96-well plates at a density of 3 x 103 cells/well. Cells
were treated with JA (n=4) and incubated for 72 h after allowing to
adhere for 24h. MTT assays repeated ≥3 times. HCT-116 was made
resistant to 2 µM of vincristine, nearly 400x the GI50 value (5 nM)
against naïve HCT-116 cells. Last known GI50 value for vincristine on
this cell line was 1.96 µM.
Figure 2.6: Growth inhibitory eﬀects of vincristine and JA from one inde-
pendent trial in JA-HCT-116.
Cells were seeded in 96-well plates at a density of 3 x 103 cells/well. Cells
were treated with JA (n=4) and incubated for 72 h after allowing to
adhere for 24h. MTT assays repeated ≥3 times. V-R HCT-116 were
treated with subsequently increasing concentrations of JA starting at 800
nM (GI50) up to 2 µM. Even though cells were maintained in 2 µM of JA,
cells were consistently sensitive to concentrations <1µM.
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2.2.1.2 Jerantinine A acetate has potent growth inhibitory ac-
tivities against the NCI60 cell line panel
JAA eﬀectively inhibited growth in all 60 cells lines tested by the NCI
yielding GI50 values of less than 2 µM (ﬁg.2.7). JAA is considerably more
stable than JA and hence was used in the NCI60 cell line screen. A brief re-
view about procedures and analyses pertinent to the NCI60 cell line screen
is covered by Robert Shoemaker [149]. The NCI also employs the use of
MTT assays to determine patterns of growth inhibition in all these cell
lines after treatment with a particular agent [149]. Leukaemic cell lines
were most sensitive to JAA with GI50 values less than 0.5 µM, followed
by prostate cancer, central nervous system (CNS), and ovarian cancer cell
lines. HT-29 was the least sensitive in comparison to HCT-116 being the
most sensitive colon cancer cell line to JAA, which concurs with results
obtained in table 2.1 (2.74 ± 0.17 µM and 0.69 ± 0.36 µM respectively).
Single-dose data of JAA at 1 µM also showed consistently potent growth
inhibition in all leukaemic cell lines. Interestingly, vincristine has also been
shown to have potent growth inhibition against leukaemic cell lines.
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Figure 2.7: Growth inhibitory activity of JAA against the NCI60-cell line
panel.
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2.2.1.3 Jerantinine A inhibits the ability of cancer cells to form
colonies
To determine whether growth inhibitory concentrations of JA were able to
inhibit colony formation, clonogenic assays were performed in all cell lines
except MDA-468 cells which were unable to grow from low seeding densities
required for this assay, and were therefore excluded from this test. Brieﬂy,
cells were seeded in 6-well plates and allowed to attach for 24 h. They
were then treated with the test agent for an additional 24 h. After removal
of treatment media, fresh media was added and cells were incubated until
they grew to ≥ 50 cells per colony in control wells. Colonies were then
stained and counted (refer to 6.2.5).
JA potently inhibited colony formation in cell lines tested (ﬁg. 2.8; see
ﬁg. 2.9); dose-dependent prevention of colony formation was observed in
A549 cells: at 1 x and 2 x GI50 values, JA inhibited colony formation by
35 and 90% respectively. Intriguingly, in colorectal carcinoma (CRC) cell
lines, GI50 and 2 x GI50, JA concentrations almost abolished the ability of
HCT-116 and HT-29 cells to generate colonies: HCT-116 (ﬁg. 2.8; GI50=
97%; 2 x GI50= 99.6% inhibition), and HT-29 (GI50= 97.7%; 2 x GI50=
97.4% inhibition). In contrast, MCF-7 colony formation (dose-dependently
inhibited) was only signiﬁcantly reduced at 2 x GI50 (1.8 µM; 63% inhibi-
tion). MCF-7 cells were able to survive after a brief exposure to the test
agents and recover proliferative capacity at GI50 (900 nM). JA and JAA
also signiﬁcantly inhibited colony formation in MIA PaCa-2 at GI50 (250
nM; 21.8% and 31.4% respectively) and 2 x GI50 (500 nM; 88% and 75%
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respectively) (refer to A.3).
Figure 2.8: Eﬀect of JA on colony formation in A549, HCT-116, HT-29
and MCF-7 cells.
Mean survival fraction as a % of control represented as the mean and
SEM of four independent samples. Asterisk indicates signiﬁcant reduction
(p<0.05) in colony formation. Mean plating eﬃciencies from at least two
individual experiments were calculated and are as follows: A549
(93.67%), HCT-116 (68.75%), HT-29 (78.63%), and MCF-7 (75.84%).
Refer to 6.2.5 for experimental methodology.
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Figure 2.9: Eﬀect of JA on colony formation.
Representative photographs from one of the trials demonstrating potent
inhibition of A549, HCT-116, HT-29, and MCF-7 colonies at 1 x and 2 x
GI50.
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2.2.1.4 Jerantinine A induces apoptosis
Results obtained from the MTT and clonogenic assays suggest that cancer
cell growth and viability have been compromised by JA. Annexin V assays
were conducted to study whether JA induced apoptosis.
During early stages of apoptosis, membrane symmetry is lost result-
ing in translocation of phosphatidylserine from the inner to the outer
membrane of the cell making it accessible for binding to a ﬂuorescein-
labelled protein known as annexin V (annexin V-Fluorescein isothiocyanate
(FITC)). Propidium Iodide (PI) is used concurrently with the annexin V-
FITC antibody in order to discriminate between early stage apoptosis and
late stage apoptosis/necrosis [150, 151]. Fluorescence intensity is then mea-
sured using a ﬂow cytometer. Refer to 6.2.6.2 for experimental methodol-
ogy.
We investigated the eﬀects of JA (1 x and 2 x GI50 concentrations) on
HCT-116 (most sensitive in MTT assays), MCF-7, and A549 (least sensi-
tive in MTT assays) cellular apoptosis after 24 h, 48 h, and 72 h exposure
periods. Figures 2.10 and 2.11 show that JA induced signiﬁcant (p<0.05)
dose- and time-dependent apoptosis when compared to controls. Incremen-
tal progression from early stage apoptosis (A+/PI−) to late stage apoptosis
(A+/PI+) was clearly evident. The highest percentage of apoptosis (an-
nexin V-positive) was present in the A549 cell line at 2 x GI50 after 72 h
treatment (60 ± 5.97%), compared to 34 ± 1.67% seen in HCT-116 cells.
However, MCF-7 cells were resistant to 0.9 µM (GI50) of JA and were able
to slightly recover after a 72 h exposure (approximately a 4% decrease in
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apoptotic events relative to 24 h). The data corroborates well with those
obtained in the clonogenic assay which also showed that MCF-7 cells were
able to recover proliferative capacity and form colonies at GI50.
Figure 2.10: Apoptotic eﬀects of JA on A549 (a), HCT-116 (b), MCF-7 (c)
cells at GI50 and 2 x GI50.
JA induced dose- and time-dependent apoptosis (with the exception of
MCF-7 at GI50. The percentage of cells undergoing apoptosis was deﬁned
as the sum of early apoptotic cells (annexin V-positive) and late
apoptotic cells (annexin V-positive and PI-positive). Data are
representative of at least four independent samples. Asterisk indicates
signiﬁcant (p<0.05) increase in annexin V-positive events with respect to
the control. SD bars represent variation of total % of annexin V + cells
within treatments. Refer to 6.2.6.2 for experimental methodology.
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Figure 2.11: Representative dot plots illustrating apoptotic eﬀects of JA (2
x GI50) on A549, HCT-116, and MCF-7 after 24 h, 48 h, and 72 h exposure.
Dose- and time-dependent induction of apoptosis were prevalent in all cell
lines. MCF-7 had the least percentage of total A+ cells (approximately
19%) compared to 60% in A549, and 34% in HCT-116 cells at 2 x GI50.
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2.2.1.5 Biomarkers of apoptosis
The presence of apoptosis in JA-treated cells was additionally conﬁrmed
by results obtained from Western blots (refer to 6.2.10). Figure 2.12 shows
increased and decreased expression of pro- and anti-apoptotic proteins re-
spectively. Interactions between p53 and Hdm2 have been widely studied
in various tenets of cancer that include apoptosis. The interplay between
p53 and Hdm2 are integral to cell cycle arrest, DNA repair, and apoptosis
which ultimately govern cell fate by activating downstream eﬀector proteins
such as p21 (cell cycle arrest) and/or cleaved PARP (apoptosis) and/or nu-
cleotide/base excision repair pathways (DNA repair) [152, 153, 154]. An-
tiapoptotic proteins such as Bcl-2 and Mcl-1 can act as key determinants
of cell proliferation, diﬀerentiation, and tumourigenesis [155]. Caspase 3
and PARP are both enzymes that play important roles in apoptosis and
the DNA damage response respectively. PARP plays a key role in re-
pairing DNA single strand breaks and works through the base excision
repair pathway (BER). It binds directly to the site of DNA damage and
recruits other repair enzymes such as DNA ligase III [156]. Several forms
of cancer rely on PARP more so than normal cells and is therefore used
as a marker for apoptosis induced by potential anticancer agents [157].
Degradation of cyclin B is necessary for cells to exit mitosis. This pro-
cess is usually mediated by the anaphase-promoting complex/cyclosome
(APC/C), an ubiquitin-protein ligase E3 [158]. Interestingly, some stud-
ies have shown that decreased levels of cyclin B results in expression of
functional p53 which concurs with blots shown below [159].
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Figure 2.12: Upregulation and downregulation of pro- and anti-apoptotic
proteins conﬁrm JA-induced cell death.
Protein expression in HCT-116 and MCF-7 lysates following 72 h
exposure of cells to JA. Western blots were performed using antibodies to
detect whole and cleaved PARP, whole and cleaved caspase 3, Mcl-1,
Bcl-2, cyclin B1, Hdm2 and housekeeping gene GAPDH. HCT-116 cells
were treated at 1 x GI50 (0.8 µM), 2 x GI50 (1.6 µM), and 5 x GI50 (4
µM) JA. PARP cleavage was observed ≥0.8 µM and was accompanied by
a dose-dependent increase in cleaved caspase-3 and complete
down-regulation of Mcl-1. Bcl-2 and Mcl-1 down-regulation was also seen
in MCF-7 cells (1 x GI50 (0.9 µM), 2 x GI50 (1.8 µM), and 5 x GI50 (4.5
µM)). GAPDH was used as an internal loading control. Refer to 6.2.10
for experimental methodology.
As mentioned in 1.3.3, the apoptotic pathway can be activated extrin-
sically or intrinsically depending on the stimulus (see Fig.2.13 below). The
extrinsic pathway is receptor-mediated whereas the intrinsic pathway is
mediated by the mitochondria.
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Figure 2.13: Schematic representation of apoptotic events.
[160]
In response to diverse upstream stress stimuli originating intrinsically
and/or extrinsically, p53 exerts its eﬀects on several downstream genes that
regulate important biological processes such as the cell cycle and apop-
tosis. These stress signals are detected by enzymes such as Hdm2 that
regulate p53 activity. When cells are not under stress, low levels of p53
are maintained through interactions with E-3 ligase Hdm2 enzyme, which
represses p53 transcriptional activity [161]. However, stress-induced cells
have disrupted p53-Hdm2 interactions resulting in Hdm2 degradation (p53
eventually restores Hdm2 levels via transcriptional activation of the Hdm2
gene) [161]. Consequently, p53 is activated and accumulates as a result of
an increase in its half-life.
As seen in ﬁg.2.12, p53 levels were indeed upregulated in HCT-116 cells
with respect to controls in response to JA treatment. However, based on
results from MTT assays, JA potently inhibited growth in cell lines with
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varying p53 statuses (refer to 6.1.1). For instance, MCF-7 and MDA-468
have wildtype and mutant p53 respectively, but display the same sensitiv-
ity to JA (approximately 0.9 µM). Therefore, it is likely that apoptosis
induced by JA is not p53-dependent. Corresponding decreases in Hdm2
levels accompanied increases in p53 levels in both cell lines. Furthermore,
the NCI60 cell panel screen showed that JAA also had no preference for
cell lines with a particular p53 status.
Anti-apoptotic proteins such as Bcl-2 and Mcl-1 were downregulated in
MCF-7, whereas complete suppression of Mcl-1 was observed in HCT-116
≥ GI50 value. Mcl-1 is interestingly regulated at the transcriptional, post-
transcriptional, and post-translational levels [162]. It has been reported
that Mcl-1 reduction can be attributed to caspase (CASP)-dependent cleav-
age during apoptosis [162, 163].
Caspases are among the most essential players in both initiation and
execution of apoptosis. They are a family of cysteine proteases that are
divided into two groups: initiator caspases (e.g. CASP2, CASP8, CASP9,
and CASP10) and eﬀector caspases (e.g. CASP3, CASP6, and CASP7).
In order to trigger apoptosis, initiator caspases cleave inactive pro-forms
of eﬀector caspases turning them into active protease complexes capable of
cleaving cytosolic proteins and nuclear lamins which maintains structural
integrity of the nucleus, thereby triggering apoptosis. As seen in ﬁgures
2.12 and 2.14, JA convincingly induces activation of caspase 3 in HCT-116,
V-R HCT-116 and MIA PaCa-2 cells.
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Figure 2.14: Jerantinine A induces signiﬁcant activation of caspase 3/7 in
HCT-116, V-R HCT-116 and MIA PaCa-2 cells after a 48 h exposure.
All cell lines were treated with vincristine (5 nM) which served as a
positive control. GI50 concentrations of JA were used to treat HCT-116
(0.8 µM), V-R HCT-116 (0.6 µM), and MIA PaCa-2 (0.3 µM). JA
induced signiﬁcant (p<0.05) caspase 3/7 activation in all cell lines. As
expected, vincristine (5 nM) did not induce caspase 3/7 activation in V-R
HCT-116 cells. Experiments are represented as a mean of at least 2 trials
(n=4). Refer to 6.2.11 for experimental methodology.
MCF-7 cells have been reported to be deﬁcient in caspase 3 [164]. Ac-
cording to literature, apoptosis in MCF-7 cells is triggered by downregula-
tion in Bcl-2, increased levels of Bax, release of cytochrome c, and sequential
activation of caspase 9, 7, and 6, which bypasses the need for activated cas-
pase 3 in these cells [164]. However, despite Bcl-2 downregulation (ﬁg.2.12),
JA-treated (1 µM) MCF-7 cells failed to show signiﬁcant activation in cas-
pases 3, 7, 8, and 9 at 6 h, 12 h, 24 h, and 48 h (ﬁg.2.15). Interestingly,
MDA-468 cells also did not show signiﬁcant activation in these caspases
after the aforementioned time exposures suggesting that other mechanisms
of cell death may be at play in these cell lines.
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Figure 2.15: JA did not induce activation of caspases 3/7, 8, and 9 in
MCF-7 and MDA-468 cells at GI50.
MCF-7 (a) and MDA-468 (b) cells did not exhibit signiﬁcant caspase
activation when treated with 1 µM of JA for 6 h, 12 h, 24 h, and 48 h.
Cells were seeded at a density of 3 x 103 per well. Experiments shown
here are represented as the mean and SD of three trials (n=1).
Experiments were kindly performed and data provided by Dr. Chee-Onn
Leong (International Medical University, Malaysia).
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2.3 Conclusion
In this chapter, a thorough understanding of the antiproliferative activities
of JA was established. Preliminary MTT and clonogenic assays revealed
potent growth inhibitory activities of JA on A549, HCT-116, HT-29, MCF-
7, and MDA-468. MTT screens were also conducted on V-R HCT-116
and JA-HCT-116 cell lines to test for the presence of cross-resistance. V-
R HCT-116 cells were more sensitive to JA than naïve HCT-116 cells.
Initial MTT screens also showed potent growth inhibition in all cell lines
in response to JAA. The NCI60 cell line panel screen against JAA yielded
GI50 values less than 2 µM for all cell lines.
After establishing the activity of JA in the aforementioned cell lines,
further assays were carried out to elucidate the nature of cell death in re-
sponse to JA. Annexin V assays demonstrated dose- and time-dependent
increases in apoptosis in treated cells. Upregulation and downregulation
of pro- and anti-apoptotic proteins respectively, confer an apoptotic des-
tiny. Furthermore, induction of caspases 3/7 in HCT-116, V-R HCT-116
and MIA PaCa-2 conﬁrmed involvement of this execution pathway in the
cascade of events leading up to apoptosis.
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Chapter 3
Cellular Mechanism of
Jerantinine A
3.1 Introduction
The previous chapter clearly exhibited potent antitumour activities and
the nature of apoptosis of JA. This chapter aims to elucidate JA’s cellu-
lar mechanism of action and possible molecular target(s). A crucial part
of the screening protocol employed in this study entails investigating the
eﬀect of this compound on the cell cycle using ﬂow cytometry. Virtually
all cytotoxic agents aﬀect the cell cycle to some extent and it is therefore
necessary to identify if JA perturbs a speciﬁc phase of the cell cycle. From
a structural point of view, JA resembles the lower half of the bisindole al-
kaloid, vincristine, as seen in ﬁg. 3.1. It was therefore hypothesised that
JA may target microtubules based on this structural similarity. Vincristine
is known for causing signiﬁcant accumulations in the G2/M phase. If cell
cycle analyses revealed potent G2/M arrests, more targeted assays like the
tubulin polymerisation assay would be used to identify tubulin as a puta-
tive target of JA. Morphological abnormalities in cells treated with JA were
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observed by way of confocal microscopy. Furthermore, these observations
may shed light on how DNA integrity (i.e. presence of fragmentation or
aneuploidy) is compromised if at all. Investigating mechanisms that per-
tain to vincristine resistance would also help elucidate the mechanism(s)
of action of JA. As seen from the above studies, vincristine-resistant cell
lines are sensitive to JA, therefore, it was necessary to identify possible
mechanisms by which JA overcomes vincristine resistance.
Figure 3.1: Structural similarities between vincristine (a) and JA (b).
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3.2 Results and Discussion
3.2.1 Jerantinine A causes severe perturbations in cell
cycle progression
Cell cycle analyses were carried out in the manner described in 6.2.6.1.
Brieﬂy, cells were seeded at appropriate densities depending on treatment
exposure, harvested, and re-suspended in hypotonic ﬂuorochrome solution
containing PI, which is an intercalating dye that ﬂuoresces strongly when
bound to DNA. The DNA content of an individual cell is proportional to
the ﬂuorescence intensity of excited PI (excited by a blue laser at 488 nm).
A histogram of DNA content of cells in a population can be used to derive
the percentage of cells in each phase of the cell cycle and any perturbations
caused by the test agent. PI is normally excluded by intact cells that need
to be permeabilised via the use of a gentle detergent/hypotonic solution to
allow PI entry into these cells.
Cell cycle analyses were carried out in A549, HCT-116, HT-29, MCF-7,
and MDA-468 cells treated with JA (GI50 and 2 x GI50; 24 h, 48 h, 72 h;
see ﬁg. 3.2; ﬁg. 3.4). Following 24 h exposure, JA induced profoundly
signiﬁcant G2/M accumulation (p<0.05) at both 1 x GI50 and 2 x GI50
concentrations across all cell lines. Time- and dose-dependent increases
in pre-G1 events were also observed in all cell lines with the exception of
HT-29. HT-29 seemed to show trends of recovery following JA treatment
despite statistically signiﬁcant accumulations in the G2/M phase at 72 h.
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Subdiploid DNA is indicative of apoptosis. Pre-G1 events in A549, MCF-
7, and HCT-116 corroborated well with data obtained from the annexin
V assay in that A549 had the highest percentage of annexin V-positive
cells (refer to 2.10). The least sensitive cell line (indicated by MTT assays;
refer to table 2.1), A549, revealed the highest percentage of accumulated
events in G2/M (24 h treatment; 88% ± 1.25% at 8 µM) and pre-G1
(72 h treatment; 48% ± 5.43% at 8 µM) cell cycle phases. Signiﬁcant
accumulation of HCT-116 (the most sensitive cell line in MTT assays)
events in G2/M cell cycle phases were detected (ﬁg. 3.2a; 24 h treatment;
86% ± 0.65% at 1.6 µM). The presence of aneuploidy (DNA >4 N) was
also observed and is shown in ﬁg. 3.3.
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Figure 3.2: Eﬀect of JA on the cell cycle in A549 (a), HCT-116 (b), HT-29
(c), MCF-7 (d), MDA-468 (e).
Cells were treated at 1 x GI50 and 2 x GI50 after 24, 48, and 72 h
exposures. Asterisk indicates signiﬁcant (p<0.05) increase or decrease in
events with respect to control. A minimum of 10,000 events were recorded
per sample where n=2 (≥6 independent samples). Experiments were
repeated ≥3 times. All cell lines succumbed to signiﬁcant (p<0.05)
accumulations in G2/M after 24 h treatment (A549–88%; HCT-116– 85%;
HT-29–43%; MCF-7–83%; MDA-468–65%; % G2/M events at 2 x GI50).
Refer to 6.2.6.1 for experimental methodology.
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Figure 3.3: Representative cell cycle histogram of JA on HCT-116 cells 24
h, 48 h, and 72 h post-treatment from a single trial.
Signiﬁcant (p<0.05) G2/M accumulation was observed in addition to the
presence of aneuploidy (indicated by brackets) at 2 x GI50 (1.6 µM) and
appearance of subdiploid DNA.
This cell cycle proﬁle shares similarities to those exhibited by cells
treated with taxanes, vinca alkaloids, nocodazole, and colchicine [165].
Microtubule-disrupting agents (MDAs) are thought to cause a G2/M arrest
via triggering the mitotic checkpoint, a series of biochemical reactions that
ensure proper attachment of the microtubule assembly to the chromosomes
before progression into anaphase [165]. Following prolonged exposure to
MDAs, cells enter an abnormal tetraploid G1-like phase resulting in p53-
mediated upregulation of the cyclin-dependent kinase (Cdk) inhibitor p21
Waf1/Cip1 which in turn inhibits Cdc2-cyclin B complexes resulting in a G2
arrest [165].
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Figure 3.4: Representative cell cycle histograms from a single trial of A549,
HCT-116, HT-29, MCF-7, and MDA-468 cells treated with JA at respective
GI50 and 2 x GI50 concentrations for 24 h, 48 h, and 72 h.
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3.2.2 Jerantinine A inhibits tubulin polymerisation
Guided by observations of stark G2/M cell cycle arrest, an activity assay
was conducted to illustrate possible eﬀects of JA on tubulin polymerisation
in comparison to the tubulin-stabilising and destabilising eﬀects of pacli-
taxel and nocodazole respectively. As shown in ﬁg. 3.5 a and b, paclitaxel
(5 and 10 µM) promoted rapid tubulin polymerisation. In contrast, noco-
dazole (5 and 10 µM) retarded tubulin polymerisation. JA (5 and 10 µM)
unambiguously inhibited tubulin polymerisation, being as potent as noco-
dazole in that respect. These results conﬁrm that tubulin is a viable target
for JA and possibly the main mechanism of action and growth inhibition
in vitro.
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Figure 3.5: Eﬀect of JA on tubulin polymerisation.
All agents were used at 5 µM (a) and 10 µM (b). JA suppressed tubulin
polymerisation. Microtubule-stabilising agent paclitaxel, and nocodazole
which promotes depolymerisation, were included as controls. End-point
means and SDs were calculated at 75 min for all treatment groups and
are as follows: controls (5 µM: 0.442 ± 0.09; 10 µM: 0.451 ± 0.07),
paclitaxel (5 µM: 0.450 ± 0.09; 10 µM: 0.470 ± 0.03), nocodazole (5 µM:
0.299 ±0.01; 10 µM: 0.315 ± 0.02), and JA (5 µM: 0.284 ± 0.01; 10 µM:
0.329 ± 0.02). Refer to 6.2.7 for experimental methodology.
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Microtubules are composed of α/β heterodimers and are assembled in a
head-to-tail fashion to form protoﬁlaments which then associate from side
to side forming a tube [166]. They are anchored by their minus ends (less
dynamic end) at the microtubule-organising center, disposing their plus
ends (more dynamic end) to the cell periphery [166]. The ﬁgure below
details the assembly of microtubules [167].
Figure 3.6: Assembly of microtubules.
α/β heterodimers associate longitudinally to form short protoﬁlaments
(step 1). Due to probable instability, these dimers quickly associate
laterally to form curved sheets which are stable (step 2). Eventually a full
sheet consisting of 13 protoﬁlaments wraps around into a microtubule.
The microtubule then grows by addition of subunits to the ends of the
protoﬁlaments that form the microtubule wall (step 3). The free tubulin
dimers have GTP bound to the nucleotide-binding site on the β-tubulin
monomer. The GTP on the β-tubulin (not α-tubulin) is subsequently
hydrolysed to GDP after incorporation of a heterodimeric subunit into a
microtubule. If the rate of GTP hydrolysis is slower than the rate of
polymerisation, then a cap comprising of GTP-bound subunits is
generated at the plus (+) end, although the bulk of β-tubulin in a given
microtubule will contain GDP. The rate of polymerisation is twice as fast
at the (+) end when compared to the (−) end [167].
It has been reported that low concentrations of taxotere (chemical
derivative of taxol) and vinblastine (vinca alkaloids) stabilise microtubules
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by inhibiting microtubule dynamics; i.e. the lengthening and shortening
of microtubules. However, at high concentrations, vinblastine promotes
depolymerisation of microtubules and inhibits assembly of tubulin dimers
[167]. The ﬁgure below is a general illustration of diﬀerent classes of an-
timitotics and their known binding site on MTs.
Figure 3.7: Microtubule destabilisers and stabilisers and their binding sites
on tubulin.
[168]
3.2.3 Jerantinine A causes severe disruption in cyto-
skeletal architecture
After successfully identifying tubulin as a target of JA, visual validation
was needed to conﬁrm microtubule disruption in vitro using confocal mi-
croscopy. Following desired treatments, HCT-116 cells were prepared for
confocal microscopy. Images were captured to visualise the eﬀects of JA
on tubulin, DNA and cell morphology compared to vehicle alone and vin-
cristine, 24 h post-treatment. Figures 3.8 a-d represent HCT-116 cells
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treated with vehicle alone. Vincristine treatment rendered cells unable to
complete mitosis due to improper chromosomal separation (ﬁg. 3.8 g).
Formation of shortened, multipolar astral microtubules was also observed
(ﬁg. 3.8 f, h). Images of tubulin networks extending into neighbouring cells
were also captured (ﬁg. 3.8 h). Severe membrane blebbing was detected
on cells treated with JA, a characteristic most commonly associated with
apoptosis (ﬁg. 3.8 n→3, p→3). Similar to cells treated with vincristine,
tubulin network disruption led to improper segregation of chromosomes in
cells exposed to JA (ﬁg. 3.8 j). Aneuploidy and multinucleation were also
detected in HCT-116 cells exposed to JA (ﬁg. 3.8 k, m). Aberrant mitoses
where one daughter cell completely lacked DNA content also featured as a
common characteristic following JA treatment (ﬁg. 3.8 k). This may serve
as a possible explanation to the population of cells with aneuploidy (>4N;
ﬁg. 3.3) previously detected in cell cycle analyses.
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Figure 3.8: Eﬀects of JA and vincristine on HCT-116 cells after 24 h ex-
posure.
a–d Controls with vehicle (medium) only; e–f Vincristine (GI50= 5 nM);
g Vincristine (10 nM); h Vincristine (25 nM); i–j JA (0.8 µM); k–l JA
(1.6 µM); m–p JA (4 µM). JA causes multinucleation (1) and improper
chromosomal segregation due to tubulin disruption (2) and blebbing (3).
Multipolar spindles were also evident in samples treated with JA and
vincristine (4). Experiments were repeated 3 times. Refer to 6.2.8 for
experimental methodology.
As seen in SEM images (ﬁg. 3.9) membrane blebbing is a distinguishing
feature of JA treated cells. Membrane blebbing is a phenomenon that has
been shown to be present during the execution phase of apoptosis and is
identical to those occurring in ﬁlament-deﬁcient cells or during cytokinesis
in dividing cells [169]. However, the role of blebs during apoptosis remains
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Figure 3.9: Scanning Electron Microscope (SEM) images illustrating the
extent of cell blebbing caused by JA.
a-b Taken using a cryo-SEM. (a) HCT-116 control cells and (b)
JA-treated HCT-116 (0.8 µM); c-d Taken using an environmental SEM
(ESEM) (c) HCT-116 control cells and (d) JA-treated HCT-116 cells at
(0.8 µM). Images were provided by the Nottingham Nanotechnology and
Nanoscience Centre (NNMC) and the Nottingham Advanced Materials
research Group.
unclear. It is suggested that connective ﬂows of cytosol that give rise to
blebs serve to fragment the nucleus and organelles in the apoptosing cell
[169]. This corroborates well with the images obtained from the confo-
cal microscopy studies illustrated above. Furthermore, the development
of multipolar spindles has been reported in vincristine-induced apoptosis
[170]. It is possible that the formation of multipolar spindles also seen with
JA treatment may contribute to apoptosis.
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3.2.4 Jerantinine A inhibits activity of kinases involved
in mitosis
Taken together, cell cycle analyses, tubulin polymerisation assays, and con-
focal images have evidently illustrated that JA interferes with growth in
cells going through the G2/M transition. Consequently, we were interested
in identifying if JA had an aﬃnity to polo-like kinase 1 (PLK1) and aurora
kinases (AURKs; AURKA, AURKB, and AURKC), all of which have di-
rect roles in mitosis. JA was sent to Merck Millipore to be screened against
puriﬁed kinases, PLK1 and AURKS. As seen in ﬁg. 3.10, JA signiﬁcantly
inhibited PLK1 activity in a dose-dependent manner. AURKB activity was
slightly but signiﬁcantly inhibited at lower concentrations (1 and 5 µM).
Figure 3.10: Eﬀect of JA on the activity of aurora A, B, C and PLK1
AURKB was slightly but signiﬁcantly inhibited (27%, 20% inhibition at 1
and 5 µM respectively; p<0.05). Inhibition of PLK1 was signiﬁcant (22%,
32%, and 67% inhibition at 1, 5, and 10 µM respectively; p<0.05) at all
three concentrations tested. Experiments were carried out once where n
= 2. A one-way ANOVA was used to determine signiﬁcance at the 95%
conﬁdence interval.
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PLK1 belongs to a family of serine/threonine kinases and is an essential
enzyme involved in cell cycle progression through M phase in addition to
playing an important role in genomic stability [171]. It has been shown
to recruit γ-tubulin ring complexes to centromeres to promote maturation
[171, 172]. Another important role of PLK1 is to prevent premature entry
into mitosis via phosphorylation of cyclin B1 leading to cytoplasmic re-
tention, thus preventing nuclear translocation of cyclin B1-Cdk1 complex
[173]. PLK1 has been reported to be overexpressed in several haemato-
logical malignancies in comparison to normal tissue and may be used as a
prognostic factor [171, 174]. PLK1 was recently shown to be a signiﬁcant
prognostic factor in medulloblastoma with high expression correlating with
poor prognosis in patients [175]. Inhibition of PLK1 prevented prolifera-
tion in medulloblastoma cell lines that expressed high levels of PLK1 by
causing microtubule instability and inducing apoptosis. It was also shown
that B12536, a potent PLK1 inhibitor, was not able to inhibit growth of
human astrocytes, cerebellar tissue, and neural stem cells, due to low lev-
els of PLK1 [175]. However, medulloblastoma cell lines with high PLK1
expression were sensitive to B12536.
Collaborative studies with Dr. Beth Coyle (personal communication)
have shown a correlation between growth inhibition and PLK1 expression
in paediatric MB cell lines. Three medulloblastoma cell lines were used for
this particular study: DAOY (high PLK1 expression), MED1 (intermediate
PLK1 expression), and UW228-3 (low PLK1 expression). Vincristine was
used as a positive control alongside JA treatments in MTT and clonogenic
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assays (refer to ﬁg. A.4). Results showed signiﬁcant growth inhibition in
DAOY cells after treatment with JA in both MTT and clonogenic assays
compared to MED1 and UW228-3 cell lines (table A.1).
Like the PLKs , the Aurora kinase family are a collection of highly con-
served serine/threonine kinases that regulate mitosis and multiple signaling
pathways. Alterations in aurora kinase activity has been associated with
chromosomal aneuploidy and mitotic errors in cancer cells. Several stud-
ies have shown that certain haematologic malignancies and solid tumours
overexpress AURKA and AURKB. Results from the activity assays shown
above indicate that JA may have an aﬃnity to AURKB and therefore in-
hibit its activity at lower concentrations (i.e. 1 and 5 µM). Interestingly,
AURKB is a chromosomal passenger protein critical for accurate chromo-
somal segregation, cytokinesis, protein localisation to the centromere and
kinetochore, correct microtubule-kinetochore attachments, and regulation
of the mitotic checkpoint [176]. Abnormalities in some of these features
such as chromosomal segregation and aneuploidy were clearly evident in
images obtained from confocal microscopy of HCT-116 cells treated with
JA, hence our rationale for testing possible inhibitory activity of these ki-
nases (see ﬁg. 3.8).
3.2.5 Monitoring DNA double strand breaks by ob-
serving phosphorylated γH2AX
Confocal microscopy studies also revealed some DNA fragmentation as a
consequence of JA treatment. We were therefore interested in identifying
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if JA caused DNA double strand breaks (DSBs) in cells. A ﬂow cytometry
based method was adapted to test for the presence of DSBs inherent within
samples (refer to 6.2.6.3 for more details). DSBs are paradoxical in nature
in that they may lead to cancer by initiating genomic instability, but can
also be used to kill cancer cells. One of the key components of DNA repair
is the histone protein H2AX, which becomes rapidly phosphorylated on a
serine (c-4) to form γH2AX at nascent DSB sites [177]. Large numbers
of γH2AX molecules form in the chromatin around the DSB site, creating
foci and accumulation of proteins involved in DNA repair and chromatic
remodelling making it possible to detect individual DSBs using an antibody
targeted to γH2AX. Results obtained from this assay revealed that JA did
induce signiﬁcant (p<0.05) DNA DSBs after a 24 h exposure. Cell cycle
analyses were also carried out concurrently and revealed a vast majority of
DNA damage occurred in the G2/M phase (see ﬁgs. 3.12, 3.11). Vincristine
also caused relatively similar levels of phosphorylated γH2AX compared
to JA. A very recent study convincingly demonstrated that microtubule
targeting agents (MTAs) are able to prolong DNA damage by interfering
with the traﬃcking of DNA repair proteins that associate with dynein
and interphase microtubules [178]. It was further suggested that this may
be a reason as to why MTAs work well in combinatorial chemotherapy
with other DNA damaging agents. Indeed, it was shown that cells treated
with vincristine along with a DNA damaging agent exhibited higher and
sustained levels of phosphorylated γH2AX [178].
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Figure 3.11: JA induces DNA DSBs in HCT-116 and MCF-7 cell after a
24 h exposure.
Both HCT-116 (a) and MCF-7 (b) cells were treated with 1 µM of JA for
24 h. Etoposide was used as a positive control as it is a known DNA
damaging agent. Vincristine was used as a comparator control as it is a
known microtubule depolymerising agent. Experiments were repeated at
least 3 times (n=2). Refer to 6.2.6.3 for experimental methodology.
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Figure 3.12: Representative cell cycle histograms and γH2AX dot plots
from an independent trial illustrating induction of DNA DSBs in HCT-116
and MCF-7 cells after 24 h of JA treatment.
HCT-116 (a, e) and MCF-7 (i, m) controls. Etoposide [2µM; HCT-116 (b,
f) and MCF-7 (j, n)] was used on both cell lines as a positive control as it
is a known DNA damaging agent. Being a depolymerising agent,
vincristine [5 nM; HCT-116 (c, g) and MCF-7 (k, o)] was used as a
comparison to JA [1 µM; HCT-116 (d, h) and MCF-7 (l, p)]. Cell cycle
and γH2AX were run concurrently which made it possible for
simultaneous gating (yellow= Pre-G1 phase; pink= G1 phase; teal= S
phase; black= G2/M phase). Experiments were repeated at least 3 times
where n=2.
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3.2.6 Investigating possible mechanisms by which jer-
antinine A overcomes vincristine resistance
The use of vincristine in the clinic has been plagued with various forms
of resistance in patients, many of which have been reported [179]. One
of the earliest forms of resistance identiﬁed in association with vincristine,
was the increased expression of the Pgp also known as multidrug resis-
tance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1
(ABCB1). Pgp, encoded by the MDR1 gene, is a member of the ABC
transporter family and is implicated in facilitating the eﬄux of various
anticancer drugs, including anthracyclines, epipophyllotoxins, kinase in-
hibitors, taxanes, and vinca alkaloids, from the cell [180]. It is expressed in
only a limited number of tissues with barrier function which include epithe-
lia of the kidney, liver, small and large intestine and capillary endothelial
cells in brain, ovary, and the testis [181]. The proposed structure of human
Pgp is thought to comprise of two transmembrane (TM) domains, each con-
sisting of six TM segments along with two nucleotide-binding domains (ﬁg.
3.13). Polymorphisms in the MDR1 gene may aﬀect pharmacokinetics of
many commonly used drugs, including anticancer agents [181]. Substrate
recognition of drugs takes place at the multiple overlapping binding sites
in TM domains. Transferring these substrates from binding sites on Pgp
to the extracellular environment is energised by the hydrolysis of two ATP
molecules for every molecule of drug transported.
An important part of this investigative study is to identify if Pgp ex-
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pression aﬀects the sensitivity of cancer cells in response to JA treatment.
Our studies conﬁrm that cells do indeed retain sensitivity to JA regardless
of Pgp expression and hence JA is not a substrate of Pgp as shown in ﬁg.
3.14. Results corroborate with those obtained in the MTT assay in Chap-
ter 2 (refer to 2.3). Pgp was clearly not expressed in HCT-116 and MCF-7
cells treated with vehicle alone or JA for all time exposures. In support of
these results, there is some evidence suggesting that wildtype p53 usually
represses the expression of Pgp, whereas mutant p53 has been shown to
activate the Pgp gene promoter [182].
Figure 3.13: Predicted 2-D structural model of Pgp with a schematic rep-
resentation showing the distribution of single nucleotide polymorphisms of
the MDR1 gene.
[181]
97
Figure 3.14: V-R HCT-116 cells retain sensitivity to JA despite expressing
high levels of Pgp.
V-R HCT-116 that were resistant to 2 µM of vincristine were treated with
0.6 µM of JA for 1, 2, 4, 8, 16, 24, 48, and 72 h. Protein lysates were
collected and subsequently used for Western blots to detect expression
levels of Pgp. Lysates from HCT-116 and MCF-7 cells were also obtained
from samples treated for the aforementioned time exposures. Experiments
were repeated at least 3 times on two separate batches of lysates.
Furthermore, our collaborative studies with Dr. Beth Coyle (personal
communication) have also shown that the activity of JA in MB cells is
not related to Pgp expression using verapamil, an ABCB1 inhibitor, which
potentiated vincristine and not JA activity (refer to B.1). Verapamil is
a calcium channel blocker developed for the treatment of hypertension.
However, ABCB1 inhibitors like verapamil exhibit higher toxicities than
chemotherapy alone leading to severe myelosuppression, due to high ex-
pression of ABCB1 in bone marrow cells [183]. Additionally, verapamil
alone results in cardiac toxicity which prevents its concurrent use with vin-
cristine in the clinic. Therefore, it may be more eﬃcient to ﬁnd drugs that
circumvent ABCB1 rather than inhibiting its function for the treatment
of cancer. In this study, medulloblastoma cell lines (DAOY, MED1, and
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UW228-3) were treated with vincristine and JA alongside verapamil. As
seen in ﬁg. B.1, there was no diﬀerence between survival percentages in
clonogenic assays between cells treated with JA alone or with both JA
and verapamil. Vincristine and verapamil on the other hand did exhibit a
synergistic eﬀect resulting in a signiﬁcant decrease in colony formation.
3.2.6.1 Overcoming resistance via production of Reactive Oxy-
gen Species
A few anticancer agents generate Reactive Oxygen Species (ROS) that re-
sult in cell death via apoptosis. However, prolonged treatment with the
same drug has been shown to reduce ROS levels that contribute to the
development of drug-resistant cancer cells [184]. Exogenous ROS in con-
junction with the same drug resensitises these drug-resistant cells. There
is increasing evidence illustrating that apoptosis caused by elevated ROS
levels and drug resistance by lack of ROS may very well be one of the
principle mechanisms underlying drug resistance and drug sensitivity in
cancer cells [184]. Interestingly, ROS levels have also been closely linked to
Pgp expression [185]. It was found that both chronic and transient ROS
stress upregulated Pgp expression at the RNA, protein, and functional lev-
els, which could be counteracted by antioxidants [186, 187]. In contrast,
low levels of ROS downregulated Pgp expression [188]. ROS have also
been implicated as mediators of apoptosis by activating diﬀerent caspases
and signalling pathways such as mitogen activated protein kinase (MAPK)
pathway, extracellular signal-regulated kinase (ERK) pathway, and phos-
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phoinositide 3-kinase(PI3K) signaling pathways among others [185].
Our investigations demonstrated that JA produced signiﬁcantly higher
levels of ROS in V-R HCT-116 cells compared to vincristine treatment
(refer to 6.2.12 for methodological details). Vincristine did not generate
signiﬁcant ROS in V-R HCT-116 which corroborates the aforementioned
literature (see ﬁg. 3.15). It can be argued that V-R HCT-116 cells do not
eﬃciently retain vincristine within the cell due to expression of Pgp. How-
ever, JA still produced higher levels of ROS in comparison to vincristine
in naïve HCT-116 cells. JA also evoked signiﬁcant ROS production in
JA-R HCT-116 cells further providing credence to the fact that these cells
were not able to develop resistance even though they were maintained and
cultured in 2 µM of JA. Interestingly, JA-HCT-116 inherently possessed
approximately 2.09 times the ROS levels than V-R HCT-116 cells which
may be attributed to possibly diﬀerent processes involved in metabolism of
JA and vincristine within these cells.
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Figure 3.15: JA generated signiﬁcantly higher ROS levels in V-R HCT-116
cells compared to vincristine.
Vincristine treatment (5 nM) did not generate signiﬁcant ROS in V-R
HCT-116 cells compared to the same treatment in naïve HCT-116 cells.
Interestingly, JA generated more ROS than vincristine in naïve HCT-116
cells (1 µM), V-R HCT-116 (0.6 µM), and JA-R HCT-116 cells (1 µM).
Experiments were repeated ≥2 times where n=2. Two-way ANOVAs were
used to compute signiﬁcance (p<0.05). Refer to 6.2.12 for experimental
methodology.
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3.2.6.2 Differences in binding sites on microtubules can account
for the lack of cross-resistance
As seen below in ﬁg. 3.16, microtubule disrupting agents (MDAs) are capa-
ble of binding on multiple sites on microtubules, thus altering their dynam-
ics during mitosis. It is possible that JA binds to a completely diﬀerent site
on microtubules than vincristine despite structural similarities, which may
account for the lack of cross-resistance in addition to its enhanced activity
in V-R HCT-116 cells.
Figure 3.16: Tubulin binding sites of various MDAs.
[189]
Indeed, one of the most important ﬁndings to arise towards the end of
this investigative study was the identiﬁcation of the binding site of JBA.
With the help of our collaborators at the Paul Scherrer Institute (PSI;
Switzerland), we were able to obtain high resolution crystal structures
showing that JBA binds to the colchicine site on microtubules as illus-
trated below in ﬁg. 3.17. Refer to ﬁg. B.2 for more details.
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Figure 3.17: 2.4Å crystal structures illustrating that JBA binds to the
colchicine site on microtubules. Images were provided by Dr. Michel O.
Steinmetz et al. (PSI, Switzerland). Refer to B.2.
Colchicine was initially extracted from the poisonous meadow saﬀron
Colchicum autumnale L. and was the ﬁrst tubulin destabilising agent [189].
Colchicine like vincristine can eﬀectively inhibit mitosis and is thus inves-
tigated as an anticancer agent. Unfortunately, due to its low therapeutic
window, colchicine is not clinically approved to treat cancer. However,
there have been multiple eﬀorts to clinically develop colchicine binding
site agents primarily because of their ability to inhibit tumour vasculature
and overcome MDR resistance which includes Pgp expression [189]. This
is consistent with results showing that Pgp expression and blocking Pgp
does not aﬀect activity of JA. It was also reported that colchicine binding
site agents are not aﬀected by expression patterns of β-tubulin and still
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maintain potent activity against cancer cells.
Interestingly, a recent study involving the total synthesis and biologi-
cal evaluation of jerantinine E (JE) also matched colchicine as the closest
neighbour of JE based on impedance proﬁling that comprised of 27 other
MDAs [190]. The study additionally conﬁrmed JE as a potent inhibitor of
tubulin polymerisation [190].
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3.3 Conclusion
Cell cycle analyses revealed potent G2/M arrests in A549, HCT-116, HT-
29, MCF-7, and MDA-468 cells. These cell cycle proﬁles were similar to
those associated with other MDAs like the taxanes or the vinca alkaloids
leading to the hypothesis that JA may target microtubules. Tubulin poly-
merisation assays were carried out with JA, paclitaxel (microtubule stabil-
ising agent) and nocodazole (microtubule destabilising agent) as controls.
Results revealed that JA did indeed inhibit tubulin polymerisation and is
thus similar to destabilising agents such as the vinca alkaloids. Visualising
microtubule disruption as a consequence of JA treatment using confocal
microscopy revealed striking changes in cell morphology with regards to
cytoskeletal architecture, membrane blebbing associated with apoptosis,
multipolar spindle formation, DNA fragmentation, and aneuploidy, all of
which are consistent with data obtained from cell cycle analyses and an-
nexin V apoptosis assays. The integrity of DNA in JA-treated cells was also
investigated by carrying out ﬂow cytometric assessments of phosphorylated
γH2AX levels in HCT-116 and MCF-7 cells. Results revealed signiﬁcant
increases in phosphorylated-γH2AX indicative of DNA DSBs. This cor-
roborates confocal images that show some DNA fragmentation. PLKs and
AURKs (A, B, C) are both integral to the mitotic process and inhibition
of these kinases have been reported to result in many of the characteris-
tics observed in the above studies. Furthermore, studies have shown that
PLK1 serves as an important prognostic factor in cancers such as medul-
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loblastomas. Our collaborative studies illustrated that JA was more active
against a high expressing PLK1 cell line like DAOY. Hence, it was neces-
sary to identify if JA has an aﬃnity to PLK1 as well AURKs. Data ob-
tained from this kinase screen revealed dose-dependent inhibition of PLK1
activity in the presence of JA. Aurora kinase B was only slightly, but sig-
niﬁcantly inhibited at low concentrations of JA. Initial cell viability stud-
ies clearly demonstrated potent growth inhibitory activities of JA in V-R
HCT-116 cells. Hence, a more detailed investigation that probed mecha-
nisms of resistance was carried out. Pgp expression has played a huge role
in drug resistance faced in the clinic, especially seen in cases that involve
vincristine-resistance. However, this does not appear to hinder the activity
of JA as our data illustrates that Pgp expression in V-R HCT-116 cells re-
main unchanged for all treatment exposures. Increased levels of ROS have
also contributed to mechanisms driving evolution of acquired resistance -
through upregulation of many enzymes responsible for neutralising ROS.
Indeed, ROS levels were higher in cells treated with JA compared to vin-
cristine. JA-HCT-116 cells also inherently possessed 2.09 times the levels
of ROS than V-R HCT-116 cells which may indicate diﬀerences in the way
that these agents are metabolised in cells. Based on previous literature and
crystal structures provided by our collaborators, one of the most important
ﬁndings in this study was determining with a degree of conﬁdence that the
jerantinine family binds to the colchicine site on microtubules. This could
explain why V-R HCT-116 cells are more sensitive to JA as it binds to a
diﬀerent site than vincristine.
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Chapter 4
Genomic and Proteomic Studies
in Cells Treated with Jerantinine
A
4.1 Introduction
Investigating signal transduction pathways associated with JA’s mecha-
nism(s) of action through the use of genomics and proteomics can help
elucidate key biological processes involved in evoking a growth inhibitory
response. Both genomics and proteomics studies were conducted on the
premise of corroborating phenotypes made evident in chapters 2 and 3. An
additional aim within this chapter was identiﬁcation and biological vali-
dation of genes that are needed for cell sensitivity towards JA. For this
study, a genome-wide RNAi screen was carried out in collaboration with
colleagues at the International Medical University (Malaysia). RNAi loss
of function screening using complex lentiviral-based short hairpin RNAs
(shRNA) expression libraries provides a unique and powerful approach to
identify genes required for deﬁned cell responses in a single assay. The
pooled genome-wide shRNA libraries contain approximately 80,000 shRNA
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constructs targeting 15,000+ genes. The pooled virus is added to the cell
population at a predetermined multiplicity of infection (ratio of virus to the
ratio of target cells within a deﬁned space). Cells are then incubated and
exposed to a selective pressure such as the test agent and selected based on
desired phenotype or ﬂow sorting. After selection, cells are then isolated
and the integrated shRNA constructs are identiﬁed via "Next Generation"
sequencing. The identiﬁcation of potential "hits" can then be used to de-
velop hypotheses regarding biological role(s) of the corresponding gene(s).
To identify genes functionally required for cell sensitivity to a treatment
or compound, the most straightforward approach is to conduct a RNAi
rescue screen, where the selection is a treatment, such as a drug, that
kills almost all cells and is applied to a population that is infected with a
heterogeneous lentiviral shRNA expression library. Brieﬂy, the process ﬁrst
involves infecting cells (MCF-7) with this library, and then treating them
with the test agent (JA) at a concentration that under normal conditions
kills virtually 100% of cells, then determining which shRNA are present
in the surviving cell population. Presumably, the genes targeted by the
shRNA in the surviving cell population are essential for eliciting the killing
response caused by the compound, factor, or small molecule since silencing
the gene prevents the cell-death signal from propagating. Thus, analysis
of the “rescued” survivors indicates which genes are necessary for lethal
activity of the compound or factor.
The second section in this chapter explores temporal changes in pro-
tein expression of cells after an 8 h, 16 h, and 24 h exposure to JA using
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Multidimensional Protein Identiﬁcation Technology (MudPIT). This tech-
nique combines 2-dimensional (2D) liquid chromatography with tandem
mass spectrometry. The ﬁgure below summarises the workﬂow associated
with this technique.
Figure 4.1: General illustration showing the workﬂow for MudPIT.
Proteins are extracted from samples, prepared, and digested into
constituent peptides which are then subjected to separation via 2D liquid
chromatography and analysed via tandem mass spectrometry.
SCX=strong cationic exchange; RP=reversed-phase [191].
MudPIT speciﬁcally combines both strong cation exchange (SCX) pre-
fractionations and reverse phase high-performance liquid chromatography
(RP-HPLC). The SCX resin initially binds all peptides before they pass
through to the octadecyl carbon chain (C18) bonded silica material which
is frequently used in reversed-phase chromatography. As seen in the above
ﬁgure, the SCX resin and C18 material are packed in tandem. Peptides
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are eluted in a stepwise manner using ammonium salts starting with low
concentrations and ending with high concentrations. This is followed by
a cycle of organic gradients that are used to elute the peptides from the
C18 and into the mass spectrometer for sequencing. Spectra are then gen-
erated and uploaded into databases that match peptide sequences to their
corresponding protein (refer to 6.2.13 for more details).
4.2 Results and Discussion
4.2.1 Genome-wide RNAi screen in MCF-7 cells
Upon generating a stable pool of MCF-7 cells that were transduced with
the shRNA library, cells were treated with JA for 72 h. As seen in ﬁg.4.2,
JA induced signiﬁcant morphological changes in MCF-7 cells transduced
with non-targeting shRNA, similar to changes observed in parental MCF-7
cells. However, cells transduced with the genome-wide shRNAs were more
resistant to JA based on morphological characteristics. Genomic DNA was
obtained from these samples, ampliﬁed via polymererase chain reaction
(PCR), and lastly subjected to high throughput sequencing. The sequences
were then queried against The RNAi Consortium shRNA Library (TRC)
to identify targets with corresponding shRNA sequence(s) that match the
sequencing data. Analyses of data revealed 381 candidate genes mediating
sensitisation and 121 genes mediating resistance to JA and are listed in
tables 4.1 and 4.2 (refer to appendix C.1 for more details on data analysis).
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Figure 4.2: MCF-7 transduced with a pooled genome-wide shRNA confers
resistance to JA.
MCF-7 cells transduced with a non-targeting shRNA (Top) or a pooled
genome-wide shRNA (Bottom) were treatedwith 1µM of JA for 72h and
their morphological changes observed using inverted light microscopy.
Note that some of the cells transduced with genome-wide shRNA were
resistant to JA compared to the non-targeting control cells which retained
sensitivity to JA. Images were provided in collaboration with Dr.
Chee-Onn Leong (IMU, Malaysia).
111
Table 4.1: List of genes mediating the sensitivity of MCF-7 to JA (these
genes when knocked-down confer resistance).
A1CF CPSF3 GRSF1 MARK1 PCBP3 RCOR3 SNIP1 USP54
ABCB9 CSNK1G1 GSG2 MARK3 PCCA RDH11 SNRNP40 USP6
ABCC1 CSNK2A1 GSK3B MASTL PCCB RDH5 SNRPA VANGL1
ABP1 CTNNB1 GSPT1 MBIP PDE5A REL SNRPD2 VPS29
ACAD9 CWC22 GSTA3 MCCC1 PDHA2 REXO1 SNRPD3 WBP11
ACIN1 CYTL1 GUCY1B2 MCCC2 PDILT RIC8B SNRPE WDR33
ACMSD DDR2 HADHB MCTP1 PGD RNF180 SNRPF WNK2
ACY1 DDX17 HAT1 MCTP2 PGK1 ROCK1 SNRPG WNK3
ADC DDX6 HMGCS1 ME1 PGR RPE SNW1 WSB2
ADCK1 DERA HNRNPA3 ME2 PHF5A RPL12 SRRT XAB2
ADH4 DISC1 HNRNPH3 MELK PIK3C2A RPL13 STK31 ZC3HC1
ADH6 DLST HNRNPUL1 MET PIK3C2B RPL18A STK33 ZFC3H1
AGMAT DNAJC17 HSD17B7 MFSD11 PIM2 RPL21 STRADB ZIM2
AK4 DSPP HSPA1L MICALL1 PLCB2 RPL22 SUGP1 ZNF10
AKAP11 DUOX1 HUNK MKI67IP PLCG2 RPL23A SUZ12 ZNF331
ALDH1A3 DUSP19 IFT46 MMP27 PLCL1 RPL39 SYT16 ZNF568
ALDH3A1 DYRK1B IGF2BP3 MSH5 PLCL2 RPL4 SYTL5 ZNF658
ALDH3A2 EEF2K IL1F8 MST1R PLCXD2 RPL5 TAAR8
AMD1 EFHA1 IL31 MST4 PLCZ1 RPLP0 TAF1
ANKRD40 EFTUD2 INSRR MTHFD2L PLOD3 RPS10 TALDO1
ANO6 EGR2 IRAK4 MXRA8 PLXNC1 RPS11 TAOK1
AP1S2 EIF2AK3 IRS1 MYO3A PPAT RPS17 TARS2
AQR EIF2S2 ITCH NAA15 PPM1J RPS18 TAS1R2
ARHGEF25 EIF3I ITGB3 NAA38 PRCC RPS25 TAS2R19
ATF7IP2 EIF4A3 JAK1 NCOR1 PRKAA2 RPS27 TBX5
BLMH EMP1 JMJD7-PLA2G4B NDST2 PRKACB RPS3A TCEB1
BRDT EPHA6 KAT2A NDUFA4 PRKAR1B RPS4X TEK
C11orf46 ERI2 KDM6A NDUFAF1 PRKCG RPS4Y1 TENC1
C19orf43 EXT1 KHDRBS1 NDUFB6 PRLR RPS4Y2 TET1
C1orf55 FADD KIAA1429 NDUFB9 PRMT3 RPS6KA4 THOC5
C20orf158 FAM122B KIAA1958 NEK1 PRODH2 RPS6KC1 TIA1
C9orf11 FAM26D KIF16B NEK10 PROM1 RPS7 TJP2
CALR3 FAM32A KLK5 NINL PRPF3 RPS8 TKT
CAMKK2 FAM81A KLKB1 NNT PRPF4 RSL24D1 TKTL1
CAP2 FASTK KRT23 NPR1 PRPF6 RWDD3 TLK1
CCDC68 FER LACTB NR3C2 PSAP RYK TMEM20
CCR2 FGF5 LDHAL6B NT5C2 PSIP1 SAFB2 TNNI3K
CDC42BPA FGFR2 LOC391513 NTF3 PTGR2 SAT1 TP53BP1
CDC7 FIP1L1 LOC401313 NTRK2 PTK6 SCYL3 TRAF6
CDK15 FLJ16124 LOC402677 NTRK3 RAB9B SEC14L1 TSPAN1
CDKL4 FYCO1 LRP6 ODC1 RAC1 SF3B1 TTBK1
CDS2 GABRA6 LRRK2 OR10X1 RAF1 SF3B3 TUBB
CELF2 GAD1 LSM11 P4HA2 RALA SF3B5 TYK2
CELF4 GAD2 LSM5 P4HA3 RALYL SGK2 UGT8
CENPA GAPDH LSM6 PABPC1 RASA2 SGK3 UHMK1
CHDH GLS MAOA PABPC4 RASSF3 SIK2 UNC13B
CLK1 GLS2 MAP3K1 PAK1 RASSF6 SLC16A6 UROD
CMPK1 GLUD1 MAP3K7 PAK3 RBL1 SLC1A5 USP11
COL4A3BP GLUD2 MAP4K2 PAN3 RBM10 SLC5A9 USP17L6P
COPS2 GPATCH1 MAP4K5 PAPOLG RBM12 SMPDL3B USP38
CPM GPD2 MAPK10 PC RBM15 SMS USP47
CPSF2 GPR113 MAPKAPK2 PCBP2 RBM8A SMU1 USP50
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Table 4.2: List of resistance-causing genes (these genes when knocked-down
confer sensitivity to JA)
ABCD3 CYP51A1 KRTAP10-6 PDE1C SRPX
AGXT2L1 DECR1 LAPTM5 PES1 SSX7
ARHGAP15 DOPEY2 LCT PIGU SSX9
ATG4A DUSP27 LEP PLEKHA5 STX7
ATG4C E2F6 LGSN PPFIA2 TACR1
ATP9B ENTPD2 LHPP RAB36 TAS2R42
ATRNL1 EPB41L4B LIG1 RAB39B TFG
ATXN7 FAM169B LOC401198 RASGRP3 TMEM120A
BTG3 FEZ2 LRP10 RHOBTB2 TNFRSF11B
BTG4 GALT M6PR RNF150 TOM1L2
C10orf12 GDF5 MAN2B2 ROBO1 TRIT1
C16orf5 GFRA1 METAP1 RUFY3 UBE2E4P
C1orf124 GK MEX3B SAMD9 UBLCP1
C3orf19 GMNN MOCS3 SDHDP7 VPS36
C4orf43 GPR174 MSN SERPIND1 WDR45L
C6orf10 GPS2 NAMPT SH2B3 WFDC3
CCNT2 GRIK3 NCRNA00288 SLC16A14 WIF1
CD40 H1FOO NKX3-1 SLC17A8 ZFP42
CDH20 HDHD2 NOS3 SLC2A2 ZNF441
CHD9 HOXA11 NPHP3 SLC4A5 ZNF510
CIR1 HUS1 NPSR1 SMARCA1 ZNF620
CLCA4 IL1B NRL SMOC1
CLPTM1 IL1F5 OR51D1 SOS2
CREB3L2 IMPDH2 P2RX1 SPINK14
CXADR ITPR2 PDE12 SREBF2
4.2.1.1 shRNA target validation in MCF-7 and MDA-468 cells
treated with JA
We chose to select a suitable candidate based on characteristics of JA treat-
ment made evident in chapters 2 and 3 and was additionally present on the
list of genes that when knocked down would confer resistance to JA. Path-
way analyses from DAVID (Database for Annotation, Visualisation and In-
tegrated Discovery) led to multiple hits in various pathways, however, the
MAPK and Toll-like receptor pathways had several components that were
identiﬁed in this shRNA screen as seen below in ﬁg.4.3. C-Jun-N-terminal
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kinase (JNK) is integral to both pathways and was thus selected as an ideal
candidate for target validation. JNKs belong to the MAPK family and are
involved in important physiological processes such as stress responses, in-
ﬂammation, apoptosis, cell proliferation, diﬀerentiation, and survival. For
the purposes of this study, we chose to knockdown JNK1/JNK2 in MCF-7
and MDA-468 cells, treat them with JA, and assess growth inhibition us-
ing the MTT assay. Interestingly, studies have shown that inhibiting JNK2
and subsequent treatments with cytoskeletal-interfering substances such as
colchicine or taxol can actually promote tumour cell growth while simulta-
neously inducing apoptosis even under the inﬂuence of the same stimulus
[192]. Microtubule-interfering agents such as paclitaxel, docetaxel, vinblas-
tine, vincristine, nocodazole, and colchicine have all been reported to acti-
vate proteins such as RAS and apoptosis signal-regulating kinase 1 (ASK-1)
which in turn activate JNK/stress-activated protein kinase (SAPK) [193].
The JNK pathway is also intriguingly tied to ROS production. Studies have
shown that activation of JNK in conjunction with ROS production in breast
cancer is capable of inducing apoptosis via the mitochondrial/caspase path-
way [194]. It could therefore be hypothesised that ROS production and
concurrent activation in the JNK pathway may mediate apoptosis to some
extent in cells treated with JA.
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Figure 4.3: Pathway analyses using DAVID revealed possible involvement
of the JNK pathway in conferring sensitivity to JA.
JNK is an integral component that is shared between the MAPK and
Toll-like receptor pathways identiﬁed by DAVID and was therefore
selected for subsequent target validation studies.
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Results obtained from experiments conducted in collaboration with Dr.
Chee-Onn Leong revealed that knockdown of JNK1(M1a/M9 shRNA vari-
ants) and JNK 2 (J21/J22 shRNA variants) in MCF-7 and MDA-468 cells
did indeed confer some resistance to JA when compared to vector controls
(pLKO) suggesting that the JNK pathway may play a role in mediating
sensitivity of these cell lines to JA (refer to ﬁgs. C.3 and C.4). Mean IC50
values are tabulated below (see tables 4.3 and 4.4). Blots conﬁrming knock
down are illustrated in ﬁg. C.2.
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Table 4.3: Mean IC50 values of MCF-7 cells transduced with JNK1/2
shRNA variants and subsequently treated with JA 1µM for 72 h.
MCF-7
pLKO M1A M9 J21 J22
Log IC50 3.865 3.881 4.406 4.15 5.801
IC50 (nM) 7320 7602 >10000 >10000 >10000
Mean IC50 values were obtained from at least 2 independent trials where
n >4. Experiments were done in collaboration with Dr.Chee-Onn Leong
(IMU, Malaysia).
Table 4.4: Mean IC50 values of MDA-468 cells transduced with JNK1/2
shRNA variants and subsequently treated with JA 1µM for 72 h.
MDA-468
pLKO M1A M9 J21 J22
Log IC50 3.079 3.529 3.399 3.155 3.038
IC50 (nM) 1199 3377 2509 1429 1091
Mean IC50 values were obtained from at least 2 independent trials where
n >4. Experiments were done in collaboration with Dr.Chee-Onn Leong
(IMU, Malaysia).
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4.2.2 Proteome profiling in JA-treated MCF-7 cells
Examining temporal changes in protein expression may help elucidate other
mechanisms that contribute to the apoptotic destiny of cells treated with
JA (1µM). We chose to look at protein expression in MCF-7 cells treated
with vehicle (medium) alone in conjunction with cells treated with JA for 8
h, 16 h, and 24 h. Protein samples were collected and prepared in the man-
ner described in 6.2.13. Each of the 4 treatment samples were subjected to
6 SCX fractions which would allow for greater depth in the identiﬁcation of
protein groups. Figures. 4.4 and 4.5 were compiled from the entire dataset
obtained which showed that proteins aﬀecting cytoskeletal architecture and
cell cycle were among the top 25 upregulated and downregulated biological
processes. The wealth of data obtained from these proteomic proﬁles can
be overwhelming and as such we chose to validate hits based on biological
processes that resembled the phenotype of JA-treated cells as demonstrated
in previous experiments; i.e. cell cycle perturbations and confocal images
showing abnormal changes in cytoskeletal architecture. First and foremost,
ﬁltering data and ranking proteins by fold change and trends (high to low
R2 values) in temporal protein expression for all four samples may help
unravel mechanisms more closely linked to biological processes aﬀected by
JA treatment. Data were therefore clustered into ﬁve categories: proteins
that were expressed exclusively in the control (control >8 h = 16 h = 24
h = 0; see 4.6), proteins that were not present in the control, but grad-
ually increased over time (control = 0 <8 h <16 h <24 h; see ﬁg.4.7),
proteins present in the control that increased over time (control <8 h <16
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h <24 h; see ﬁg.4.8), proteins present in the control that decreased over
time (control >8 h >16 h >24 h), and lastly proteins that decreased to a
fold change of 0 by 24 h (control >8 h >16 h >24 h = 0). Information
in all GO ﬁgures were obtained from DAVID, a bioinformatics tool which
is available online [195]. Some common terms that appeared across all
applied ﬁlters were RNA splicing, RNA processing, protein transport and
localisation, and more importantly the cytoskeleton, which corroborates
images from confocal microscopy studies. As seen from the progression of
applied ﬁltering parameters, we were ﬁnally able to attain enriched terms
covering biological processes such as those pertaining to microtubules and
spindle organisation, which are relevant to JA’s mechanism of action and
its primary target.
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Figure 4.4: Top 25 enriched gene ontology (GO) terms from the entire
dataset representing upregulated biological processes in MCF-7 cells as a
consequence of JA treatment (1 µM).
Upregulation in biological processes involving components of the
cytoskeleton corroborates data obtained from confocal microscopy
showing dramatic changes in cell morphology. It is possible that cells
increase proteins that maintain the cytoskeleton in an eﬀort to oppose the
eﬀects exerted by JA. Bars in red represent processes associated with JA.
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Figure 4.5: Top 25 enriched GO terms from the entire dataset representing
downregulated biological processes in MCF-7 cells as a consequence of JA
treatment (1 µM).
mRNA splicing, protein transport/localisation, and cell cycle were among
the the list of downregulated biological processes. Decreased expression in
proteins that facilitate the cell cycle were prioritised for further validation.
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Figure 4.6: GO terms representative of biological processes comprising of
proteins present exclusively in the control and absent in treatment samples
(control >8 h = 16 h = 24 h = 0).
Proteins involved in chromosome organisation were among the top hits in
this category. As seen in ﬁg.3.8, chromosome misalignment due to
microtubule disruption caused by JA, does indeed correspond with this
set of ﬁltered data. Proteins involved in RNA processing/splicing and
protein transport and localisation were also among the most
downregulated biological processes.
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Figure 4.7: GO terms representative of biological processes comprising pro-
teins absent in the control but increase in a time-dependent manner (control
= 0 <8 h <16 h <24 h).
Increased gene counts in biological processes pertaining to cell cycle and
mitosis were even more evident in this ﬁlter. RNA processing and splicing
were also among upregulated processes.
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Continued...
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Figure 4.8: GO terms representative of biological processes comprising pro-
teins present in the control that increase in a time-dependent manner (con-
trol <8 h <16 h <24 h).
Biological processes pertaining to the cytoskeleton (red bars) were not
particularly prevalent in this ﬁlter. However, RNA processing and splicing
(yellow bars) had higher gene counts and were more prevalent at this level.
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Continued...
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Figure 4.9: GO terms representative of biological processes comprising pro-
teins present in the control that decrease in a time-dependent manner (con-
trol >8 h >16 h >24 h).
Processes related to the cell cycle (red bars) have increased gene counts in
this particular ﬁlter. Yet again, RNA processing/splicing (yellow bars)
have consistently been among the top enriched terms in both upregulated
and downregulated processes for all ﬁlters applied thus far, suggesting
that JA treatment may ultimately aﬀect protein synthesis due to
perturbations in the processing of their precursors.
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Figure 4.10: GO terms representative of biological processes consisting of
proteins present in the control that decrease in a time-dependent manner
(control >8 h >16 h >24 h = 0)
The last ﬁlter applied strongly corresponds with our target of interest.
This is the only ﬁlter that consisted of enriched terms such as
microtubule-based processes and spindle organisation (red bars) which is
in line with JA’s mechanism of action. We therefore pursued possible
protein candidates and pathways for validation using this ﬁlter as a
starting point.
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Proteins comprising biological processes represented in ﬁg.4.10 are tab-
ulated below with fold-changes of MCF-7 cells treated with JA for 8 h, 16 h,
and 24 h relative to untreated control cells. R2 values obtained from linear
regression analyses are also displayed in order of strength. As seen in 4.5,
all proteins had strong linear trends (over 85%) showing downregulation at
24 h post JA treatment.
Table 4.5: List of proteins associated with biological processes represented
in ﬁg.4.10.
Fold-change relative
to control
Protein Name Gene 8 h 16 h 24 h R2 value
Ensconsin MAP7 0.70 0.30 0 0.99
Equilibrative nucleoside
transporter 1 SLC29A1 0.62 0.23 0 0.99
Zinc ﬁnger protein 277 ZNF277 0.57 0.34 0 0.99
Tumor protein p53-
inducible protein 11 TP53I11 0.80 0.48 0 0.97
Syntaxin-16 STX16 0.83 0.49 0 0.96
TAF6-like RNA polymerase II
p300/CBP-associated factor-
65 kDa subunit 6L TAF6L 0.84 0.49 0 0.95
60S ribosomal protein L22-like 1 RPL22L1 0.66 0.56 0 0.93
Lysosome-associated membrane
glycoprotein 1 LAMP1 0.50 0.45 0 0.93
Tight junction protein ZO-3 TJP3 0.72 0.58 0 0.92
Nitric oxide synthase-
interacting protein NOSIP 0.42 0.35 0 0.91
Phosphopantothenate-
cysteine ligase PPCS 0.67 0.58 0 0.91
Thymidine kinase, cytosolic TK1 0.56 0.53 0 0.91
Fanconi anemia group A protein FANCA 0.56 0.53 0 0.91
Poly(A) polymerase alpha;
Poly(A) polymerase beta PAPOLA;PAPOLB 0.82 0.60 0 0.91
Ribonucleoside-diphosphate
reductase subunit M2 RRM2 0.42 0.11 0 0.91
Protein FAM208A FAM208A 0.39 0.26 0 0.91
5-AMP-activated protein kinase
subunit gamma-1 PRKAG1 0.80 0.61 0 0.91
UV excision repair protein
RAD23 homolog A RAD23A 0.71 0.61 0 0.90
Mitochondrial import
receptor subunit TOM34 TOMM34 0.52 0.54 0 0.89
Serine/threonine-protein kinase N1 PKN1 0.34 0.21 0 0.88
ZW10 interactor ZWINT 0.90 0.63 0 0.88
Mitotic checkpoint serine/threonine-
protein kinase BUB1 beta BUB1B 0.79 0.67 0 0.87
ADP-ribosylation factor 4 ARF4 1.04 0.53 0 0.86
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We were able to identify two proteins (in bold) that were part of the
mitotic process from table 4.5. ZWINT has been shown to play an essential
role in mitotic checkpoint signaling [196]. It is speciﬁcally required for kine-
tochore localisation which is involved in crucial interactions with spindle
microtubles that orchestrate proper chromosomal segregation [196]. Unfor-
tunately, the exact role of ZWINT in kinetochore localisation and function
is unknown leaving BUB1B as an ideal protein candidate for MudPIT val-
idation.
4.2.2.1 Validating the spindle assembly checkpoint
BUB1B, also known as BUBR1, is a serine/threonine protein kinase and
an integral component of the spindle assembly checkpoint (SAC). As dis-
cussed previously, the cell cycle is governed by speciﬁc checkpoints that
ensure proper progression of each phase. The SAC is needed for appro-
priate segregation of chromosomes during mitosis or meiosis, speciﬁcally
at the metaphase-anaphase transition [197, 198]. Interestingly, the very
ﬁrst studies that identiﬁed checkpoints such as the SAC that govern mito-
sis were done so with the use of microtubule depolymerising agents [198].
Figure 4.11 brieﬂy illustrates central components of the SAC [199].
The main function of the SAC is to delay anaphase during mitosis to
ensure that all chromosomes are attached to the mitotic spindle and aligned
along the metaphase plate. Prolonged mitotic arrest occurs if requirements
of the SAC are not met, which often leads to cell death. The SAC however,
can be overcome by the release of CDC20 from the mitotic checkpoint com-
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Figure 4.11: The spindle assembly checkpoint and cell fate.
[199]
plex (MCC) which consists of MAD2-BUBR1-BUB3-CDC20 or by direct
inhibition of Cdk1. This mitotic slippage can result in polyploidy, increased
cell survival, and provide a potential mechanism for escaping mitotic cell
death [199]. In summary, when the SAC is not satisﬁed, MCC is formed
and inactivates CDC20, which in turn prevents the APC/C from degrad-
ing cyclin B, a signal for metaphase, ultimately arresting cells in metaphase
until rectiﬁcation. On the other hand, if the SAC is satisﬁed, the MCC
does not form, leaving CDC20 in an active state, which then directs the
APC/C to degrade cyclin B and once degraded allows cells to progress to
anaphase (refer to 2.12).
Results from MudPIT showing a decrease in BUB1B levels over time
was corroborated by Western blots illustrated in ﬁg.4.13. Several com-
ponents of the APC (ANAPC1, 2, 4, 7) were also identiﬁed by MudPIT
analyses. APC is a large ubiquitin E3 ligase that consists of at least 13
proteins [200]. Trends showed that levels of APC components increased at
24 h relative to 16 h.
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Figure 4.12: MudPIT results illustrating temporal protein expression of
key components in the spindle assembly checkpoint in MCF-7 cells after
JA treatment for 8, 16, and 24 hours.
All treatment samples are expressed in fold change relative to the control
which is set to 1.
Another key protein integral to the SAC is CDC20. CDC20 was not
indentiﬁed in our MudPIT studies, but was validated based on its asso-
ciation with the MCC. CDC20 levels decreased in MCF-7 and HCT-116
cell lines post 8 h treatment with JA. Interestingly, levels of CDC20 did
not decrease in V-R HCT-116 cells even after 72 h exposure. This con-
curs with the idea that CDC20 is constantly active in V-R HCT-116 cells,
which allows APC/C to degrade cyclin B, thus permitting cells to progress
to anaphase. This defect in the SAC may paradoxically contribute to vin-
cristine resistance and JA sensitivity as well.
MAD1L1 is one of the main proteins that is responsible for recruiting
components of the MCC, speciﬁcally MAD2 to unattached kinetochores.
As seen in ﬁg.4.12, MAD1L1 levels quadrupled at 24 h. It may be that
the number of unattached kinetochores cause increased levels of MAD1L1
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Figure 4.13: Western blots validating temporal protein expression observed
in MudPIT of key components of the spindle assembly checkpoint in MCF-
7, HCT-116 and V-R HCT-116 cells after JA treatment.
The red box indicates time exposures that were investigated in MudPIT
studies.
at this time point, where the G2/M arrest was at its highest following JA
treatment as observed from cell cycle analyses. Some studies have shown
that upregulation of MAD1 leads to chromosomal instability and more
importantly resistance to microtubule poisons [201].
PLK1 is another protein that we validated in reference to the SAC
pathway. A very recent study showing that PLK1 is indeed needed to
strengthen SAC signaling and acts cooperatively with Monopolar spindle
1 (MPS1) to regulate checkpoint establishment and maintenance. MPS1
is a protein kinase that establishes and maintains the MCC inhibitory sig-
nal, which accumulates and autoactivates unattached or misaligned kine-
tochores [202]. MudPIT studies revealed a decrease in PLK1 expression by
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24 h which concurs with blots showing the same in MCF-7 cells. However,
PLK1 expression relative to the control in MudPIT did not match Western
blot data as levels at 24 h seemed higher. Levels of PLK1 did decrease in
MCF-7, HCT-116, and V-R HCT-116 cells after 48 h exposure to JA.
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4.2.2.2 Increased expression of ROS scavengers is indicative of
ROS production
As discussed in 3.2.6.1, JA induces ROS in HCT-116, V-R HCT-116, and
JA-R HCT-116 cells. MudPIT studies conﬁrmed signiﬁcant fold changes in
key ROS scavengers such as glutathione S-transferase (GST) and catalase
at 24 h (see ﬁg.4.14). GSTs represent a major group of detoxiﬁcation en-
zymes. There is evidence suggesting that the level of GST is an important
factor in determining cell sensitivity to a broad spectrum of chemicals which
include antitumour agents and products of oxidative stress [203]. Further-
more, induction of GST by ROS may represent an adaptive response as
these enzymes detoxify some toxic metabolites containing epoxides (present
in JB), peroxides, and carbonyls that are produced within the cell by oxida-
tive stress [203]. Catalases and peroxiredoxins catalyse the decomposition
or reduction of hydrogen peroxide into its constituents, water and oxy-
gen. Some studies have found that migration and proliferative capacities
of MCF-7 cells are impaired by the overexpression of catalases [204]. Per-
oxiredoxins come from a family of highly conserved antioxidant enzymes
[205]. As seen in ﬁg.4.14, levels of peroxiredoxin enzymes remain relatively
stable compared to the control. Increased expression of thioredoxin re-
ductase 1 (TXNRD1) was evident by 24 h post JA treatment. TXNRD1
reduces and activates thioredoxin, an oxidoreductase containing a dithiol-
disulﬁde active site, which in turn reduces oxidized cysteine residues on
cellular proteins and scavenges peroxides by peroxiredoxins [206].
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Figure 4.14: JA induces expression of key enzymes involved in detoxiﬁca-
tion in MCF-7 cells after treatment.
All treatment samples are expressed in fold change relative to control
which is set to 1.
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Figure 4.15: JA induces signiﬁcant levels of ROS production in MCF-7
cells.
Cells treated with JA (1 µM) and vincristine (5 nM) also induced
signiﬁcant ROS in MCF-7 cells compared to the control (***p<0.001 and
**p<0.01). However, diﬀerences in ROS levels between JA and vincristine
treatment were not signiﬁcant (ns). Experiments were repeated at least 2
times (n=4). Refer to 6.2.12 for experimental methodology.
This reducing environment mediated by thioredoxin is conducive to
DNA binding of redox-sensitive transcription factors such as p53 and NF-
κB [206]. Its main role is to bind ROS before they can harm cells, protecting
them from oxidative stress [206]. Increase in ROS production in MCF-
7 cells after JA treatment may have caused TXNRD1 levels to increase
over time. Taken together, ROS assays and increased expression of ROS
scavengers conﬁrm ROS generation.
4.2.2.3 JA treatment causes reduced levels of differentially ex-
pressed tubulin types in MCF-7 cells
As seen in ﬁg.3.7, β-tubulin is a target for clinically used antimitotic agents.
Western blots conﬁrmed reduction in TUBB levels observed in MudPIT af-
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ter treatment with 1 µM JA. However, levels of TUBB remain unchanged
in HCT-116 and V-R HCT-116 cells after 8 h, 16 h, and 24 h of JA ex-
posure. However, decreases were seen at 72 h in HCT-116 cells. V-R
HCT-116 clearly expressed higher levels of TUBB at 72 h in comparison to
HCT-116 and MCF-7 cells which showed decreased expression of TUBB at
that same time point (see ﬁgs.4.16) and 4.17. An interesting study showing
that treatment with vincristine, a depolymerising agent, decreased tubu-
lin levels in cancer cell lines [207]. This decrease was suggested to be a
result of proteasome-mediated degradation of tubulin, albeit the process
was signiﬁcantly enhanced in neural cells [207]. Other studies have shown
that novel peroxisome proliferator-activated receptor gamma (PPAR-γ) in-
hibitors induced tubulin degredation via proteasomal-dependent pathway
without aﬀecting polymerisation [208].
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Figure 4.16: Jerantinine A (1 µM) reduced levels of various tubulin com-
ponents in MCF-7 cells after treatment.
Control levels are normalised to 1 and any changes observed in treatment
samples are displayed as fold changes relative to the control.
Figure 4.17: Blots showing reduction in TUBB in MCF-7 cells correspond
to TUBB levels obtained in MudPIT after 8 h, 16 h, and 24 h exposure to
JA (1 µM).
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4.2.2.4 Short-term exposure to jerantinine A potently inhibits
growth
In order to validate the use of an 8 h time exposure in our investigations of
the proteome after JA treatment, it was necessary to determine if this short
treatment was enough to inhibit growth in cells. We therefore conducted
assays that were identical to MTTs with the exception of cells that were
treated for 8 h instead of a continuous 72 h exposure, washed with PBS,
replenished with medium, and incubated for 64 h alongside continuous
exposure (72 h) as an appropriate control for agent activity. If cell growth
was inhibited, we can deduce that this short term exposure was enough to
cause changes in the proteome that ultimately lead to cell death. As seen
in a representative graph (ﬁg.4.18), HCT-116 cells were unable to recover
from the short treatment yielding a mean GI50 value of 0.546 ± 0.140 µM.
These results suggest that JA is able to permeate the cell membrane and
inhibit cell proliferation within a short span of time. However, JA was
not able to inhibit growth of MCF-7 cells by 50% at 1 µM after an 8 h
exposure. A mean GI50 value of 4.362 ± 0.935 µM was obtained from
three experimental trials. This is nearly 4.5 times the concentration used
for our MudPIT studies. We know that 1µM is enough to evoke a signiﬁcant
G2/M block in MCF-7 cells after 24 h exposure to JA and perhaps proteins
reﬂective of that phenotype appear closer to or at that particular time
point. This is evident from the last ﬁlter (proteins that gradually and
completely disappeared by 24 h i.e. 100% depletion) applied to MudPIT
data showing spindle and microtubule-based organisation as possible hits
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for pathway validation.
Figure 4.18: JA inhibits growth of HCT-116 cells after only 8 h exposure.
GI50 values were determined by MTT assays following an 8 h exposure in
addition to a 64 h recovery period and expressed as a mean ± standard
deviation of 3 independent trials (n=4).
Figure 4.19: JA does not inhibit growth of MCF-7 cells by 50% at 1µM
after 8 h exposure.
GI50 values were determined by MTT assays following an 8 h exposure in
addition to a 64 h recovery period and expressed as a mean ± standard
deviation of 3 independent trials (n=4).
141
Early changes in proteins representing the phenotype of JA-treated cells
may be masked after only an 8 h exposure due to the fact that a lower than
optimal JA concentration was used. However, as seen in ﬁg. 4.20, diﬀer-
ences in expression proﬁles between control and 8 h treatment samples were
distinct enough to be clustered under diﬀerent branches (i.e. all treatment
samples were more similar to each other than the control).
142
Figure 4.20: Clustered heatmap showing distribution of perturbed proteins
across samples
Clustering protein expression proﬁles from all four samples revealed that
the proﬁle from the control sample was distinct from all three treatment
samples (8, 16, 24 h) and that each treatment sample shared some
similarity in expression proﬁles.
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4.3 Conclusion
The genome-wide RNAi screen revealed several candidate genes of interest
thought to mediate cell resistance or sensitivity to JA. Our investigations
were narrowed to genes controlling JNK1/2 expression because of its in-
volvement in multiple pathways identiﬁed by DAVID such as those related
to MAPK and TLR. These targets were obtained from the list consist-
ing of genes that when knocked down confer resistance to JA (table 4.1).
JNK1/2 and variants were knocked down in MCF-7 and MDA-468 cells
and then treated with JA (1 µM) for 72 h. Results showed that knocking
down JNK1 or JNK2 made cells more resistant to JA relative to controls
(up to 1.5 times in MCF-7 cells and 3 times more resistant in MDA-468
cells). Considering the important roles that JNKs play in cell proliferation,
apoptosis, ROS production, and stress responses, it is possible that these
proteins do in fact contribute to the phenotype observed in cells after JA
treatment.
Analysis of the proteome using MudPIT in JA-treated cells also cor-
roborated phenotypes observed throughout this study. Data analyses by
way of ﬁltering and using bioinformatics resources such as DAVID aided
identiﬁcation of BUB1B as a suitable candidate for validation. BUB1B is
a key player in the SAC and is essential to mitotic integrity. Western blots
showing protein expression of speciﬁc SAC components were in agreement
with levels obtained in MudPIT trials. Increased expression of proteins
involved in scavenging ROS were also identiﬁed by MudPIT suggesting
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that this process may be involved in apoptotic events resulting from JA
treatment. As discussed in chapter 3, JA is a potent inhibitor of tubu-
lin polymerisation. Interestingly, MudPIT analysis of MCF-7 treated cells
revealed decreased expression in α, β, and γ-tubulin. However, decreases
in β-tubulin were not observed in HCT-116 or V-R HCT-116 cells at 8,
16, and 24 h post treatment with JA. It is possible that altered expression
of tubulin isotypes and modulation of β-tubulin levels may impact the re-
sponse of MCF-7 cells to JA as some studies have shown this to be the case
in docetaxel-resistant MCF-7 and MDA-MB-231 cells [209].
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Chapter 5
Concluding Remarks and Future
Studies
5.1 Concluding Remarks
The contribution of natural product drug discovery to the ﬁeld of medicine
has been invaluable throughout human history. The impact of natural
products in cancer chemotherapy alone has been signiﬁcant by way of pro-
viding lead structures that can be used as templates for the construction
of novel compounds that possess enhanced biological properties. The in-
vestigations carried out in this study serve as a testament to the untapped
potential of natural products. In 2008, Lim et al. reported the isolation of
seven novel indole alklaoids, jerantinines A-G, from a leaf ethanolic extract
of the Malayan Tabernaemontana corymbosa. JA was the major constituent
of the leaf extract and was thus used for the biological studies detailed here.
Preliminary antiproliferative screens revealed potent growth inhibition of
JA on multiple human-derived cancer cell lines (A549, HCT-116, HT-29,
MCF-7, MDA-468, MiaPaCa-2, DAOY, MED1, and UW228-3). GI50 val-
ues obtained from MTT assays were ≤ 4 µM for all jerantinines (JA, JAA,
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JB, JBA) tested. V-R HCT-116 cells were generated and shown to express
Pgp. These cells were found to retain sensitivity to JA, being slightly more
sensitive than parent HCT-116 cells, which is indicative of JA’s ability to
overcome vincristine resistance. A NCI60 cell line panel screen against
JAA yielded GI50 values of less than 2 µM across all cell lines. JA was also
able to potently inhibit colony formation in A549, HCT-116, HT-29, and
MCF-7 cells after a brief 24 h exposure. Further assays were carried out in
order to determine the nature of cell death in response to JA. Annexin V
assays revealed dose- and time-dependent increases in apoptosis in treated
cells. This was corroborated by upregulation and downregulation of pro-
and anti-apoptotic proteins respectively.
Cell cycle analyses revealed potent G2/M arrests in A549, HCT-116,
HT-29, MCF-7, and MDA-468 cells. Considering that JA shares a de-
gree of structural similarity with vincristine and its ability to cause potent
G2/M arrests typically seen in cells after treatment with taxanes and vinca
alkaloids, it was hypothesised that JA may target microtubules. Indeed,
tubulin polymerisation assays convincingly demonstrated that JA inhibited
tubulin polymerisation and is thus similar to the vinca alkaloids. Pheno-
types of JA-treated cells were determined using confocal microscopy. Im-
ages showed severe perturbations in cytoskeletal architecture such as mem-
brane blebbing, multipolar spindle formation, DNA fragmentation, and
aneupolidy. The integrity of DNA in JA-treated cells was investigated by
measuring phophorylated γH2AX levels which is indicative of DNA DSBs.
JA induced signiﬁcant levels of phophorylated γH2AX after only a 24 h ex-
147
posure. As mentioned earlier, JA demonstrated potent growth inhibition in
V-R HCT-116 cells. This was consistent with Western blots showing that
expression of Pgp did not hinder the activity of JA. Increased levels of ROS
have also been reported to play a role in acquired resistance. JA induced
more signiﬁcant levels of ROS than vincristine in HCT-116 and MCF-7
cells. Our collaborative studies revealed that JBA binds to the colchicine
binding site on microtubules, suggesting the same may be true for the jer-
antinine family of compounds. Modelling studies exploring diﬀerences in
JA and JB binding are currently under way.
Analyses of data from the genome-wide shRNA screen revealed involve-
ment of JNK1/2 in mediating sensitivity of MCF-7 cells to JA. Validation
of this data entailed knocking down JNK1/2 in MCF-7 and MDA-468 cells,
treating them with JA, and measuring growth inhibition after 72 h expo-
sure using MTT assays. Results showed that depletion in JNK1/2 conferred
resistance to JA. Global proteome analysis was carried out using MudPIT.
Data analyses and validation using Western blots revealed abberations in
the SAC, increased expression in key ROS scavengers, and decreased ex-
pression in α, β, and γ-tubulin.
As studies that probe the mechanistic nature of JA continue, it should
be taken into consideration that its eﬀects in vivo are presently unknown.
One of the most common problems associated with MTAs is the issue of
neurotoxicity. Our assumption that JA may be neurotoxic stems from
the fact that other clinically available MTAs like paclitaxel and vincristine
cause neurotoxicity. Even though JA fulﬁls Lipinski’s rule of 5, by no
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means does it indicate suitability as a lead compound. On the other hand,
both paclitaxel and vincristine violate Lipinski’s rule of 5, but are still
approved for use in the clinic. Additionally, our studies have conﬁrmed
that JA is not a Pgp substrate unlike paclitaxel and vincristine, which
could potentiate neurotoxicity if it passes the blood-brain barrier. Further
studies of JA’s eﬀects in vivo as it pertains to absorption, distribution,
metabolism, and excretion need to be thoroughly explored in order to fully
discern its potential as a chemotherapeutic agent.
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5.2 Future Studies
Having identiﬁed the mechanism of action for JA in vitro, a more thorough
understanding of its properties and suitability for in vivo testing needs to
be achieved. Based on our observations throughout this study, JA appears
to be more unstable than JB. Therefore, it is necessary to investigate how
this compound breaks down in conditions similar to those subjected in cells
after treatment. For instance, measuring stability and biproducts of JA at
various time points when treated cells are incubated in 37℃ using LC/MS
may give an indication of extracellular and intracellular concentrations of
the agent. Another alternative is to use dialysis tubing as a model for the
semi-permeable cell membrane which may provide a crude estimation of
how much of the agent gets into the cell at various time points. This also
can be measured using LC/MS, however, the model does not take other
modes of cellular transportation (inﬂux and eﬄux) into account i.e. active
transport systems such as drug eﬄux pumps etc. One approach that is
currently being explored by collaborators is the use of a ﬂuorophore that
is tagged on to JA. This would not only aid in measuring extracellular and
intracellular concentrations, but also help in visualising possible localisation
of the compound within the cell post-treatment.
The revelation that the jerantinines most likely bind to the colchicine
binding site on microtubules allows for further investigations into the nature
of binding between these compounds and tubulin. For instance, competitive
binding assays with radio-labelled colchicine may be employed to determine
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the aﬃnity of the jerantinines to this particular site. This can be carried out
using a scintillation proximity assay (SPA) constituting biotinylated tubu-
lin, SPA streptavidin beads, tritiated colchicine and a competitor, which
in this case is JA. SPA technology requires a close association between a
solid phase scintillant (the beads) and a radio-ligand for signal emission
and detection. The medium that brings the tritiated colchicine and SPA
beads in close association is the biotinylated tubulin. If the radio-ligand
occupies the binding sites on tubulin and is in close range of the SPA beads,
the signal detected would be proportional to the number of sites occupied
by this ligand. On the other hand, if an unlabelled competitor occupied
these binding sites on tubulin, the decrease in signal would be proportional
to the concentration of said competitor (see ﬁg.5.1).
An additional advantage of this assay is that it allows identiﬁcation of
reversible or irreversible binding to the colchicine site over a long period
of time. Colchicine was a failure in the clinic partly due to the fact that
it binds to tubulin in an irreversible manner which contributed to severe
toxicities. If JA binds reversibly to tubulin, it may be easier to liberate or
metabolise the agent more readily.
It may be interesting to explore diﬀerential expression of proteins in-
volved in metabolising colchicine and JA using LC-MS/MS (metabolomics)
as this technique can provide a good indication of bioactivation and drug-
induced cytoxicity in both in vitro and in vivo settings.
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Figure 5.1: SPA assay with biotin-tubulin and streptavidin beads
Accessed from:
http://www.cytoskeleton.com/pdf-storage/datasheets/cds15.pdf
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Chapter 6
Materials and Methods
6.1 Materials
6.1.1 Cell Lines
The A549 cell line was ﬁrst developed in 1972 from the culturing of an
explanted tumour of a 58-year-old male [210]. They are alveolar basal
epithelial cells that have an adherent mode of growth and have a doubling
time of approximately 22 hours [210]. These cells are particularly unique
because of their ability to produce lecithin, a phospholipid, and constitute
high levels of desaturated fatty acids that are crucial to maintaining the
integrity of the phospholipid bilayer forming the cell membrane [211]. It has
been suggested that these changes in the cell membrane can be attributed
to this cell line’s increased resistance to chemotherapeutic agents [211].
The HCT-116 (wildtype p53; mutant RAS) cell line is one of three
malignant cell lines (HCT-116a and HCT-116b) isolated from a male with
colonic carcinoma. These cells are adherent and have a short doubling time
of 17.4 hours in addition to possessing a modal chromosome number of 46
[212]. They are also reported to have higher levels of colony formation
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capability [212].
The HT-29 (mutant p53) cell line was isolated from a woman with colon
adenocarcinoma in 1964 [213].This cell line also has an adherent mode of
growth with a doubling time of approximately 19.5 hours and is considered
to be more invasive than the HCT-116 cell line [213]. HT-29 cells grow
in vitro as discrete semispheroid clusters and have a rounded appearance
[214].
MCF-7 (wildtype p53)is an ER+ breast cancer cell line derived from
the pleural eﬀusion of a 69-year-old woman who had invasive breast ductal
carcinoma in 1970 [215].These cells form tightly cohesive structures thereby
illustrating robust cell to cell adhesions and display a luminal epithelial
phenotype [216].
The MDA-MB 468 is a triple negative (ER-, PR-, and Her2/neu-) p53
mutant cell line derived from the pleural eﬀusion of a 51-year-old female
who had metastatic breast adenocarcinoma and possesses an epithelial mor-
phology that resembles loosely cohesive grape-like structures which is con-
sistent with a more invasive phenotype [216].
The MRC-5 cell line was ﬁrst derived from normal lung tissue of a
14-week-old male foetus in 1966 [217]. These cells are capable of 40-42
population doublings before the onset of senescence [217].
The cell lines used in this project were originally obtained from the
ATCC and subsequently stored in the CBS cell bank for experimental use
(see 6.2.1).
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6.1.2 Cell Culture Media
MRC-5 ﬁbroblasts were cultured in minimum essential medium (MEM)
(Sigma-Aldrich UK, Catalogue No.: M2279) supplemented with 10% v/v
foetal bovine serum (FBS) (Sigma-Aldrich UK, Catalogue No.: F9665),
7.5% sodium bicarbonate (Sigma-Aldrich UK, Catalogue No.: S8761), 1%
0.1 mM non-essential amino acids (Sigma-Aldrich UK, Catalogue No. M71
45), 1% 1 M HEPES (Sigma-Aldrich UK, Catalogue No. H0887), 1% 200
mM L-glutamine (Sigma-Aldrich UK, Catalogue No.: G7513), and 1%
penicillin-streptomycin (Sigma-Aldrich UK, Catalogue No.: P4333). All
other cell lines were maintained in RPMI-1640 (Sigma-Aldrich UK, Cata-
logue No.: R8758) growth medium supplemented with 10% FBS.
6.1.3 Compounds
Jerantinine A, B, and their acetate derivatives were kindly provided by Dr.
Kam Toh Seok (University of Malaya) and Dr. Kuan Hon Lim (University
of Nottingham Malaysia Campus).
6.1.4 Chemicals and Reagents
The chemicals used in this study are of analytical, biological or molecular
biology grade. Trypsin 10x (Sigma-Aldrich UK, Catalogue No.: T1763);
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Alfa
Aesar UK, Catalogue No.: L11939); DMSO (Sigma-Aldrich UK, Catalogue
No.: D5879); FBS-heat inactivated (Sigma-Aldrich UK, Catalogue No.:
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F9665); methylene blue solution (Sigma-Aldrich UK, Catalogue No.: 7220-
79-3); ethanol/IMS (Sigma-Aldrich UK, Catalogue No.: 458600-2.5L);
methanol HPLC grade (Fisher Scientiﬁc UK, Catalogue No.: M/4056/17);
formaldehyde solution (Sigma-Aldrich UK, Catalogue No.: 252549); 16%
formaldehyde solution (w/v), methanol-free (Thermo Scientiﬁc UK, Cata-
logue No.: 28908); propidium iodide(PI) (Sigma-Aldrich UK, Catalogue
No.: P4170); Triton-X100 (Sigma-Aldrich UK, Catalogue No.: X100);
RNAse A (Sigma-Aldrich UK, Catalogue No.: R6513); annexin V-FITC,
PI and annexin binding buﬀer (0.1 M HEPES/NaOH, pH 7.4, 1.4 M NaCl,
25 mM CaCl2); hypotonic ﬂuorochrome solution (0.1% sodium citrate;
0.1% Triton X-100; 50µg/ml PI; 100µg/ml RNAseA); ammonium per-
sulfate (AMPS) (Sigma-Aldrich UK, Catalogue No.: A3678); N,N,N,’N’-
tetramethylethylenediamine (Sigma-Aldrich UK, Catalogue No.: T9281);
β mercapto ethanol (Sigma-Aldrich, Catalogue No.: M3148); bromophenol
blue (Sigma-Aldrich UK, Catalogue No.: B0126); Glycerol (Sigma-Aldrich
UK, Catalogue No.: G5516); Tween-20 (Sigma-Aldrich UK, Catalogue No.:
P9416); acrylamide/
bis-acrylamide (30%) (Sigma-Aldrich UK, Catalogue No.: A3574); Pro-
tease inhibitor cocktail tablets (Roche diagnostics UK), Catalogue No.:
11836153001); PhosStop inhibitor (Roche diagnostics UK), Catalogue No.:
04906837001), Bradford reagent (Sigma-Aldrich UK, Catalogue No.: B6916),
Developer (Sigma-Aldrich UK, Catalogue No.: P7042); Fixer (Sigma-Aldrich
UK, Catalogue No.: P7167); sodium dodecyl sulphate (SDS) (Melford UK,
Catalogue No.: B2008); PageRuler plus prestained protein ladder (10-
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250 kDa) (Thermo Scientiﬁc UK, Catalogue No.: 26619); Colour-coded
prestained protein marker, High range (43-315 kDa) (New England Bi-
olabs Ltd. UK, Catalogue No.: 12949S); cassettes 1.5 mm (Invitrogen
UK, Catalogue No.: NC2015); bovine serum albumin (BSA) (VWR In-
ternational Ltd. UK, Catalogue No.: 421501J); Bradford reagent (Sigma-
Aldrich UK, Catalogue No.: B6916); AmershamTM ECLTM Western blot-
ting detection reagents (GE Healthcare UK, Catalogue No.: RPN2106);
Amersham Hyperﬁlm TM ECL high performance chemi-luminescence ﬁlm
(GE Healthcare UK, Catalogue No.: 28906837); Apo-one homogeneous
caspase 3/7 assay kit (Promega USA, Catalogue No.: G7790) containing
caspase substrate Z-DEVD-R110, 100x apo-one homogeneous caspase 3/7
buﬀer; ROS-GloTM H2O2 Assay (Promega USA, Catalogue No.: G8820)
containing H2O2 substrate (10 mM), signal enhancer solution, H2O2 sub-
strate dilution buﬀer, D-Cysteine (100x), luciferin detection reagent, and
reconstitution buﬀer; tubulin polymerisation assay kit (Cytoskeleton USA,
Catalogue No.: BK006P) containing tubulin protein, GTP stock, gen-
eral tubulin buﬀer, tubulin glycerol buﬀer, paclitaxel, DMSO, and a half-
area 96-well plate; vincristine (sulfate) (Cayman Chemical USA; Cata-
logue No.: 11764); 2,2,2-Triﬂuoroethanol (Sigma-Aldrich Canada, Cat-
alogue No.: T63002); DL-Dithiothreitol (DTT) (Sigma-Aldrich Canada,
Catalogue No.: D0632); Iodoacetamide (IAA) (Sigma-Aldrich Canada,
Catalogue No.: I1149); Ammonium bicarbonate (Sigma-Aldrich Canada,
Catalogue No.: A6141); trypsin gold, mass spectrometry grade (Promega
USA, Catalogue No.: V5280); STAGE Tips [Built in-lab using P200 tips
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stuﬀed with SCX teﬂon disc (Millipore) and C18 reverse phase teﬂon disc
(Millipore)]; ammonium acetate (Sigma-Aldrich Canada, Catalogue No.:
A1542); ammonium hydroxide solution (Sigma-Aldrich Canada, Catalogue
No.: 338818).
6.1.5 Buffers
Phosphate buﬀered saline tablet (Sigma-Aldrich Catalogue No.: P4417; 1
tablet /200 ml of deionised water yields 0.01 M phosphate buﬀer, 0.0027
M potassium chloride and 0.137 sodium chloride, pH 7.4); Resolving gel
buﬀer (1.5 M Tris-Cl, pH 8.8, 0.4% SDS); Stacking gel buﬀer [1 M Tris-Cl,
pH 6.8, 0.8% SDS); resolving gel 7.5% per 10 mL (30% acrylamide (2.5
ml), resolving buﬀer (2.51 ml), dH2O (4.99 ml)]; resolving gel 10% per 10
ml [30% acrylamide (3.33 ml), resolving buﬀer (2.51 ml), dH2O (4.16 ml)];
Lysis buﬀer /10ml (1.5 ml of Nacl, 100 µL of NP-40, 0.5 ml of Tris pH
8.0, ﬁlled to a total volume of 10 ml ddH2O, 1 tablet each of protease and
phosphatase inhibitor).
6.1.6 Antibodies
The antibodies used in this project are summarised below along with sup-
plementary information detailing blocking, dilution, and storage conditions
in addition to suppliers and catalogue numbers:
Antibody Blocking Dilution Storage Supplier Cat. No.
p53 10% milk 1:1000 4℃ Dako M7001
158
HDM2 10% milk 1:1000 -20℃
Thermo Scien-
tiﬁc
MA1-
2331B
Cyclin B1 10% milk 1:1000 -20℃ Cell Signaling 4135
Caspase 3 10% milk 1:1000 -20℃ Cell Signaling 9668
PARP 10% milk 1:1000 -20℃ Cell Signaling 9532
Mcl-1 10% milk 1:1000 -20℃ Cell Signaling 4572
P-
Glycoprotein
5% milk 1:1000 -20℃ GeneTex GTX23364
BUB1B 5% milk 1:1000 -20℃
Thermo scien-
tiﬁc
MA1-
16577
CLASP1 5% milk 1:1000 -20℃ GeneTex GTX62531
GEF-H1 5% BSA 1:1000 -20℃ Cell Signaling 4076
MARK2 5% BSA 1:1000 -20℃ Cell Signaling 9118
CDC20 5% BSA 1:1000 -20℃ Cell Signaling 4823
CLIP1/-
CLIP170
5% BSA 1:1000 -20℃ Cell Signaling 8977
CRMP-2 5% BSA 1:1000 -20℃ Cell Signaling 9393
Rac1/Cdc42 5% BSA 1:1000 -20℃ Cell Signaling 4651
Diap2 5% BSA 1:1000 -20℃ Cell Signaling 5474
APC 5% BSA 1:1000 -20℃ Cell Signaling 2504
EB-1 5% BSA 1:1000 -20℃ Cell Signaling 2164
GSK-3β 5% BSA 1:1000 -20℃ Cell Signaling 9832
GAPDH 5% milk 1:1000 -20℃ Cell Signaling 5174
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β-actin 5% milk 1:1000 -20℃ Cell Signaling 4970
p-Histone
H2A.X
1% FBS 1:3333 4℃
EMD-
Millipore
05-636
TUBB1 5% milk 1:1000 -20℃
Source Bio-
science
SBS403514
Goat Anti-
Mouse
IgG/HRP
5% milk 1:4000 4℃ Dako PO447
Goat Anti-
Rabbit
IgG/HRP
5% milk 1:4000 4℃ Dako PO448
Alexa
Flourr 488
F(ab’)2
fragment
goat anti-
mouse
IgG
1% BSA 1:400 4℃ Invitrogen A-11017
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6.1.7 Software
All statistical analysis were conducted using GraphPad Prism 6. The
DAVID bioinformatics resources 6.7 database was used to visualise func-
tionally annotated MudPIT data. The Reactome database and Thermo
Scientiﬁc’s ProteinCenter software were also used for functional annota-
tion. All visual statistics for the proteomics section (graphs, plots, etc.)
were done using R statistics. Zeiss LSM 510 image browser was used to
add appropriate scale bars to all confocal images obtained. FACS data
were analysed using Beckman Coulter’s ExpoTM 32 software.
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6.2 Methods
6.2.1 Cell Culture
Cell culture was carried out aseptically in a BioMat2 MDH Class II mi-
crobiological safety cabinet constituting a laminar ﬂow system. The safety
cabinet was swabbed with 70% IMS in dH2O. All cell lines were passaged
twice weekly upon reaching 80% conﬂuency in order to maintain logarith-
mic cell proliferation. Cells were sub-cultured in 25 cm2 and 75 cm2 Corning
and Costar tissue culture ﬂasks with RPMI 1640 medium containing 0.3
g/L L-glutamine and 2 g/L sodium bicarbonate supplemented with 10%
heat-inactivated FBS. The FBS was heat-inactivated by heating to approx-
imately 56℃ for 1 h and either added immediately to RPMI 1640 medium
or frozen in 50 ml aliquots. Upon sub-culturing, the medium was aspirated
from the ﬂask containing the cells and washed with 1 mL of PBS. Cells
were then trypsinised with 1 mL of trypsin – EDTA 1X solution to detach
the cells from the ﬂask which was placed in the incubator for approximately
2 min. Fresh medium (5 ml) was added to neutralise the trypsin and re-
suspend the cells. Cells were split at a 1:5 ratio in new ﬂasks containing 7
ml of medium and placed in a Sanyo LEEC incubator at 37℃ in an atmo-
sphere constituting 5% CO2. The incubator also contained a tray of dH2O
to provide a humidiﬁed environment. All cells were initially taken from the
cell bank containing liquid nitrogen and brieﬂy incubated in 37℃ to thaw.
Cells were then transferred from the cryovial into 25 cm2 ﬂasks with 10 ml
of growth medium to allow growth. The newly revived cells were passaged
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at least three times before experiemntal use. For long-term storage, cells
were sub-cultured in 75 cm2 ﬂasks and allowed to reach approximately 80%
conﬂuence. They were detached using trypsin - EDTA 1X solution and sus-
pended in sterile cryovials with 8% DMSO in FBS and subject to gradual
cooling from -20℃ initially to -80℃ for 1-2 days and ﬁnally into the liquid
nitrogen storage bank.
6.2.2 Compound Stock Solutions
Jerantinine A and B were provided in powdered form in bottled vials and
reconstituted with the appropriate amount of DMSO to yield a concen-
tration of 10 mM. Jerantinine A and B acetate were provided in oil form,
bottled and reconstituted in the same manner as above. These vials were
used as top stocks for subsequent experiments where dilutions were freshly
prepared. Stocks were stored at -80℃ and protected from light in 10 µL
aliquots to minimise freeze/thaw cycles. Vincristine (sulfate) was pur-
chased and prepared in the same manner described above.
6.2.3 MTT Assay
The method used for this assay was adapted from Mosmann [218]. The
MTT assay is colorimetric in nature and can be used to assess cell growth
and viability, following treatment with therapeutic agents or toxic com-
pounds. MTT (yellow) is reduced to a purple formazan in living cells by
the activity of cellular enzymes, speciﬁcally mitochondrial dehydrogenases,
and the intensity of the dye can be quantiﬁed by a spectrophotometer [218].
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The assay is rapid, economical, and reproducible [219]. Cells harvested
from cell culture were syringed through a 23 g (gauge) needle to attain a
single cell suspension. The cells were counted and seeded at a density of 3
x 103 cells per well in a 96-well plate. The cells were suspended in 180 µl of
RPMI 1640 tissue culture medium per well. The outer columns of the plate
were ﬁlled with 300 µl of medium to minimise evaporation from experimen-
tal wells in addition to providing blank readings for the plate reader. Cells
were additionally seeded in a time zero (t0) plate in the same manner as
the experimental treatment plate. The cells were incubated overnight at
37℃ in a 5% CO2 environment to allow for attachment. Cells were then
treated with serial dilutions of various concentrations the following day. A
volume of 20 µl of each dilution was added to respective treatment wells
(total volume 200 µl) to yield ﬁnal concentrations of 0.005 µM, 0.01 µM,
0.05 µM, 0.1 µM, 0.5 µM, 1 µM, and 5 µM. A separate DMSO control
trial was done to ensure that it did not aﬀect any of the results obtained.
A volume of 20 µl from DMSO serial dilutions was added to two columns
containing cells without any treatment. A t0 measurement was taken to
obtain a measurement of cell viability at the time of treatment. Treated
cells were incubated for 72 h at 37℃. After the treatment exposure pe-
riod, 50 µl of MTT (concentration of 2 mg/mL in PBS) was added to
each well and cells were incubated at 37℃ for 3-4 h. After incubation, all
wells were carefully aspirated and 150 µl of DMSO was added to each well
to solubilise formazan crystals. The plate was then placed in an orbital
plate shaker for 2-3 min to aid formazan dissolution before obtaining the
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absorbance reading at 555 nm on a Perkin Elmer Envision plate reader.
All readings were recorded on an Excel spreadsheet supplied by the Wallac
Envisionr software. Resultant curves and GI50 calculations were obtained
from GraphPad Prism.
6.2.4 Generating Vincristine and Jerantinine A-resistant
HCT-116 cells
Vincristine- and jerantinine A-resistant HCT-116 cell lines were generated
in the Centre for Biomolecular Sciences (CBS) using the aforementioned
parent HCT-116 cells. HCT-116 cells were initially subbed into 25 cm2
ﬂasks and allowed to grow to approximately 80% conﬂuence. Cells were
then treated with GI50 values obtained from the MTT assay. Media were
frequently changed every 3-4 days with the addition of compounds. Sub-
sequently increasing concentrations from 5 nM up to 2 µM were used once
cells were observed to have grown back to approximately 80-90% conﬂu-
ence. Cells were maintained at a ﬁnal concentration of 2 µM thereafter.
6.2.5 Clonogenic Assay
The clonogenic assay was once considered the “gold standard” of cell sen-
sitivity assays and originated from the evaluation of radiosensitivities of
tumour cells in vitro [220]. It was thought that only a clonogenic assay
was sensitive enough to detect cell kill at low percentage survivals (<1%).
More speciﬁcally, it measures the ability of a single cell to survive a brief
exposure to the test agent and maintain proliferative potential to form
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colonies. The duration it takes for the cells to form colonies is compara-
ble to recovery time. Furthermore, cytotoxic and cytostatic eﬀects can be
distinguished from each other after only a brief exposure to the test agent.
This assay was used in addition to the MTT assay as an initial screen in
this study.
Cells were counted using a haemocytometer and approximately 250-350
cells (depending on the cell line) were seeded per well in 6-well plates with
2 ml of medium. Cells were allowed to attach for 24 h. The cells were then
treated using the GI50 values obtained from the MTT assays i.e. 1 x GI50
and 2 x GI50. Cells in control wells were treated with vehicle (medium)
alone. Following 24 h exposure to Jerantinine A, medium was aspirated
along with the compound. Wells were washed 2 x with 1 ml of PBS and
2 ml of fresh medium was added to each well. Plates were placed in the
incubator at 37℃ and inspected daily until cells in control wells formed
colonies of ≥ 50 cells. The cells were washed with PBS before ﬁxation with
100% methanol (0.5 ml) for 15 min and then stained with 0.7 ml of 0.5%
methylene blue (1:1 water:methanol) for an additional 10 min. Colonies
were counted and recorded graphically using GraphPad Prism.
6.2.6 Flow Cytometry
Flow cytometry is a powerful tool primarily used to measure properties of
individual particles. Cells are analysed one at a time made possible through
hydrodynamic focusing. Beams of light pass through each cell and are
scattered in two distinct ways: forward scatter and side scatter. Forward
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scatter (FSC) is an indication of the size of the cell and side scatter (SSC)
depicts the granularity of the cell. Cumulatively, this data is represented
as a dot plot of FSC versus SSC and allows for the estimation of viable
cell fractions. Appropriate gates are set up and dependent upon the type
of assay performed.
6.2.6.1 Cell Cycle Analysis
Cell cycle analysis was carried out using a method based on Nicoletti et al
(1991) [221]. PI is an intercalating DNA dye that ﬂuoresces strongly when
bound to DNA. The DNA content of an individual cell is proportional to
the ﬂuorescence intensity of exited PI (excited by an argon laser at 488
nm). A histogram of DNA content of cells in a population can be used to
derive the percentage of cells in each phase (pre-G1, G1/G0, S, and G2/M)
of the cell cycle and any perturbations caused by the tests compounds. PI
is normally excluded by intact cells that need to be permeabilised via the
use of a gentle detergent/hypotonic solution to allow PI entry into these
cells.
Cells were seeded in 6-well plates at the following densities in 2 ml of
medium and treated for the respective time exposures: A seeding density
of 1x105 cells was used for 24 h and 48 h treatment exposures in all cell
lines, whereas a lower seeding density of 5x104 cells in all cell lines for 72
h treatments was optimal to maintain logarithmic growth.
Following treatment, medium containing any ﬂoating cells was pipetted
into labelled FACS tubes and kept on ice. Cells were trypsinised and once
167
detached pooled together with medium and then pelleted in a Beckman
Coulter Allegro centrifuge at 1200 rpm for 5 min at 4℃. The supernatant
was discarded and the pellet broken up by gently ﬂicking the tube. The
cells were re-suspended in 0.3-0.5 ml of ﬂuorochrome solution and stored
overnight in the dark at 4℃. A single cell suspension was achieved by gently
passing the cells through a 23 g needle immediately prior to analysis on a
Coulter Epics XL-MCLTM ﬂow cytometer. Appropriate gates were set up
relative to the control and data stored for further statistical analyses.
6.2.6.2 Annexin V-FITC and Propidium Iodide Apoptosis As-
says
One of the events triggered in early stage apoptosis involves the “ﬂipping”
of phosphatidyl serine (PS) from the inner to the outer leaﬂet of the cell
membrane. At this stage, cells still retain membrane integrity, a fact that
can be exploited to distinguish between early and late apoptosis/necrosis,
where membranes have become compromised [150]. Annexin V is a small
protein that binds to PS with high aﬃnity. PI is also used to stain DNA
and can be used as an indicator of cell membrane integrity. Combining
ﬂuorescently labelled Annexin V with PI allows discrimination of healthy
cells (annexin V – FITC negative, PI negative) from early apoptotic cells
(annexin V – FITC positive, PI negative) or late apoptotic/necrotic cells
(annexin V- FITC positive, PI positive) [151].
Cells were seeded and harvested in the same manner described in section
7.2.5.1. After pelleting the cells, the supernatant was discarded, pellets
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gently broken up by agitation and re-suspended in 2 ml of cold medium
and kept on ice for 10 min to recover from any damage caused by trypsin.
PBS (1 ml) was added to each tube and pelleted again at 1200 rpm for 5
min at 4℃. The supernatant was discarded, ensuring all the PBS had been
removed and the pellet broken up by gentle ﬂicking of the tube. Annexin
binding buﬀer (100 µL; 1 x) was added to each tube followed by addition
of 5 µl of Annexin V-FITC. Tubes were brieﬂy vortexed and left at room
temperature in the dark for approximately 15 min. Annexin binding buﬀer
(400 µL; 1 x) and 10 µl of PI solution were added to each tube. Tubes were
vortexed and kept on ice in the dark for 10 min prior to analysis on the ﬂow
cytometer. Samples were analysed within 1 h of completion of the above
protocol to avoid deterioration of cells. Gates were set up on a dual colour
plot for vehicle treated samples and the percentages of early apoptotic cells
(annexin V – FITC positive, PI negative) or late apoptotic/necrotic cells
(annexin V – FITC positive, PI positive) recorded.
6.2.6.3 Assessing DNA Damage using Flow Cytometry
DNA double-strand breaks (DSBs) are lesions that contribute to genomic
instability and can lead to cancer. Paradoxically, DSBs can also cause can-
cer cell death [222]. H2AX is a key histone protein involved in recognition of
DNA DSBs [223]. As DSBs occur, H2AX undergoes rapid phosphorylation
to form γH2AX which in turn recruits and localises DNA repair proteins.
The appearance of γH2AX foci represent DSBs in a 1:1 manner and can be
used as a biomarker for DNA damage [223]. These foci are quantiﬁed by
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ﬂuorescence using primary γH2AX and ﬂuorescently conjugated secondary
antibodies [223].
Cells were seeded at a density of 1-1.5x106 in 10 cm2 dishes and allowed
to adhere for 24 h at 37℃. Test agents were added along with fresh medium
at desired concentrations. Following treatment, media/ﬂoating cells were
decanted into labelled FACS tubes (12x75 mm). A ml of trypsin (1x) was
added after washing cells with 1 ml of PBS, and incubated at 37℃ until
detached. Cells were ﬂushed from the bottom of the petri dish, added
to respective FACS tubes, and pelleted in a centrifuge at 1300 rpm for
10 min at room temperature. Supernatant was aspirated leaving a small
amount at the bottom of the tube to avoid disturbing the pellet. Pellets
were resuspended by gently ﬂicking the tubes.
Note: Repetitions of the above three steps will be referred to SAR (Spin
- Aspirate - Resuspend) when required again.
This process was then repeated after adding 1 ml of PBS. Cells were
ﬁxed in a vented class II cabinet by adding 500 µl of 1% methanol-free
formaldehyde in PBS and pipetted up and down several times to ensure a
single cell suspension. Following a 5 min incubation at room temperature,
cells were permeabilised by adding 500 µl of Triton-X-100 in PBS and
mixed gently. Cells were allowed to sit at room temperature for 1 min and
subjected to a SAR cycle. Cells were resuspended with 1 ml of 1% FBS in
PBS, gently mixed, and incubated at room temperature for 30 min (same
day analysis) or stored at 4℃ for up to 1 week for convenient analysis.
Cells were then subjected to a SAR cycle. Primary antibody (γH2AX
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antibody was prepared using a 1:3333 dilution in 1% FBS in PBS) was
added to each sample (200 µl), mixed gently, and allowed to incubate for
1.5 h at room temperature. Following incubation, cells were once again
subjected to a SAR cycle after addition of 1 ml of PBS to each sample.
Secondary antibody (goat anti-mouse Alexa Fluor 488, prepared using a
1:1750 dilution in 1% FBS in PBS to a ﬁnal concentration of 1 µg/ml) was
added to each sample, were mixed gently, and incubated for 1 h at room
temperature in the dark. A last SAR cycle was carried out after addition
of 1 ml of PBS. For concurrent cell cycle analysis, cells were resuspended
in 300 µl of 50 µg/ml propidium iodide/ 0.1 mg/ml RNAse A in PBS and
incubated for at least 10 min at room temperature before analysis on a
Beckman Coulter Cytomics FC 500 MCL ﬂow cytometer.
6.2.7 Tubulin Polymerisation Assay
The tubulin polymerisation assay is based on an adaptation of the origi-
nal method of Shelanski et al. and Lee et al , which demonstrated that
there is a proportional relationship between light scatter and concentration
of microtubule polymer [224, 225]. Absorption spectral data in the form
of polymerisation curves reveal three distinct phases of microtubule poly-
merisation: nucleation, growth, and steady state equilibrium. Compounds
that interfere with tubulin polymerisation will aﬀect one or more of these
phases. Therefore, this assay can be used to identify novel antimitotic (or
antimicrotubule) agents. Instructions for reconstituting the general tubulin
buﬀer (PEM), guanosine triphosphate (GTP) were followed prior to begin-
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ning the assay. The appropriate absorbance (340 nm) and temperature (37
℃) settings for the Perkin Elmer Vision plate reader were also set prior
to beginning the assay in order to maximise polymerisation activity. The
plate reader was set to kinetic mode measuring 61 cycles of 1 reading per
minute.
PEM (500 µl; required for tubulin ligand dilutions) was warmed to room
temperature. The test compounds (paclitaxel and jerantinine A) were then
diluted with PEM to yield ﬁnal concentrations of 5 µM and 10 µM. Cold
G-PEM minus glycerol buﬀer was made to re-suspend the tubulin and
kept on ice for approximately 3 min. Paclitaxel and jerantinine A (10 µl)
concentrations in addition to G-PEM buﬀer (control) were pipetted into
their respective wells on a microtiter plate and placed in the incubator
for 2 min at 37 ℃. Tubulin (100 µl) was added and pipetted into the wells
containing the test compounds and immediately placed into the plate reader
to obtain absorbance data. Data were recorded in an excel spreadsheet
supplied by the Wallac Envision software and graphed using GraphPad
Prism 6.
6.2.8 Confocal Microscopy
HCT-116 cells were seeded eight-well µ-slides (Ibidi Germany, Catalogue
No.: 80826) and were allowed to adhere for 24 h at 37℃ before treat-
ment with test agents for an additional 24 h. Cells were then ﬁxed with
formaldehyde (3.7% in PBS) and incubated at room temperature for 10-
15 min before permeabilisation using PBT (PBS + 0.1% Triton-X-100).
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Following incubation for 2-3 min at room temperature, cells were blocked
using PBT + 1% BSA for 1 h to prevent non-speciﬁc binding of labelled an-
tibodies. Cells were then incubated with 1o Ab (monoclonal anti α-tubulin
antibody; 1:200 dilution; excited by the 488 nm blue laser) for 2 h at room
temperature before being washed with PBT and incubated with the appro-
priate ﬂuorescent 2o Ab (1:400 dilution) at room temperature in the dark
for 1 h. After washing with PBT, cells were incubated with DRAQ5 (1:3000
dilution; excited by the 633 nm far red laser), a cell permeant DNA binding
dye, at room temperature for 5 min in the dark. Images were captured on
a Zeiss LSM510 Meta confocal microscope.
6.2.9 Kinase Assay
In vitro kinase inhibition assay for compounds was examined using a radio-
metric assay employed by Millipore kinaseProﬁler service. Kinases (5-20
mU diluted in 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% β-mercaptoethanol,
1 mg/ml BSA, 100 µM vanadate) were assayed against appropriate sub-
strate peptide in a ﬁnal volume of 25.5 µl containing 50 mM Tris pH
7.5,0.05% β-mercaptoethanol, 10 µM vanadate, 300 µM substrate pep-
tide, 10 mM magnesium acetate and 0.005 mM [33P-γ-ATP] (50-1000
cpm/pmole) and incubated for 30 min at room temperature. 1 µM of JA
was used to test for the presence of inhibitory activity. Assays were stopped
by addition of 5 µl of 0.5 M (3%) orthophosphoric acid and then harvested
onto P81 Uniﬁlter plates with a wash buﬀer of 50 mM orthophosphoric
acid.
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6.2.10 Western Blotting Analysis
6.2.10.1 Preparation of cell lysates
Cells were seeded at a density of 1x106 and allowed to grow for 24 h. Test
agents were then added for the desired duration. Following treatment,
growth medium was collected in universal tubes and placed on ice. All
plates were washed with ice cold PBS (10 ml). After aspiration, 300 µl of
ice-cold lysis buﬀer was added to each plate. Cells were then scraped using
a cell scraper and pooled into labelled 1.5 ml eppendorf tubes and placed on
ice for 25 min. Universals containing media/ﬂoating cells were centrifuged
at 1200 rpm for 5 min at 4 ℃. Supernatant was aspirated and cells were
resuspended with ice cold PBS (5 ml) and centrifuged as before. PBS was
aspirated, and cells were resuspended with 100 µl of lysis buﬀer and added
to their respective eppendorf tubes. After centrifugation (13300 rpm for
10 min at 4 ℃) supernatant was collected in new labelled eppendorf tubes
and the pellets were discarded. Cell lysates were stored at -20 ℃.
6.2.10.2 Determining protein concentration
Protein concentrations were determined using the Bradford reagent ﬁrst
described by M. Bradford [226]. It is a colourimetric assay based on an
absorbance shift of the Coomassie Brilliant Blue G-250 dye from 465 nm
to 595 nm. The amount of complexes that form between the protein’s
tertiary structure and the dye is proportional to the intensity of the dye
which can be measured by obtaining an absorbance reading, thus yielding
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an estimation of protein concentration.
Lysate (10 µl) sample was added to three wells containing 150 µl of
Bradford reagent. After a 15 min development time, the absorbances were
read at 595 nm. A standardised curve was constructed using BSA at con-
centrations ranging from 0-1 mg/ml and subsequently used to obtain esti-
mated protein concentrations from acquired absorbances.
6.2.10.3 SDS-PAGE
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
was used to separate proteins in lysates acording to size. Polyacrylamide
gels of diﬀerent percentages (7.5-15%) were prepared depending on the
molecular weight of the protein to be detected. Protein gels consisted of
two phases: the lower resolving gel for separation and the upper stack-
ing gel for loading. Appropriate volumes of acrylamide/bis-acrylamide,
resolving buﬀer, and distilled water were mixed together depending on gel
percentage. Polymerisation was initiated by adding 1 µl of TEMED and
4.5 µl of 10% AMPS per ml of gel and were allowed 30 min to polymerise.
Isopropanol was immediately added to avoid any air bubbles after pour-
ing the resolving gel into the cassette. The stacking gel was poured after
washing oﬀ isopropanol with dH2O. The stacking gel percentage was 4%
and was formed by mixing 0.67 ml acrylamide stock, 0.63 ml of stacking
buﬀer, and 3.7 ml of dH2O. 3 µl of TEMED and 6 µl of 10% AMPS per
ml of gel was added to initiate polymerisation. A comb was immediately
inserted to create loading wells. Cell lysates containing a total of 50 µg was
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mixed with loading buﬀer and denatured at 95 ℃ for 5 mins. Cassettes
were inserted into an electrophoretic tank ﬁlled with running buﬀer during
this time. After heating, samples were then loaded into wells along with a
PageRuler Plus Prestained Protein Ladder (5 µl) to serve as a molecular
marker and proteins were separated at a voltage of between 60-150 V. Elec-
trophoresis was run for 1.5 h and the gel containing the separated proteins
was removed and immersed in transfer buﬀer.
6.2.10.4 Immunoblotting
The proteins separated by SDS-PAGE were then electro-blotted onto nitro-
cellulose membranes previously soaked in transfer buﬀer. The membrane
and the gel were sandwiched between 8 blot papers that were also previ-
ously soaked in transfer buﬀer before commencing with semi-dry transfer
at 25 V for 1.5 h in a transfer machine. Gels were later discarded and the
membranes were blocked in 5% dried non-fat milk in TBST for 1 h at room
temperature with gentle shaking to prevent non-speciﬁc protein binding.
After blocking, membranes were incubated with the primary antibody at
4 ℃ overnight. Membranes were washed with TBST the following day for
30 min to remove residual primary antibody (TBST was discarded and re-
placed with fresh TBST every 10 min for a total of 30 min). Membranes
were then incubated with the appropriate horseradish peroxidase (HRP)
conjugated secondary antibody (depending on the source of the primary
antibody) for 1 h at room temperature. After incubation, membranes were
washed for 30 min with TBST replaced every 10 min.
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6.2.10.5 Enhanced chemiluminescence detection
The protein of interest on the membrane was detected by applying Amer-
sham TM ECL TM Western blotting detection reagents following manufac-
turer’s instructions. After removal of excess reagent, the membrane was
exposed to high performance chemiluminescence ﬁlm in the dark room for
appropriate exposure time. The ﬁlm was then developed by insertion into
developer solution until bands were observed under red light. Following a
quick wash (in running water), the ﬁlm was ﬁxed in ﬁxer solution for ap-
proximately 2 min and air-dried after an additional wash to remove excess
solution.
6.2.11 Caspase 3/7 Assay
Caspase 3/7 activity was assayed according to the Apo-ONE homogeneous
Caspase 3/7 kit instructions supplied by Promega. Cells were seeded at a
density of 1 x 104 in 96-well plates and incubated at 37 ℃, 5% CO2 before
introduction of test agents. Compound concentrations of GI50 were used for
a 48 h exposure. After treatment, Apo-ONE caspase 3/7 reagent (caspase
substrate + Apo-ONE caspase 3/7 buﬀer) was added to each well (100 µl)
and mixed on a plate shaker for 1 min. Fluorescence was measured following
a 30 min incubation at room temperature at an excitation wavelength of
485 nm and an emission wavelength of 530 nm using EnVision multilabel
plate reader (Perkin Elmer). The amount of ﬂuorescent product generated
is proportional to the amount of caspase 3/7 present in the well.
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6.2.12 ROS-GloTM H2O2 Assay
Levels of reactive oxygen species (ROS) were measured as per the kit in-
structions supplied by Promega. ROS generated in cells can act as sig-
nalling molecules and in excess can cause cell damage or death [227]. H2O2
is one of many ROS that can be generated in cell cultures or enzyme
reactions and is convenient to use as it possesses the longest half-life of
all ROS in cultured cells. Additionally various ROS can be converted to
H2O2 within cells. Therefore, changes in H2O2 reﬂect a general change in
ROS levels. The assay utilises a luciferin precursor which is produced as
a biproduct from the reaction of the H2O2 substrate and H2O2 itself. The
precursor is converted to luciferin after addition of a detection agent con-
taining D-cysteine generating a luminescent signal proportional to H2O2
concentration.
Cells were seeded at a density of 5 x 103 in 70 µl of medium per well and
allowed to attach overnight for 24 h in white-walled 96-well plates. Test
agent or vehicle (10 µl) was added to respective wells for an additional
24 h. The H2O2 substrate was added for the ﬁnal 6 h of the treatment.
Upon terminating treatment, a 100 µl of ROS-GloTM Detection solution
was added to each well and samples were incubated for 20 min at room
temperature. Relative luminescence units (RLU) were recorded using a
Perkin Elmer plate reader.
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6.2.13 Proteomics
Liquid Chromatography-tandem mass spectrometry (LC-MS/MS) has been
subject to exponential growth in clinical laboratories during the last 10-15
years [228]. Furthermore, it has become a powerful technology in pro-
teomics studies in drug discovery, including target protein characterization
and discovery of biomarkers [229]. Proteome analysis was conducted using
Multidimensional Protein Identiﬁcation Technology (MudPIT). MudPIT
separates peptides in 2D liquid chromatography and allows greater sepa-
ration of peptides that can be directly interfaced with the ion source of
a mass spectrometer, which maximizes sensitivity. Mass spectra of frag-
mented ions from peptides can then be used to identify proteins from online
databases.
Cells were seeded at a density of 5 x 106 and treated with test agent for
desired time exposures. Upon termination of treatment, cells were scraped
in ice-cold PBS and centrifuged at 2000 g for 10 min at 4℃. The pellet was
resuspended in 50% (v/v) triﬂuoroethanol (TFE) in PBS (pH 7.4). Cells
were subjected to 5 freeze/thaw cycles followed by 7 cycles of sonication
lasting 30 seconds each to aid lysis. Proteins in cellular lysates were dena-
tured by heat via incubation at 60 ℃ for 2 h. Subsequently, cysteines were
reduced by addition of DTT to a ﬁnal concentration of 5 mM and incubated
for an additional 30 min at 60 ℃. Reduced cysteines were alkylated using
IAA (ﬁnal concentration of 25 mM) by incubating in the dark for 30 min
at room temperature. Upon completion, samples were diluted 5x using 100
mM ammonium bicarbonate (pH 8.0). Proteins in the lysate were digested
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into peptides using mass spectrometry grade trypsin and proteolysis was
allowed overnight at 37 ℃.
Following digestion, samples were centrifuged at 12,000 relative cen-
trifugal force (rcf) for 10 min at room temperature. The supernatant was
enriched for peptides using C18 based reverse phase STAGE tips. Peptides
were eluted from the reverse phase using 80% acetonitrile and captured on
a SCX based stage tip. Bound peptides were eluted in six steps, with each
step increasing in pH. Buﬀers for the six steps were: steps 1-5 (50, 75, 125,
200, 300 mM) ammonium acetate, 20% (v/v) acetonitrile with 0.5% (v/v)
formic (methanoic) acid. The last step consisted of elution with 5% (v/v)
ammonium hydroxide in 80% (v/v) acetonitrile.
Peptides from all fractions were dried using vacuum centrifugation and
resuspended in 10 µl of HPLC grade water with 0.1% formic acid. Hence,
six SCX based fractions were produced for each fraction. All 10 µl of
peptides for each fraction were injected using an Easy LC 1000 nano ﬂow,
liquid chromatography system. Peptides were separated on a 50 cm C18
based reverse phase EasySpray column and analysed on a Thermo Scientiﬁc
Orbitrap XL to obtain tandem mass spectrometry data.
The collected data were searched using MaxQuant (Version 1.5.2.8) and
uniprot human fasta was used for protein sequences. Target-decoy was used
for controlling false discovery of peptides and set to 1%. All protein groups
were ﬁltered to contain two peptides or more for further analysis.
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6.2.14 Statistical Analysis
All experiments were repeated at least three times with representative ex-
periments being selected for ﬁgures. Statistical diﬀerences between groups
were assessed using a two-way ANOVA unless stated otherwise and ex-
pressed as mean or mean ± SD. Dunnett’s multiple comparisons test was
used to assess signiﬁcance, deﬁned in this study as a p-value < 0.05.
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Figure A.1: Representative MTT graphs from a single trial displaying the
eﬀect of DMSO on all cell lines initially tested.
Eﬀect of DMSO from one independent trial in A549 (a), HCT-116 (b),
HT-29 (c), MCF-7 (d), MDA-468 (e), cells. Cells were seeded in 96-well
plates at a density of 3 x 103 cells/well. After allowing to adhere (24 h),
cells were treated with JA (n=4) and incubated for 72 h. MTT assays
repeated ≥3 times.
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Figure A.2: Representative MTT graph from a single trial displaying the
growth inhibitory properties of JA and JAA against a pancreatic carcinoma
cell line MIA PaCa-2.
Growth inhibitory eﬀects of JA and JAA from one independent trial in
MIA PaCa-2. Cells were seeded in 96-well plates at a density of 3 x 103
cells/well. After allowing to adhere (24 h), cells were treated with JA
(n=4) and incubated for 72 h. MTT assays repeated ≥3 times. Both JA
and JAA potently inhibited growth with a GI50 value of approximately
250 nM. This ﬁgure was kindly provided by Yan Lui (Undergraduate
research student).
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Figure A.3: Eﬀect of jerantinine A and jerantinine A acetate on colony
formation in MIA PaCa-2.
a) Mean graphs and SEMs showing potent inhibition of colony formation
in MIA PaCa-2 cells after a 24 h exposure to JA and JAA (p<0.001; n=4
per trial) b) Representative photos taken from an individual trial clearly
showing inhibition of colony formation (JA top; JAA bottom). Figures
were kindly provided by Yan Lui (Undergraduate research student).
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Table A.1: IC50 values obtained from clonogenic assays and MTT assays
for vincristine and jerantinine A in DAOY, MED1, UW228-3 and FB83
cell lines.
IC50 = concentration required to cause 50% of colony formation in
clonogenic assays, and to cause 50% cell viability in MTT assays (both
relative to vehicle treated controls). Table was provided by Amy Lloyd
supervised by Dr. Beth Coyle (QMC, University of Nottingham)
Figure A.4: Comparison of relative IC50 values from clonogenic and MTT
assays for vincristine and jerantinine A in DAOY, MED1 and UW228-3
medulloblastoma cell lines.
One way ANOVA and unpaired t-tests were used to calculate signiﬁcant
diﬀerences. (**** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05). Data
represents mean ± SD. Figures were provided by Amy Lloyd supervised
by Dr. Beth Coyle (QMC, University of Nottingham)
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Figure B.1: The eﬀects of Verapamil with Vincristine (A-C) and Jeranti-
nine A (D-F) on the potentiation of inhibitory eﬀects on colony formation
using clonogenic assays.
DAOY, MED1, and UW228-3 cells were treated with JA or vincrsitine
alone. JA and vincristine treatments along with verapamil were used to
investigate if inhibition of ABCB1 enhanced the potency of JA. Verapamil
clearly exhibited a synergistic eﬀect with vincristine, but did not aﬀect JA
activity on all three cell lines. Experiments were repeated at least three
times where n=2 (****= p<0.0001, one way ANOVA, paired T-test).
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Figure B.2: Detailed crystal structures of jerantinine B acetate binding to
the colchicine site on microtubules
(a) Detailed view of JBA binding to the colchicine site of microtubules.
(b) Superimposed image comparing colchicine and JBA binding (c, d)
Detailed interactions with amino acid residues within the colchicine
binding site. Images (2.4Å) were provided by Natacha Olieric, Andrea E.
Prota and Michel O. Steinmetz from the Paul Scherrer Institute
(Switzerland).
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C.1 Data Analysis of Genome-wide shRNA
Screen
To deﬁne JA-modulating eﬀects from the screen data, we used three par-
allel strategies previously used in RNA interference screens. In the ﬁrst in-
stance we selected signiﬁcant eﬀects according to the variance of the entire
dataset. We calculated the median absolute deviation (MAD) to estimate
the variance of the normalized data and deﬁned resistance-causing hits as
those shRNAs that gave DE scores <2 x MAD (Z score <2), a threshold
approximately equal to 2 SDs from the median. Sensitization eﬀects were
deﬁned as shRNAs that returned DE scores of Z <−2. In addition to this
approach we also used RNAi Gene Enrichment Ranking (RIGER), as im-
plemented in the Broad Institute’s GENE-E software package. In brief,
RIGER is derived from the weighted sum of the two top-ranked shRNAs
for each gene on the basis of the log fold change for each condition, and pro-
vided a normalized enrichment score per gene. Finally, we also used RNAi
Set Analysis (RSA), a modiﬁcation of Gene Set Analysis (http://wwwstat.
stanford.edu/∼tibs/GSA/) that uses maximum–mean statistics to identify
signiﬁcantly enriched or depleted shRNA sets.
In total, Z score threshold identiﬁed 680 resistance-causing genes and
753 sensitization genes, RIGER generated a list of 821 resistance-causing
and 790 sensitization genes with a P value of <0.05, and RSA generated a
list of 651 resistance-causing genes and 339 sensitization genes with a false
discovery rate approaching zero. Given the limitations of each method, we
took a pragmatic approach and considered a subset of the genes identiﬁed
by all three methods for further examination. This intersection approach
identiﬁed 381 candidate genes mediating sensitization and 121 candidate
genes mediating resistance to JA (see ﬁg.C.1).
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Figure C.1: Detection of JA sensitization and resistance-causing eﬀects.
(A) Venn diagrams indicating the number of candidate hits deﬁned by
three parallel analysis methods. (B) Plot of shRNA DE Z scores ranked
by size of eﬀect.
Data analysis ﬁgures and procedure was kindly provided by Dr.
Chee-Onn Leong (IMU, Malaysia).
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Figure C.2: Blots illustrating knockdown of JNK1/2 in MCF-7 and MDA-
468 cells compared to their respective vector controls (pLKO).
M1a/M19 shRNA variants target JNK1 and J21/J22 shRNA variants
target JNK2. MCF-7 cells transduced with the M9 variant did not appear
to knock down JNK1 when compared to the vector control. Blots were
kindly provided in collaboration with Dr. Chee-Onn Leong and Dr.
Felicia Chung (IMU, Malaysia).
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Figure C.3: Mean MTT graphs of JA-treated (1 µM) MCF-7 cells that are
deﬁcient in either JNK1 or JNK2.
Treatments were terminated after 72 h by addition of MTT and
subsequently incubated for 4 hours. Absorbances were measured using a
tecan microplate reader.
Figure C.4: Mean MTT graphs of JA-treated (1 µM) MDA-468 cells that
are deﬁcient in either JNK1 or JNK2.
Treatments were terminated after 72 h by addition of MTT and
subsequently incubated for 4 hours. Absorbances were measured using a
tecan microplate reader.
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